

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
27 May 2004 (27.05.2004)

PCT

(10) International Publication Number
WO 2004/044004 A2

(51) International Patent Classification⁷: **C07K 14/705**,
C12N 15/10

LI, Yi [CN/GB]; Avidex Limited, 57 C Milton Park,
Abingdon, Oxfordshire OX14 4RX (GB). **BOULTER,**
Jonathan, Michael [GB/GB]; Avidex Limited, 57c Milton
Park, Abingdon, Oxfordshire OX14 4RG (GB).

(21) International Application Number:
PCT/GB2003/004636

(74) Agent: **WALLS, Alan, J.**; Avidex Limited, 57 C Milton
Park, Abingdon, Oxfordshire OX14 4RX (GB).

(22) International Filing Date: 30 October 2003 (30.10.2003)

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(26) Publication Language: English

(30) Priority Data:
0226227.7 9 November 2002 (09.11.2002) GB
0301814.0 25 January 2003 (25.01.2003) GB
0304067.2 22 February 2003 (22.02.2003) GB
60/463,046 16 April 2003 (16.04.2003) US
0311397.4 16 May 2003 (16.05.2003) GB
0316356.5 11 July 2003 (11.07.2003) GB

(84) Designated States (*regional*): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **AVIDEX
LIMITED** [GB/GB]; 57C Milton Park, Abingdon, Ox-
fordshire OX14 4RX (GB).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **JAKOBSEN, Bent,**
Karsten [DK/GB]; Avidex Limited, 57 C Milton Park,
Abingdon, Oxfordshire OX14 4RX (GB). **ANDERSEN,**
Torben, Bent [DK/GB]; Avidex Limited, 57 C Milton
Park, Abingdon, Oxfordshire OX14 4RX (GB). **MOL-**
LOY, Peter, Eamon [IE/GB]; Avidex Limited, 57 C
Milton Park, Abingdon, Oxfordshire OX14 4RX (GB).

Published:

— *without international search report and to be republished
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: T CELL RECEPTOR DISPLAY

(57) Abstract: A proteinaceous particle, for example a bacteriophage, ribosome or cell, displaying on its surface a T-cell receptor (TCR). The displayed TCR is preferably a heterodimer having a non-native disulfide bond between constant domain residues. Such display particles may be used for the creation of diverse TCR libraries for the identification of high affinity TCRs. Several high affinities are disclosed.

WO 2004/044004 A2

T Cell Receptor Display

The present invention relates to proteinaceous particles, for example phage or ribosome particles, displaying T cell receptors (TCRs), and diverse libraries thereof.

5

Background to the Invention

Native TCRs

As is described in, for example, WO 99/60120 TCRs mediate the recognition of specific Major Histocompatibility Complex (MHC)-peptide complexes by T cells and, as such, are essential to the functioning of the cellular arm of the immune system.

10

Antibodies and TCRs are the only two types of molecules which recognise antigens in a specific manner, and thus the TCR is the only receptor for particular peptide antigens presented in MHC, the alien peptide often being the only sign of an abnormality within a cell. T cell recognition occurs when a T-cell and an antigen presenting cell (APC) are in direct physical contact, and is initiated by ligation of antigen-specific TCRs with pMHC complexes.

15

The native TCR is a heterodimeric cell surface protein of the immunoglobulin superfamily which is associated with invariant proteins of the CD3 complex involved in mediating signal transduction. TCRs exist in $\alpha\beta$ and $\gamma\delta$ forms, which are structurally similar but have quite distinct anatomical locations and probably functions. The MHC class I and class II ligands are also immunoglobulin superfamily proteins but are specialised for antigen presentation, with a highly polymorphic peptide binding site which enables them to present a diverse array of short peptide fragments at the APC cell surface.

20

25

Two further classes of proteins are known to be capable of functioning as TCR ligands. (1) CD1 antigens are MHC class I-related molecules whose genes are located on a different chromosome from the classical MHC class I and class II antigens. CD1 molecules are capable of presenting peptide and non-peptide (eg lipid, glycolipid)

30

moieties to T cells in a manner analogous to conventional class I and class II-MHC-pep complexes. See, for example (Barclay et al, (1997)The Leucocyte Antigen Factsbook 2nd Edition, Academic Press) and (Bauer (1997) Eur J Immunol 27 (6) 1366-1373)) (2) Bacterial superantigens are soluble toxins which are capable of binding both class II MHC molecules and a subset of TCRs.(Fraser (1989) Nature 339 221-223) Many superantigens exhibit specificity for one or two Vbeta segments, whereas others exhibit more promiscuous binding. In any event, superantigens are capable of eliciting an enhanced immune response by virtue of their ability to stimulate subsets of T cells in a polyclonal fashion.

10

The extracellular portion of native heterodimeric $\alpha\beta$ and $\gamma\delta$ TCRs consist of two polypeptides each of which has a membrane-proximal constant domain, and a membrane-distal variable domain. Each of the constant and variable domains includes an intra-chain disulfide bond. The variable domains contain the highly polymorphic loops analogous to the complementarity determining regions (CDRs) of antibodies. CDR3 of $\alpha\beta$ TCRs interact with the peptide presented by MHC, and CDRs 1 and 2 of $\alpha\beta$ TCRs interact with the peptide and the MHC. The diversity of TCR sequences is generated via somatic rearrangement of linked variable (V), diversity (D), joining (J), and constant genes

20

Functional α and γ chain polypeptides are formed by rearranged V-J-C regions, whereas β and δ chains consist of V-D-J-C regions. The extracellular constant domain has a membrane proximal region and an immunoglobulin region. There are single α and δ chain constant domains, known as TRAC and TRDC respectively. The β chain constant domain is composed of one of two different β constant domains, known as TRBC1 and TRBC2 (IMGT nomenclature). There are four amino acid changes between these β constant domains, three of which are within the domains used to produce the single-chain TCRs displayed on phage particles of the present invention. These changes are all within exon 1 of TRBC1 and TRBC2: N₄K₅->K₄N₅ and F₃₇->Y (IMGT numbering, differences TRBC1->TRBC2), the final amino acid change

30

between the two TCR β chain constant regions being in exon 3 of TRBC1 and TRBC2: V₁->E. The constant γ domain is composed of one of either TRGC1, TRGC2(2x) or TRGC2(3x). The two TRGC2 constant domains differ only in the number of copies of the amino acids encoded by exon 2 of this gene that are present.

5

The extent of each of the TCR extracellular domains is somewhat variable. However, a person skilled in the art can readily determine the position of the domain boundaries using a reference such as The T Cell Receptor Facts Book, Lefranc & Lefranc, Publ. Academic Press 2001.

10

Recombinant TCRs

The production of recombinant TCRs is beneficial as these provide soluble TCR analogues suitable for the following purposes:

15

- Studying the TCR / ligand interactions (e.g. pMHC for $\alpha\beta$ TCRs)
- Screening for inhibitors of TCR-associated interactions
- Providing the basis for potential therapeutics

20

A number of constructs have been devised to date for the production of recombinant TCRs. These constructs fall into two broad classes, single-chain TCRs and dimeric TCRs, the literature relevant to these constructs is summarised below.

Single-chain TCRs (scTCRs) are artificial constructs consisting of a single amino acid strand, which like native heterodimeric TCRs bind to MHC-peptide complexes.

25

Unfortunately, attempts to produce functional alpha/beta analogue scTCRs by simply linking the alpha and beta chains such that both are expressed in a single open reading frame have been unsuccessful, presumably because of the natural instability of the alpha-beta soluble domain pairing.

30

Accordingly, special techniques using various truncations of either or both of the alpha and beta chains have been necessary for the production of scTCRs. These formats appear to be applicable only to a very limited range of scTCR sequences. Soo Hoo *et*

al (1992) PNAS. **89** (10): 4759-63 report the expression of a mouse TCR in single chain format from the 2C T cell clone using a truncated beta and alpha chain linked with a 25 amino acid linker and bacterial periplasmic expression (see also Schodin *et al* (1996) Mol. Immunol. **33** (9): 819-29). This design also forms the basis of the m6
5 single-chain TCR reported by Holler *et al* (2000) PNAS. **97** (10): 5387-92 which is derived from the 2C scTCR and binds to the same H2-Ld-restricted alloepitope. Shusta *et al* (2000) Nature Biotechnology **18**: 754-759 and US 6,423,538 report using a murine single-chain 2C TCR constructs in yeast display experiments, which produced mutated TCRs with, enhanced thermal stability and solubility. This
10 report also demonstrated the ability of these displayed 2C TCRs to selectively bind cells expressing their cognate pMHC. Khandekar *et al* (1997) J. Biol. Chem. **272** (51): 32190-7 report a similar design for the murine D10 TCR, although this scTCR was fused to MBP and expressed in bacterial cytoplasm (see also Hare *et al* (1999) Nat. Struct. Biol. **6** (6): 574-81). Hilyard *et al* (1994) PNAS. **91** (19): 9057-61 report a
15 human scTCR specific for influenza matrix protein-HLA-A2, using a V α -linker-V β design and expressed in bacterial periplasm.

Chung *et al* (1994) PNAS. **91** (26) 12654-8 report the production of a human scTCR using a V α -linker-V β -C β design and expression on the surface of a mammalian cell
20 line. This report does not include any reference to peptide-HLA specific binding of the scTCR. Plaksin *et al* (1997) J. Immunol. **158** (5): 2218-27 report a similar V α -linker-V β -C β design for producing a murine scTCR specific for an HIV gp120-H-2D^d epitope. This scTCR is expressed as bacterial inclusion bodies and refolded *in vitro*.

25 A number of papers describe the production of TCR heterodimers which include the native disulphide bridge which connects the respective subunits (Garboczi, *et al.*, (1996), Nature **384**(6605): 134-41; Garboczi, *et al.*, (1996), J Immunol **157**(12): 5403-10; Chang *et al.*, (1994), PNAS USA **91**: 11408-11412; Davodeau *et al.*, (1993), *J. Biol. Chem.* **268**(21): 15455-15460; Golden *et al.*, (1997), J. Imm. Meth. **206**: 163-
30 169; US Patent No. 6080840). However, although such TCRs can be recognised by

TCR-specific antibodies, none were shown to recognise its native ligand at anything other than relatively high concentrations and/or were not stable.

5 In WO 99/60120, a soluble TCR is described which is correctly folded so that it is capable of recognising its native ligand, is stable over a period of time, and can be produced in reasonable quantities. This TCR comprises a TCR α or γ chain extracellular domain dimerised to a TCR β or δ chain extracellular domain respectively, by means of a pair of C-terminal dimerisation peptides, such as leucine zippers. This strategy of producing TCRs is generally applicable to all TCRs.

10

Reiter *et al*, Immunity, 1995, **2**:281-287, details the construction of a soluble molecule comprising disulphide-stabilised TCR α and β variable domains, one of which is linked to a truncated form of Pseudomonas exotoxin (PE38). One of the stated reasons for producing this molecule was to overcome the inherent instability of single-
15 chain TCRs. The position of the novel disulphide bond in the TCR variable domains was identified via homology with the variable domains of antibodies, into which these have previously been introduced (for example see Brinkmann, *et al.* (1993), Proc. Natl. Acad. Sci. USA **90**: 7538-7542, and Reiter, *et al.* (1994) Biochemistry **33**: 5451-5459). However, as there is no such homology between antibody and TCR constant
20 domains, such a technique could not be employed to identify appropriate sites for new inter-chain disulphide bonds between TCR constant domains.

As mentioned above Shusta *et al* (2000) Nature Biotechnology **18**: 754-759 report using single-chain 2 C TCR constructs in yeast display experiments. The principle of
25 displaying scTCRs on phage particles has previously been discussed. For example, WO 99/19129 details the production of scTCRs, and summarise a potential method for the production of phage particles displaying scTCRs of the V α -Linker-V β C β format. However, this application contains no exemplification demonstrating the production of said phage particles displaying TCR. The application does however refer to a co-
30 pending application:

“The construction of DNA vectors including a DNA segment encoding a sc-TCR molecules fused to a bacteriophage coat protein (gene II or gene VIII) have been described in said pending U.S. application No. 08/813,781.”

5 Furthermore, this application relies on the ability of anti-TCR antibodies or super-antigen MHC complexes to recognise the soluble, non-phage displayed, scTCRs produced to verify their correct conformation. Therefore, true peptide-MHC binding specificity of the scTCRs, in any format, is not conclusively demonstrated. Finally, a further study (Onda *et al.*, (1995) *Molecular Immunology* **32** (17-18) 1387-
10 1397) discloses the phage display of two murine TCR α chains in the absence of their respective β chains. This study demonstrated that phage particles displaying one of the TCR α chains (derived from the A1.1 murine hybridoma) bound preferentially to the same peptides immobilised in microtitre wells that the complete TCR would normally respond to when there were presented by the murine Class I MHC I-A^d.

15

Screening Use

A number of important cellular interactions and cell responses, including the TCR-mediated immune synapse, are controlled by contacts made between cell surface receptors and ligands presented on the surfaces of other cells. These types of specific
20 molecular contacts are of crucial importance to the correct biochemical regulation in the human body and are therefore being studied intensely. In many cases, the objective of such studies is to devise a means of modulating cellular responses in order to prevent or combat disease.

25 Therefore, methods with which to identify compounds that bind with some degree of specificity to human receptor or ligand molecules are important as leads for the discovery and development of new disease therapeutics. In particular, compounds that interfere with certain receptor-ligand interactions have immediate potential as therapeutic agents or carriers.

30

Advances in combinatorial chemistry, enabling relatively easy and cost-efficient production of very large compound libraries have increased the scope for compound testing enormously. Now the limitations of screening programmes most often reside in the nature of the assays that can be employed, the production of suitable receptor and ligand molecules and how well these assays can be adapted to high throughput screening methods.

Display Methods

It is often desirable to present a given peptide or polypeptide on the surface of a proteinaceous particle. Such particles may serve as purification aids for the peptide or polypeptide (since the particles carrying the peptide or polypeptide may be separated from unwanted contaminants by sedimentation or other methods). They may also serve as particulate vaccines, the immune response to the surface displayed peptide or polypeptide being stimulated by the particulate presentation. Protein p24 of the yeast retrotransposon, and the hepatitis B surface coat protein are examples of proteins which self assemble into particles. Fusion of the peptide or polypeptide of interest to these particle-forming proteins is a recognised way of presenting the peptide or polypeptide on the surface of the resultant particles.

However, particle display methods have primarily been used to identify proteins with desirable properties such as enhanced expression yields, binding and/or stability characteristics. These methods involve creating a diverse pool or 'library' of proteins or polypeptides expressed on the surface of proteinaceous particles. These particles have two key features, firstly each particle presents a single variant protein or polypeptide, and secondly the genetic material encoding the expressed protein or polypeptide is associated with that of the particle. This library is then subjected to one or more rounds of selection. For example, this may consist of contacting a ligand with a particle-display library of mutated receptors and identifying which mutated receptors bind the ligand with the highest affinity. Once the selection process has been completed the receptor or receptors with the desired properties can be isolated, and their genetic material can be amplified in order to allow the receptors to be sequenced.

These display methods fall into two broad categories, *in-vitro* and *in-vivo* display.

5 All *in-vivo* display methods rely on a step in which the library, usually encoded in or
with the genetic nucleic acid of a replicable particle such as a plasmid or phage
replicon is transformed into cells to allow expression of the proteins or polypeptides.
(Plückthun (2001) Adv Protein Chem **55** 367-403). There are a number of
replicon/host systems that have proved suitable for *in-vivo* display of protein or
polypeptides. These include the following

10

Phage / bacterial cells

plasmid / CHO cells

Vectors based on the yeast 2 μ m plasmid / yeast cells

baculovirus / insect cells

15

plasmid / bacterial cells

In-vivo display methods include cell-surface display methods in which a plasmid is
introduced into the host cell encoding a fusion protein consisting of the protein or
polypeptide of interest fused to a cell surface protein or polypeptide. The expression
20 of this fusion protein leads to the protein or polypeptide of interest being displayed on
the surface of the cell. The cells displaying these proteins or polypeptides of interest
can then be subjected to a selection process such as FACS and the plasmids obtained
from the selected cell or cells can be isolated and sequenced. Cell surface display
systems have been devised for mammalian cells (Higuchi (1997) J Immunol.
25 Methods **202** 193-204), yeast cells (Shusta (1999) J Mol Biol **292** 949-956) and
bacterial cells (Sameulson (2002) J. Biotechnol **96** (2) 129-154).

Numerous reviews of the various in-vivo display techniques have been published. For
example, (Hudson (2002) Expert Opin Biol Ther (2001) **1** (5) 845-55) and (Schmitz
30 (2000) **21** (Supp A) S106-S112).

In-vitro display methods are based on the use of ribosomes to translate libraries of mRNA into a diverse array of protein or polypeptide variants. The linkage between the proteins or polypeptides formed and the mRNA encoding these molecules is maintained by one of two methods. Conventional ribosome display utilises mRNA sequences that encode a short (typically 40-100 amino acid) linker sequence and the protein or polypeptide to be displayed. The linker sequence allow the displayed protein or polypeptide sufficient space to re-fold without being sterically hindered by the ribosome. The mRNA sequence lacks a 'stop' codon, this ensures that the expressed protein or polypeptide and the RNA remain attached to the ribosome particle. The related mRNA display method is based on the preparation of mRNA sequences encoding the protein or polypeptide of interest and DNA linkers carrying a puromycin moiety. As soon as the ribosome reaches the mRNA/DNA junction translation is stalled and the puromycin forms a covalent linkage to the ribosome. For a recent review of these two related *in-vitro* display methods see (Amstutz (2001) Curr Opin Biotechnol 12 400-405).

Particularly preferred is the phage display technique which is based on the ability of bacteriophage particles to express a heterologous peptide or polypeptide fused to their surface proteins. (Smith (1985) Science 217 1315-1317). The procedure is quite general, and well understood in the art for the display of polypeptide monomers. However, in the case of polypeptides that in their native form associate as dimers, only the phage display of antibodies appears to have been thoroughly investigated.

For monomeric polypeptide display there are two main procedures:
Firstly (Method A) by inserting into a vector (phagemid) DNA encoding the heterologous peptide or polypeptide fused to the DNA encoding a bacteriophage coat protein. The expression of phage particles displaying the heterologous peptide or polypeptide is then carried out by transfecting bacterial cells with the phagemid, and then infecting the transformed cells with a 'helper phage'. The helper phage acts as a source of the phage proteins not encoded by the phagemid required to produce a functional phage particle.

Secondly (Method B), by inserting DNA encoding the heterologous peptide or polypeptide into a complete phage genome fused to the DNA encoding a bacteriophage coat protein. The expression of phage particles displaying the heterologous peptide or polypeptide is then carried out by infecting bacterial cells with the phage genome. This method has the advantage of the first method of being a 'single-step' process. However, the size of the heterologous DNA sequence that can be successfully packaged into the resulting phage particles is reduced. M13, T7 and Lambda are examples of suitable phages for this method.

A variation on (Method B) the involves adding a DNA sequence encoding a nucleotide binding domain to the DNA in the phage genome encoding the heterologous peptide to be displayed, and further adding the corresponding nucleotide binding site to the phage genome. This causes the heterologous peptide to become directly attached to the phage genome. This peptide/genome complex is then packaged into a phage particle which displays the heterologous peptide. This method is fully described in WO 99/11785.

The phage particles can then be recovered and used to study the binding characteristics of the heterologous peptide or polypeptide. Once isolated, phagemid or phage DNA can be recovered from the peptide- or polypeptide-displaying phage particle, and this DNA can be replicated via PCR. The PCR product can be used to sequence the heterologous peptide or polypeptide displayed by a given phage particle.

The phage display of single-chain antibodies and fragments thereof, has become a routine means of studying the binding characteristics of these polypeptides. There are numerous books available that review phage display techniques and the biology of the bacteriophage. (See, for example, Phage Display – A Laboratory Manual, Barbas *et al.*, (2001) Cold Spring Harbour Laboratory Press).

A third phage display method (Method C) relies on the fact that heterologous polypeptides having a cysteine residue at a desired location can be expressed in a

soluble form by a phagemid or phage genome, and caused to associate with a modified phage surface protein also having a cysteine residue at a surface exposed position, via the formation of a disulphide linkage between the two cysteines. WO 01/ 05950 details the use of this alternative linkage method for the expression of single-chain antibody-derived peptides.

Brief Description of the Invention

Native TCR's are heterodimers which have lengthy transmembrane domains which are essential to maintain their stability as functional dimers. As discussed above, TCRs are useful for research and therapeutic purposes in their soluble forms so display of the insoluble native form has little utility. On the other hand, soluble stable forms of TCRs have proved difficult to design, and since most display methods appear to have been described only for monomeric peptides and polypeptides, display methods suitable for soluble dimeric TCRs have not been investigated. Furthermore, since the functionality of the displayed TCR depends on proper association of the variable domains of the TCR dimer, successful display of a functional dimeric TCR is not trivial.

WO 99/18129 contains the statement: "DNA constructs encoding the sc-TCR fusion proteins can be used to make a bacteriophage display library in accordance with methods described in pending U.S. application Serial No. 08/813.781 filed on March 7, 1997, the disclosure of which is incorporated herein by reference.", but no actual description of such display is included in this application. However, The inventors of this application published a paper (Weidanz (1998) J Immunol Methods **221** 59-76) that demonstrates the display of two murine scTCRs on phage particles.

WO 01/62908 discloses methods for the phage display of scTCRs and scTCR/ Ig fusion proteins. However, the functionality (specific pMHC binding) of the constructs disclosed was not assessed.

Finally, a retrovirus-mediated method for the display of diverse TCR libraries on the surface of immature T cells has been demonstrated for a murine TCR. The library of

mutated TCRs displayed of the surface of the immature T cells was screened by flow cytometry using pMHC tetramers, and this lead to the identification TCR variants that were either specific for the cognate pMHC, or a variant thereof. (Helmut *et al.*, (2000) PNAS **97** (26) 14578-14583)

5

This invention is based in part on the finding that single chain and dimeric TCRs can be expressed as surface fusions to proteinaceous particles, and makes available proteinaceous particles displaying alpha/beta-analogue and gamma/delta-analogue scTCR and dTCR constructs. The proteinaceous particles on which the TCRs are displayed include self-aggregating particle-forming proteins, phage, virus-derived, ribosome particles and cells with a cell surface protein or polypeptide molecules to which the TCR is covalently linked. Such proteinaceous particle-displayed TCRs are useful for purification and screening purposes, particularly as a diverse library of particle displayed TCRs for biopanning to identify TCRs with desirable characteristics such as high affinity for the target MHC-peptide complex. In the latter connection, particle-displayed scTCRs may be useful for identification of the desired TCR, but that information may be better applied to the construction of analogous dimeric TCRs for ultimate use in therapy. The invention also includes high affinity TCRs identifiable by these methods

10
15
20

Detailed Description of the Invention

In one broad aspect, the present invention provides a proteinaceous particle displaying on its surface a T-cell receptor (TCR), characterised in that

25

(i) the proteinaceous particle is a ribosome and the TCR is a single chain TCR (scTCR) polypeptide, or dimeric TCR (dTCR) polypeptide pair, or

30

(ii) the proteinaceous particle is a phage particle, or a cell with cell surface protein or polypeptide molecules to which the TCR is covalently linked, and the TCR is a human scTCR or a human dTCR polypeptide pair, or

(iii) the proteinaceous particle is a phage particle, or a cell with cell surface protein or polypeptide molecules to which the TCR is covalently linked, and the TCR is a non-human dTCR polypeptide pair, or

5 (iv) the proteinaceous particle is a phage particle, or a cell with cell surface protein or polypeptide molecules to which the TCR is covalently linked, and the TCR is a scTCR polypeptide comprising TCR amino acid sequences corresponding to extracellular constant and variable domain sequences present in native TCR chains and a linker sequence, the latter linking a variable
10 domain sequence corresponding to that of one chain of a native TCR to a constant domain sequence corresponding to a constant domain sequence of another native TCR chain, and a disulfide bond which has no equivalent in native T cell receptors links residues of the constant domain sequences.

15 In one preferred embodiment, the invention provides A proteinaceous particle, displaying on its surface a dimeric T-cell receptor (dTCR) polypeptide pair, or a single chain T-cell receptor (scTCR) polypeptide wherein the dTCR polypeptide pair is constituted by TCR amino acid sequences corresponding to extracellular constant and variable domain sequences present in native TCR chains, and the scTCR is constituted
20 by TCR amino acid sequences corresponding to extracellular constant and variable domain sequences present in native TCR chains and a linker sequence, the latter linking a variable domain sequence corresponding to that of one chain of a native TCR to a constant domain sequence corresponding to a constant domain sequence of another native TCR chain; wherein the variable domain sequences of the dTCR
25 polypeptide pair or scTCR polypeptide are mutually orientated substantially as in native TCRs, and in the case of the scTCR polypeptide a disulfide bond which has no equivalent in native T cell receptors links residues of the polypeptide.

In the case of $\alpha\beta$ scTCRs or dTCRs displayed according to the invention, a requirement that the variable domain sequences of the α and β segments are mutually
30 orientated substantially as in native $\alpha\beta$ T cell receptors is merely an alternative way of saying that the TCRs are functional, and this can be tested by confirming that the

molecule binds to the relevant TCR ligand (pMHC complex, CD1-antigen complex, superantigen or superantigen/pMHC complex) - if it binds, then the requirement is met. Interactions with pMHC complexes can be measured using a Biacore 3000™ or Biacore 2000™ instrument. WO99/6120 provides detailed descriptions of the methods
5 required to analyse TCR binding to MHC-peptide complexes. These methods are equally applicable to the study of TCR/ CD1 and TCR/superantigen interactions. In order to apply these methods to the study of TCR/CD1 interactions soluble forms of CD1 are required, the production of which are described in (Bauer (1997) Eur J Immunol 27 (6) 1366-1373). In the case of $\gamma\delta$ TCRs of the present invention the
10 cognate ligands for these molecules are unknown therefore secondary means of verifying their conformation such as recognition by antibodies can be employed. The monoclonal antibody MCA991T (available from Serotec), specific for the δ chain variable region, is an example of an antibody appropriate for this task.

15 The scTCRs or dTCRs of the present invention may be displayed on proteinaceous particles, for example phage particles, preferably filamentous phage particles, by, for example, the following two means:

(i) The C-terminus of one member of the dTCR polypeptide pair, or the C-terminus of the scTCR polypeptide, or the C-terminus of a short peptide linker attached to the C-terminus of either, can be directly linked by a peptide bond to a surface exposed
20 residue of the proteinaceous particle. For example, the said surface exposed residue is preferably at the N-terminus of the gene product of bacteriophage gene III or gene VIII; and

25

(ii) The C-terminus of one member of the dTCR polypeptide pair, or the C-terminus of the scTCR polypeptide, or the C-terminus of a short peptide linker attached to the C-terminus of either, is linked by a disulfide bond to a surface exposed cysteine residue of the proteinaceous particle via an introduced cysteine residue. For example, the said
30 surface exposed residue is again preferably at the N-terminus of the gene product of bacteriophage gene III or gene VIII.

Method (i) above is preferred. In the case of a scTCR, nucleic acid encoding the TCR may be fused to nucleic acid encoding the particle forming protein or a surface protein of the replicable particle such as a phage or cell. Alternatively, nucleic acid
5 representing mRNA but without a stop codon, or fused to puromycin RNA may be translated by ribosome such that the TCR remains fused to the ribosome particle. In the case of a dTCR, nucleic acid encoding one chain of the TCR may be fused to nucleic acid encoding the particle forming protein or a cell surface protein of the replicable particle such as a phage or cell, and the second chain of the TCR
10 polypeptide pair may be allowed to associate with the resultant expressed particle displaying the first chain. Proper functional association of the two chains may be assisted by the presence of cysteines in the constant domain of the two chains which are capable of forming an interchain disulfide bond, as more fully discussed below.

15 *The displayed scTCR*

The displayed scTCR polypeptide may be, for example, one which has

a first segment constituted by an amino acid sequence corresponding to a TCR
 α or δ chain variable domain sequence fused to the N terminus of an amino
20 acid sequence corresponding to a TCR α chain constant domain extracellular sequence,

a second segment constituted by an amino acid sequence corresponding to a
TCR β or γ chain variable domain fused to the N terminus of an amino acid
25 sequence corresponding to TCR β chain constant domain extracellular sequence,

a linker sequence linking the C terminus of the first segment to the N terminus of the second segment, or vice versa, and

30 a disulfide bond between the first and second chains, said disulfide bond being one which has no equivalent in native $\alpha\beta$ or $\gamma\delta$ T cell receptors,

the length of the linker sequence and the position of the disulfide bond being such that the variable domain sequences of the first and second segments are mutually orientated substantially as in native $\alpha\beta$ or $\gamma\delta$ T cell receptors.

5

Alternatively, the displayed scTCR may be one which has

a first segment constituted by an amino acid sequence corresponding to a TCR α or δ chain variable domain

10

a second segment constituted by an amino acid sequence corresponding to a TCR β or γ chain variable domain sequence fused to the N terminus of an amino acid sequence corresponding to a TCR β chain constant domain extracellular sequence, and

15

a linker sequence linking the C terminus of the first segment to the N terminus of the second segment,

PROVIDED THAT where the proteinaceous particle is a phage, the scTCR

20

corresponds to a human TCR; or

One which has

a first segment constituted by an amino acid sequence corresponding to a TCR β or γ chain variable domain

25

a second segment constituted by an amino acid sequence corresponding to a TCR α or δ chain variable domain sequence fused to the N terminus of an amino acid sequence corresponding to a TCR α chain constant domain extracellular sequence, and

30

a linker sequence linking the C terminus of the first segment to the N terminus of the second segment

PROVIDED THAT where the proteinaceous particle is a phage, the scTCR
5 corresponds to a human TCR.

The displayed dTCR

The dTCR which is displayed on the proteinaceous particle may be one which is
constituted by

10

a first polypeptide wherein a sequence corresponding to a TCR α or δ chain
variable region sequence is fused to the N terminus of a sequence
corresponding to a TCR α chain constant domain extracellular sequence, and

15

a second polypeptide wherein a sequence corresponding to a TCR β or γ chain
variable domain sequence fused to the N terminus a sequence corresponding to
a TCR β chain constant domain extracellular sequence,

the first and second polypeptides being linked by a disulfide bond which has no
20 equivalent in native $\alpha\beta$ or $\gamma\delta$ T cell receptors.

Preferably, the dTCR is displayed on a filamentous phage particle and is one which is
constituted by

25

a first polypeptide wherein a sequence corresponding to a TCR α chain
variable domain sequence is fused to the N terminus of a sequence
corresponding to a TCR α chain constant domain extracellular sequence, and

a second polypeptide wherein a sequence corresponding to a TCR β chain variable domain sequence is fused to the N terminus a sequence corresponding to a TCR β chain constant domain extracellular sequence,

5 the first and second polypeptides being linked by a disulfide bond between cysteine residues substituted for Thr 48 of exon 1 of TRAC*01 and Ser 57 of exon 1 of TRBC1*01 or TRBC2*01 or the non-human equivalent thereof ,

10 the C-terminus of one member of the dTCR polypeptide pair being linked by a peptide bond to a coat protein of the phage.

dTCR Polypeptide Pair and scTCR Polypeptide

The constant domain extracellular sequences present in the scTCRs or dTCRs preferably correspond to those of a human TCR, as do the variable domain sequences.
15 However, the correspondence between such sequences need not be 1:1 on an amino acid level. N- or C-truncation, and/or amino acid deletion and/or substitution relative to the corresponding human TCR sequences is acceptable. In particular, because the constant domain extracellular sequences present in the first and second segments are not directly involved in contacts with the ligand to which the scTCR or dTCR binds,
20 they may be shorter than, or may contain substitutions or deletions relative to, extracellular constant domain sequences of native TCRs.

The constant domain extracellular sequence present in one of the dTCR polypeptide pair, or in the first segment of a scTCR polypeptide may include a sequence
25 corresponding to the extracellular constant Ig domain of a TCR α chain, and/or the constant domain extracellular sequence present in the other member of the pair or second segment may include a sequence corresponding to the extracellular constant Ig domain of a TCR β chain.

30 In one embodiment of the invention, one member of the dTCR polypeptide pair, or the first segment of the scTCR polypeptide, corresponds to substantially all the variable

domain of a TCR α chain fused to the N terminus of substantially all the extracellular domain of the constant domain of an TCR α chain; and/or the other member of the pair or second segment corresponds to substantially all the variable domain of a TCR β chain fused to the N terminus of substantially all the extracellular domain of the constant domain of a TCR β chain.

In another embodiment, the constant domain extracellular sequences present in the dTCR polypeptide pair, or first and second segments of the scTCR polypeptide, correspond to the constant domains of the α and β chains of a native TCR truncated at their C termini such that the cysteine residues which form the native inter-chain disulfide bond of the TCR are excluded. Alternatively those cysteine residues may be substituted by another amino acid residue such as serine or alanine, so that the native disulfide bond is deleted. In addition, the native TCR β chain contains an unpaired cysteine residue and that residue may be deleted from, or replaced by a non-cysteine residue in, the β sequence of the scTCR of the invention.

In one particular embodiment of the invention, the TCR α and β chain variable domain sequences present in the dTCR polypeptide pair, or first and second segments of the scTCR polypeptide, may together correspond to the functional variable domain of a first TCR, and the TCR α and β chain constant domain extracellular sequences present in the dTCR polypeptide pair or first and second segments of the scTCR polypeptide may correspond to those of a second TCR, the first and second TCRs being from the same species. Thus, the α and β chain variable domain sequences present in dTCR polypeptide pair, or first and second segments of the scTCR polypeptide, may correspond to those of a first human TCR, and the α and β chain constant domain extracellular sequences may correspond to those of a second human TCR. For example, A6 Tax sTCR constant domain extracellular sequences can be used as a framework onto which heterologous α and β variable domains can be fused.

In another embodiment of the invention, the TCR δ and γ chain variable domain sequences present in the dTCR polypeptide pair or first and second segments of the scTCR polypeptide respectively, may together correspond to the functional variable domain of a first TCR, and the TCR α and β chain constant domain extracellular sequences present in the dTCR polypeptide pair or first and second segments of the scTCR polypeptide respectively, may correspond to those of a second TCR, the first and second TCRs being from the same species. Thus the δ and γ chain variable domain sequences present in the dTCR polypeptide pair or first and second segments of the scTCR polypeptide may correspond to those of a first human TCR, and the α and β chain constant domain extracellular sequences may correspond to those of a second human TCR. For example, A6 Tax sTCR constant domain extracellular sequences can be used as a framework onto which heterologous γ and δ variable domains can be fused.

In one particular embodiment of the invention, the TCR α and β , or δ and γ chain variable domain sequences present in the dTCR polypeptide pair or first and second segments of the scTCR polypeptide may together correspond to the functional variable domain of a first human TCR, and the TCR α and β chain constant domain extracellular sequences present in the dTCR polypeptide pair or first and second segments of the scTCR polypeptide may correspond to those of a second non-human TCR. Thus the α and β , or δ and γ chain variable domain sequences present dTCR polypeptide pair or first and second segments of the scTCR polypeptide may correspond to those of a first human TCR, and the α and β chain constant domain extracellular sequences may correspond to those of a second non-human TCR. For example, murine TCR constant domain extracellular sequences can be used as a framework onto which heterologous human α and β TCR variable domains can be fused.

Linker in the scTCR Polypeptide

For scTCR-displaying proteinaceous particles of the present invention, a linker sequence links the first and second TCR segments, to form a single polypeptide strand.

5 The linker sequence may, for example, have the formula -P-AA-P- wherein P is proline and AA represents an amino acid sequence wherein the amino acids are glycine and serine.

10 For the scTCR displayed by proteinaceous particles of the present invention to bind to a ligand, MHC-peptide complex in the case of $\alpha\beta$ TCRs, the first and second segments are paired so that the variable domain sequences thereof are orientated for such binding. Hence the linker should have sufficient length to span the distance between the C terminus of the first segment and the N terminus of the second segment, or vice versa. On the other hand excessive linker length should preferably be avoided, in case
15 the end of the linker at the N-terminal variable domain sequence blocks or reduces bonding of the scTCR to the target ligand.

For example, in the case where the constant domain extracellular sequences present in the first and second segments correspond to the constant domains of the α and β
20 chains of a native TCR truncated at their C termini such that the cysteine residues which form the native interchain disulfide bond of the TCR are excluded, and the linker sequence links the C terminus of the first segment to the N terminus of the second segment.

25 The linker sequence may consist of, for example, from 26 to 41 amino acids, preferably 29, 30, 31 or 32 amino acids, or 33, 34, 35 or 36 amino acids. Particular linkers have the formula -PGGG-(SGGGG)₅-P- and -PGGG-(SGGGG)₆-P- wherein P is proline, G is glycine and S is serine.

30 *Inter-chain Disulfide bond*

A principle characterising feature of the preferred dTCRs and scTCRs displayed by proteinaceous particles of the present invention, is a disulfide bond between the constant domain extracellular sequences of the dTCR polypeptide pair or first and second segments of the scTCR polypeptide. That bond may correspond to the native inter-chain disulfide bond present in native dimeric $\alpha\beta$ TCRs, or may have no counterpart in native TCRs, being between cysteines specifically incorporated into the constant domain extracellular sequences of dTCR polypeptide pair or first and second segments of the scTCR polypeptide. In some cases, both a native and a non-native disulfide bond may be desirable.

10

The position of the disulfide bond is subject to the requirement that the variable domain sequences of dTCR polypeptide pair or first and second segments of the scTCR polypeptide are mutually orientated substantially as in native $\alpha\beta$ or $\gamma\delta$ T cell receptors.

15

The disulfide bond may be formed by mutating non-cysteine residues on the first and second segments to cysteine, and causing the bond to be formed between the mutated residues. Residues whose respective β carbons are approximately 6 Å (0.6 nm) or less, and preferably in the range 3.5 Å (0.35 nm) to 5.9 Å (0.59 nm) apart in the native TCR are preferred, such that a disulfide bond can be formed between cysteine residues introduced in place of the native residues. It is preferred if the disulfide bond is between residues in the constant immunoglobulin domain, although it could be between residues of the membrane proximal domain. Preferred sites where cysteines can be introduced to form the disulfide bond are the following residues in exon 1 of TRAC*01 for the TCR α chain and TRBC1*01 or TRBC2*01 for the TCR β chain:

25

TCR α chain	TCR β chain	Native β carbon separation (nm)
Thr 48	Ser 57	0.473
Thr 45	Ser 77	0.533
Tyr 10	Ser 17	0.359
Thr 45	Asp 59	0.560
Ser 15	Glu 15	0.59

The following motifs in the respective human TCR chains may be used to identify the residue to be mutated (the shaded residue is the residue for mutation to a cysteine).

- 5
 α Chain Thr 48: DSDVYITDKIIVLDMRSMDFK (amino acids 39-58 of exon 1 of the TRAC*01 gene) (**SEQ ID 1**)
- 10
 α Chain Thr 45: QSKDSDVYIIVDKTVLDMRSM(amino acids 36-55 of exon 1 of the TRAC*01 gene) (**SEQ ID 2**)
- α Chain Tyr 10: DIQNPDPAVYIIVQLRDSKSSDK(amino acids 1-20 of exon 1 of the TRAC*01 gene) (**SEQ ID 3**)
- 15
 α Chain Ser 15: DPAVYQLRDSIIVSKSSDKSVCLF(amino acids 6-25 of exon 1 of the TRAC*01 gene) (**SEQ ID 4**)
- β Chain Ser 57: NGKEVHSGVSIIVTDPQPLKEQP(amino acids 48- 67 of exon 1 of the TRBC1*01 & TRBC2*01 genes) (**SEQ ID 5**)
- 20
 β Chain Ser 77: ALNDSRYALSIIVSRLRVSATFW(amino acids 68- 87 of exon 1 of the TRBC1*01 & TRBC2*01 genes) (**SEQ ID 6**)
- β Chain Ser 17: PPEVAVFEPSEIIVAEISHTQKA(amino acids 8- 27 of exon 1 of the TRBC1*01 & TRBC2*01 genes) (**SEQ ID 7**)
- 25

β Chain Asp 59: KEVHSGVSTDPQPLKEQPAL(amino acids 50- 69 of exon 1
of the TRBC1*01 & TRBC2*01 genes) (SEQ ID 8)

5 β Chain Glu 15: VFPPEVAVFEPSEAEISHTQ(amino acids 6- 25 of exon 1 of
the TRBC1*01 & TRBC2*01 genes) (SEQ ID 9)

In other species, the TCR chains may not have a region which has 100% identity to the
above motifs. However, those of skill in the art will be able to use the above motifs to
identify the equivalent part of the TCR α or β chain and hence the residue to be
10 mutated to cysteine. Alignment techniques may be used in this respect. For example,
ClustalW, available on the European Bioinformatics Institute website
(<http://www.ebi.ac.uk/index.html>) can be used to compare the motifs above to a
particular TCR chain sequence in order to locate the relevant part of the TCR sequence
for mutation.

15 The present invention includes within its scope proteinaceous particle-displayed αβ
and γδ-analogue scTCRs, as well as those of other mammals, including, but not
limited to, mouse, rat, pig, goat and sheep. As mentioned above, those of skill in the
art will be able to determine sites equivalent to the above-described human sites at
20 which cysteine residues can be introduced to form an inter-chain disulfide bond. For
example, the following shows the amino acid sequences of the mouse Cα and Cβ
soluble domains, together with motifs showing the murine residues equivalent to the
human residues mentioned above that can be mutated to cysteines to form a TCR
interchain disulfide bond (where the relevant residues are shaded):

25 Mouse Cα soluble domain:
PYIQNPEPAVYQLK DPRSQDSTLCLFTDFDSQINVPKTMESGTFITDKTVLDMK
AMDSKSN GAIAWSNQT SFTCQDIFKETNATYPSSDVP (SEQ ID 10)

30 Mouse Cβ soluble domain:

EDLRNVTPPKVSLFEPKAEIANKQKATLVCLARGFFPDHVELSWVWNGREV
 HSGVSTDPQAYKESNYSYCLSSRLRVSATFWHNPRNHFRCQVQFHGLSEEDK
 WPEGSPKPVTQNISAEAWGRAD (SEQ ID 11)

- 5 Murine equivalent of human α Chain Thr 48: ESGTFITDKT¹VLDMKAMDSK
 (SEQ ID 12)
- Murine equivalent of human α Chain Thr 45: KTMESGTFIT¹DKTVLDMKAM
 (SEQ ID 13)
- Murine equivalent of human α Chain Tyr 10: YIQNPEPAV¹YQLKDPRSQDS
 10 (SEQ ID 14)
- Murine equivalent of human α Chain Ser 15: AVYQLKDPRS¹QDSTLCLFTD
 (SEQ ID 15)
- Murine equivalent of human β Chain Ser 57: NGREVHSGV¹STDPQAYKESN
 (SEQ ID 16)
- 15 Murine equivalent of human β Chain Ser 77: KESNYSYCL¹SSRLRVSATFW
 (SEQ ID 17)
- Murine equivalent of human β Chain Ser 17: PPKVSLFEP¹SKAEIANKQKA
 (SEQ ID 18)
- Murine equivalent of human β Chain Asp 59: REVHSGV¹STDPQAYKESNYS
 20 (SEQ ID 19)
- Murine equivalent of human β Chain Glu 15: VTPPKVSLF¹EPKAEIANKQ
 (SEQ ID 20)

As discussed above, the A6 Tax sTCR extracellular constant domains can be used as
 25 framework onto which heterologous variable domains can be fused. It is preferred that
 the heterologous variable domain sequences are linked to the constant domain
 sequences at any point between the disulfide bond and the N termini of the constant
 domain sequences. In the case of the A6 Tax TCR α and β constant domain
 sequences, the disulfide bond may be formed between cysteine residues introduced at
 30 amino acid residues 158 and 172 respectively. Therefore it is preferred if the

heterologous α and β chain variable domain sequence attachment points are between residues 159 or 173 and the N terminus of the α or β constant domain sequences respectively.

5 *TCR Display.*

The preferred *in-vivo* TCR display method for biopanning to identify TCRs having desirable properties such as high affinity for a target peptide-MHC complex is phage display.

10 Firstly, a DNA library is constructed that encodes a diverse array of mutated scTCRs or dTCRs. This library is constructed by using DNA encoding a native TCR as the template for amplification. There are a number of suitable methods, known to those skilled in the art, for the introduction of the desired mutations into the TCR DNA, and hence the finally expressed TCR protein. For example error-prone PCR (EP-TCR),
15 DNA shuffling techniques, and the use of bacterial mutator strains such as XL-1-Red are convenient means of introducing mutations into the TCR sequences. It is particularly preferred if these mutations are introduced into defined domain of the TCRs. For example, mutations in the variable domain, particularly the complementarity-determining regions (CDRs) and/or framework regions are likely to
20 be the most appropriate sites for the introduction of mutations leading to the production of a diverse library of TCRs for the production of TCRs with enhanced ligand-binding properties. EP-PCR is an example of a method by which such 'region-specific' mutations can be introduced into the TCRs. EP-PCR primers are used that are complementary to DNA sequences bordering the region to be mutated to amplify
25 multiple copies of this region of the TCR DNA that contain a controllable level of random mutations. These DNA sequences encoding mutated regions are inserted into the DNA sequences, which encode the non-mutagenised sections of the TCR, by ligation or overlapping PCR. The DNA encoding the TCR with mutated region can then be ligated onto DNA encoding a heterologous polypeptide in order to produce a
30 fusion protein suitable for display. In the case of phage-display the expression vector utilised is either a phagemid or a phage genome vector in which the TCR DNA can be

ligated to DNA encoding a surface protein, preferably the gIII or gVIII surface protein. In the case of a scTCR such ligation is performed as for phage display of any monomeric peptide or polypeptide. In the case of dTCRs, only one of the TCR chains is ligated as aforesaid. The other chain is encoded in nucleic acid for co-expression
5 with phagemid and helper phage nucleic acid, so that the expressed second chain finds and associates with the expressed phage with surface displayed first chain. In both cases, as discussed in more detail above, properly positioned cysteines in the constant domains are helpful in causing the variable domains of the TCR to adopt their functional positions, through the formation of a disulfide bond by those cysteines.

10

For expression, an expression vector comprising (a) nucleic acid encoding one chain of a dTCR polypeptide pair, and (b) the other chain of a dTCR polypeptide pair fused to a nucleic acid sequence encoding a particle forming protein, or a cell surface protein; or nucleic acid encoding a scTCR polypeptide fused to a nucleic acid
15 sequence encoding a particle forming protein or a cell surface protein, the dTCR pair, or a composition comprising a first vector comprising nucleic acid (a) and a second vector comprising nucleic acid (b), are contacted with host cells capable of causing the expression of the encoded genetic material under conditions suitable to allow the transformation of said cells. Such expression vectors, expression systems comprising
20 phagemid or phage genome vectors encoding dTCRs and scTCRs, and host cells harbouring them form additional aspects of the current invention. In a preferred embodiment of the invention the phagemid or phage genome vectors are derived from filamentous phage.

25

The transformed cells are then incubated to allow the expression of the TCR-
displaying proteinaceous particles. These particles can then be used for screening or in assays to identify TCR variants with specific enhanced characteristics. Any particles that possess the enhanced characteristics under investigation can then be isolated. The DNA encoding these TCRs can then be amplified by PCR and the sequence
30 determined.

It is known that high expression levels of an exogenous polypeptide may be toxic to the host cell. In such cases, either a host strain which is more tolerant of the exogenous polypeptide must be found, or the expression levels in the host cell must be limited to a level which is tolerated. For example (Beekwilder *et al.*, (1999) Gene 228 (1-2) 23-31) report that only mutated forms of a potato protease inhibitor (PI2) which contained deletions or amber stop codons would be successfully selected from a phage display library. In the present case, an observation in the course of the work reported in the Examples herein suggests that it may be desirable to limit the expression levels of protein particle-displayed TCRs of the invention, at least in some strains of *E. coli*. Thus, the A6 TCR selected in Example 4 after repeated rounds of culture was shown to be derived from cells in which the phagemid had mutated relative to that introduced at the start. The mutation had created an 'opal' stop codon in the TCR β chain. This codon is 'read-through' with low frequency by ribosomes of the *E. coli* strain utilised resulting in the insertion of a tryptophan residue at this site and a much reduced overall level of full-length β chain expression.

There are several strategies for limiting the expression levels of an exogenous polypeptide from a given expression-veeter system in a host which may be suitable for the limiting the expression levels of a scTCR, or one, or both TCR chains of a dTCR . For example:

Use of a weak promoter sequence – The level of expression obtained for a given gene product, such as the TCR α or β chain, can be tailored by using promoter sequences of varying strengths. The lambda phage P_{RM} promoter is an example of a weak promoter.

Mutated ribosome binding sites (RBS's) – Mutating a single nucleic acid in the RBS associated with a gene product, such as the TCR α or β chain, can result in a reduced level of expression. For example, mutating a wild-type AGGA sequence to AGGG.

Mutated 'start codons' - Mutating a single nucleic acid in the start codon associated with a gene product, such as the TCR α or β chain, can also result in a reduced level of expression. For example, mutating a wild-type AUG start codon to GUG.

5 Miss-sense suppressor mutations – These are inserted within the TCR β chain coding regions. Examples include the 'opal' stop codon (UGA), this 'leaky' stop codon results in the low frequency insertion of a tryptophan amino acid and read-through of the rest of the coding sequence.

10 Metabolite-mediated modification of promoter strength – The level of expression of a gene product, such as the TCR α or β chain, under the control of certain promoters can be down-regulated by the addition of a relevant metabolite to the cells containing the promoter. For example, glucose additions can be used to down-regulate expression of a gene product under the control of a Lac promoter.

15 Codon usage - Bacterial cells and, for example, mammalian cells have different 'preferences' relating to the codons they use to encode certain amino acids. For example, bacterial cells most commonly use the CGU codon to encode arginine whereas eucaryotic cells most commonly use AGA. It is possible to reduce the level
20 of expression of a gene product, such as the TCR α or β chain, by utilising DNA sequences that contain a number of codons less preferred by the expression system being utilised.

25 Details relating to the above means of down-regulating gene product expression can be found in (Glass (1982) Gene Function – *E.coli* and its heritable elements, Croom Helm) and (Rezinoff (1980) The Operon 2nd Edition, Cold Spring Harbor Laboratory).

30 It is also known that supplying bacterial cultures with a relatively high concentration of a sugar such as sucrose can increase periplasmic expression levels of soluble proteins. (See for example (Sawyer *et al.*, (1994) Protein Engineering 7 (11) 1401-1406))

After expression, correct pairing of the scTCR polypeptide variable domain sequences is preferably assisted by the introduction of a disulfide bond in the extracellular constant domain of the scTCR. Without wanting to be limited by theory, the novel disulfide bond is believed to provide extra stability to the scTCR during the folding process and thereby facilitating correct pairing of the first and second segments.

Also as mentioned above, for dTCR phage display, one of the dTCR polypeptide pair is expressed as if it were eventually to be displayed as a monomeric polypeptide on the phage, and the other of the dTCR polypeptide pair is co-expressed in the same host cell. As the phage particle self assembles, the two polypeptides self associate for display as a dimer on the phage. Again, in the preferred embodiment of this aspect of the invention, correct folding during association of the polypeptide pair is assisted by a disulfide bond between the constant sequences, as discussed above. Further details of a procedure for phage display of a dTCR having an interchain disulfide bond appear in the Examples herein.

As an alternative, the phage displaying the first chain of the dTCR may be expressed first, and the second chain polypeptide may be contacted with the expressed phage in a subsequent step, for association as a functional dTCR on the phage surface.

The preferred *in-vitro* TCR display method for biopanning to identify TCRs having desirable properties such as high affinity for a target peptide-MHC complex is ribosomal display. Firstly, a DNA library is constructed that encodes a diverse array of mutated scTCRs or dTCR polypeptides using the techniques discussed above. The DNA library is then contacted with RNA polymerase in order to produce a complementary mRNA library. Optionally, for mRNA display techniques the mRNA sequences can then be ligated to a DNA sequence comprising a puromycin binding site. These genetic constructs are then contacted with ribosomes *in-vitro* under conditions allowing the translation of the scTCR polypeptide or the first polypeptide of the dTCR pair. In the case of the dTCR, the second of the polypeptide pairs is separately expressed and contacted with the ribosome-displayed first polypeptide, for

association between the two, preferably assisted by the formation of the disulphide bond between constant domains. Alternatively, mRNA encoding both chains of the TCR may be contacted with ribosomes in-vitro under conditions allowing the translation of the TCR chains such that a ribosome displaying a dTCR is formed.

5 These scTCR- or dTCR-displaying ribosomes can then used for screening or in assays to identify TCR variants with specific enhanced characteristics. Any particles that possess the enhanced characteristics under investigation can then be isolated. The mRNA encoding these TCRs can then converted to the complementary DNA sequences using reverse transcriptase. This DNA can then be amplified by PCR and
10 the sequence determined.

Additional Aspects

A proteinaceous particle displaying a scTCR or dTCR (which preferably is constituted by constant and variable sequences corresponding to human sequences) of the present
15 invention may be provided in substantially pure form, or as a purified or isolated preparation. For example, it may be provided in a form which is substantially free of other proteins.

A phage particle displaying a plurality of scTCRs or dTCRs of the present invention
20 may be provided in a multivalent complex. Thus, the present invention provides, in one aspect, a multivalent T cell receptor (TCR) complex, which comprises a phage particle displaying a plurality of scTCRs or dTCRs as described herein. Each of the plurality of said scTCRs or dTCRs is preferably identical.

25 In a further aspect, the invention provides a method for detecting TCR ligand complexes, which comprises:

- a. providing a TCR-displaying proteinaceous particle of the current invention
- b. contacting the TCR-displaying phage with the putative ligand
30 complexes; and

detecting binding of the TCR-displaying proteinaceous particle to the putative ligand complexes.

5 TCR ligands suitable for identification by the above method include, but are not limited to, peptide-MHC complexes.

Isolation of TCR variants with enhanced characteristics

10 A further aspect of the invention is a method for the identification of TCRs with a specific characteristic, said method comprising subjecting a diverse library of TCRs displayed on proteinaceous particles to a selection process which selects for said characteristic, and isolating proteinaceous particles which display a TCR having said characteristic, and optionally to an amplification process to multiply the isolated particles, and/or a screening process which measures said characteristic, identifying those proteinaceous particles which display a TCR with the desired characteristic and
15 isolating these proteinaceous particles, and optionally to an amplification process to multiply the isolated particles.

The DNA sequences encoding the variant TCRs can then be obtained and amplified by PCR to allow the sequences to be determined. The characteristics that can be
20 enhanced include, but are not limited to, ligand binding affinity and construct stability.

Screening Use

25 The TCR-displaying proteinaceous particles of the present invention are capable of utilisation in screening methods designed to identify modulators, including inhibitors, of the TCR-mediated cellular immune synapse.

As is known to those skilled in the art there are a number of assay formats that provide a suitable basis for protein-protein interaction screens of this type.

30 Amplified Luminescent Proximity Homogeneous Assay systems such as the AlphaScreen™, rely on the use of "Donor" and "Acceptor" beads that are coated with

a layer of hydrogel to which receptor and ligand proteins can be attached. The interaction between these receptor and ligand molecules brings the beads into proximity. When these beads are subject to laser light a photosensitizer in the "Donor" bead converts ambient oxygen to a more excited singlet state. The singlet state oxygen molecules diffuse across to react with a chemiluminescer in the "Acceptor" bead that further activates fluorophores contained within the same bead. The fluorophores subsequently emit light at 520-620 nm, this signals that the receptor-ligand interaction has occurred. The presence of an inhibitor of the receptor-ligand interaction causes this signal to be diminished.

10

Surface Plasmon Resonance (SPR) is an interfacial optical assay, in which one binding partner (normally the receptor) is immobilised on a 'chip' (the sensor surface) and the binding of the other binding partner (normally the ligand), which is soluble and is caused to flow over the chip, is detected. The binding of the ligand results in an increase in concentration of protein near to the chip surface which causes a change in the refractive index in that region. The surface of the chip is comprised such that the change in refractive index may be detected by surface plasmon resonance, an optical phenomenon whereby light at a certain angle of incidence on a thin metal film produces a reflected beam of reduced intensity due to the resonant excitation of waves of oscillating surface charge density (surface plasmons). The resonance is very sensitive to changes in the refractive index on the far side of the metal film, and it is this signal which is used to detect binding between the immobilised and soluble proteins. Systems which allow convenient use of SPR detection of molecular interactions, and data analysis, are commercially available. Examples are the Iasys™ machines (Fisons) and the Biacore™ machines.

15

20

25

Other interfacial optical assays include total internal reflectance fluorescence (TIRF), resonant mirror (RM) and optical grating coupler sensor (GCS), and are discussed in more detail in Woodbury and Venton (*J. Chromatog. B.* **725** 113-137 (1999)).

30

The scintillation proximity assay (SPA) has been used to screen compound libraries for inhibitors of the low affinity interaction between CD28 and B7 (K_d probably in the

region of 4 μM (Van der Merwe *et al* J. Exp. Med. **185**:393-403 (1997), Jenh *et al*,
Anal Biochem **165**(2) 287-93 (1998)). SPA is a radioactive assay making use of beta
particle emission from certain radioactive isotopes which transfers energy to a
scintillant immobilised on the indicator surface. The short range of the beta particles
5 in solution ensures that scintillation only occurs when the beta particles are emitted in
close proximity to the scintillant. When applied for the detection of protein-protein
interactions, one interaction partner is labelled with the radioisotope, while the other is
either bound to beads containing scintillant or coated on a surface together with
scintillant. If the assay can be set up optimally, the radioisotope will be brought close
10 enough to the scintillant for photon emission to be activated only when binding
between the two proteins occurs.

A further aspect of the invention is a method of identifying an inhibitor of the
interaction between a TCR-displaying proteinaceous particle of the invention, and a
15 TCR-binding ligand comprising contacting the TCR-displaying proteinaceous particle
with a TCR-binding ligand, in the presence of and in the absence of a test compound,
and determining whether the presence of the test compound reduces binding of the
TCR-displaying proteinaceous particle to the TCR-binding ligand, such reduction
being taken as identifying an inhibitor.

20 A further aspect of the invention is a method of identifying a potential inhibitor of the
interaction between an TCR-displaying proteinaceous particle of the invention, and a
TCR-binding ligand, for example a MHC-peptide complex, comprising contacting the
TCR-displaying proteinaceous particle or TCR-binding ligand partner with a test
25 compound and determining whether the test compound binds to the TCR-displaying
proteinaceous particle and/or the TCR-binding ligand, such binding being taken as
identifying a potential inhibitor. This aspect of the invention may find particular utility
in interfacial optical assays such as those carried out using the Biacore™ system.

High Affinity TCRs

The present invention also makes available mutated TCRs specific for a given TCR ligand with higher affinity for said TCR ligand than the wild-type TCR. These high affinity TCRs are expected to be particularly useful for the diagnosis and treatment of disease.

As used herein the term 'high affinity TCR' refers to a mutated scTCR or dTCR which interacts with a specific TCR ligand and either: has a K_d for the said TCR ligand less than that of a corresponding native TCR as measured by Surface Plasmon Resonance, or has an off-rate (k_{off}) for the said TCR ligand less than that of a corresponding native TCR as measured by Surface Plasmon Resonance.

High affinity scTCRs or dTCRs of the present invention are preferably mutated relative to the native TCR in at least one complementarity determining region and/or framework regions.

In one aspect of the present invention the TCR ligand for which a given high affinity TCR is specific is a peptide-MHC complex (pMHC).

In another aspect of the present invention the TCR ligand for which a given high affinity TCR is specific is an MHC type or types.

In a further aspect of the present invention the TCR ligand for which a given high affinity TCR is specific is the HLA-A2 tax peptide (LLFGYPVYV) (SEQ ID 21) complex.

In a further aspect of the present invention the TCR ligand for which a given high affinity TCR is specific is the HLA-A2 NY-ESO peptide (SLLMITQC) (SEQ ID 22) complex.

30

A high affinity scTCR or one or both of the high affinity dTCR chains may be labelled with an imaging compound, for example a label that is suitable for diagnostic purposes. Such labelled high affinity TCRs are useful in a method for detecting a TCR ligand selected from CD1-antigen complexes, bacterial superantigens, and MHC-peptide/superantigen complexes which method comprises contacting the TCR ligand with a high affinity TCR (or a multimeric high affinity TCR complex) which is specific for the TCR ligand; and detecting binding to the TCR ligand. In tetrameric high affinity TCR complexes (formed, for example) using biotinylated heterodimers) fluorescent streptavidin (commercially available) can be used to provide a detectable label. A fluorescently-labelled tetramer is suitable for use in FACS analysis, for example to detect antigen presenting cells carrying the peptide for which the high affinity TCR is specific.

Another manner in which the soluble high affinity TCRs of the present invention may be detected is by the use of TCR-specific antibodies, in particular monoclonal antibodies. There are many commercially available anti-TCR antibodies, such as α F1 and β F1, which recognise the constant domains of the α and β chains, respectively.

A high affinity TCR (or multivalent complex thereof) of the present invention may alternatively or additionally be associated with (e.g. covalently or otherwise linked to) a therapeutic agent which may be, for example, a toxic moiety for use in cell killing, or an immunostimulating agent such as an interleukin or a cytokine. A multivalent high affinity TCR complex of the present invention may have enhanced binding capability for a TCR ligand compared to a non-multimeric wild-type or high affinity T cell receptor heterodimer. Thus, the multivalent high affinity TCR complexes according to the invention are particularly useful for tracking or targeting cells presenting particular antigens *in vitro* or *in vivo*, and are also useful as intermediates for the production of further multivalent high affinity TCR complexes having such uses. The high affinity TCR or multivalent high affinity TCR complex may therefore be provided in a pharmaceutically acceptable formulation for use *in vivo*.

The invention also provides a method for delivering a therapeutic agent to a target cell, which method comprises contacting potential target cells with a high affinity TCR or multivalent high affinity TCR complex in accordance with the invention under conditions to allow attachment of the high affinity TCR or multivalent high affinity TCR complex to the target cell, said high affinity TCR or multivalent high affinity TCR complex being specific for the TCR ligand and having the therapeutic agent associated therewith.

In particular, the soluble high affinity TCR or multivalent high affinity TCR complex can be used to deliver therapeutic agents to the location of cells presenting a particular antigen. This would be useful in many situations and, in particular, against tumours. A therapeutic agent could be delivered such that it would exercise its effect locally but not only on the cell it binds to. Thus, one particular strategy envisages anti-tumour molecules linked to high affinity T cell receptors or multivalent high affinity TCR complexes specific for tumour antigens.

Many therapeutic agents could be employed for this use, for instance radioactive compounds, enzymes (perforin for example) or chemotherapeutic agents (cis-platin for example). To ensure that toxic effects are exercised in the desired location the toxin could be inside a liposome linked to streptavidin so that the compound is released slowly. This will prevent damaging effects during the transport in the body and ensure that the toxin has maximum effect after binding of the TCR to the relevant antigen presenting cells.

Other suitable therapeutic agents include:

- small molecule cytotoxic agents, i.e. compounds with the ability to kill mammalian cells having a molecular weight of less than 700 daltons. Such compounds could also contain toxic metals capable of having a cytotoxic effect. Furthermore, it is to be understood that these small molecule cytotoxic agents also include pro-drugs, i.e. compounds that decay or are converted under physiological conditions to release cytotoxic agents. Examples of such agents include cis-platin,

maytansine derivatives, rachelmycin, calicheamicin, docetaxel, etoposide, gemcitabine, ifosfamide, irinotecan, melphalan, mitoxantrone, sorfimer sodiumphotofrin II, temozolmide, topotecan, trimetreate glucuronate, auristatin E vincristine and doxorubicin;

- 5
- peptide cytotoxins, i.e. proteins or fragments thereof with the ability to kill mammalian cells. Examples include ricin, diphtheria toxin, pseudomonas bacterial exotoxin A, DNAase and RNAase;
 - radio-nuclides, i.e. unstable isotopes of elements which decay with the concurrent emission of one or more of α or β particles, or γ rays. Examples
- 10 include iodine 131, rhenium 186, indium 111, yttrium 90, bismuth 210 and 213, actinium 225 and astatine 213; chelating agents may be used to facilitate the association of these radio-nuclides to the high affinity TCRs, or multimers thereof;
- prodrugs, such as antibody directed enzyme pro-drugs;
 - immuno-stimulants, i.e. moieties which stimulate immune response. Examples
- 15 include cytokines such as IL-2, chemokines such as IL-8, platelet factor 4, melanoma growth stimulatory protein, etc, antibodies or fragments thereof, complement activators, xenogeneic protein domains, allogeneic protein domains, viral/bacterial protein domains and viral/bacterial peptides.

20 Soluble high affinity TCRs or multivalent high affinity TCR complexes of the invention may be linked to an enzyme capable of converting a prodrug to a drug. This allows the prodrug to be converted to the drug only at the site where it is required (i.e. targeted by the sTCR).

25 A multitude of disease treatments can potentially be enhanced by localising the drug through the specificity of soluble high affinity TCRs. For example, it is expected that the high affinity HLA-A2-tax (LLFGYPVYV) (SEQ ID 21) specific A6 TCRs disclosed herein may be used in methods for the diagnosis and treatment of HTLV-1 and that the high affinity HLA-A2-NY-ESO (SLLMITQC) (SEQ ID 22) specific NY-

30 ESO TCR disclosed herein may be used in methods for the diagnosis and treatment of cancer.

Viral diseases for which drugs exist, e.g. HIV, SIV, EBV, CMV, would benefit from the drug being released or activated in the near vicinity of infected cells. For cancer, the localisation in the vicinity of tumours or metastasis would enhance the effect of toxins or immunostimulants. In autoimmune diseases, immunosuppressive drugs
5 could be released slowly, having more local effect over a longer time-span while minimally affecting the overall immuno-capacity of the subject. In the prevention of graft rejection, the effect of immunosuppressive drugs could be optimised in the same way. For vaccine delivery, the vaccine antigen could be localised in the vicinity of antigen presenting cells, thus enhancing the efficacy of the antigen. The method can
10 also be applied for imaging purposes.

The soluble high affinity TCRs of the present invention may be used to modulate T cell activation by binding to specific TCR ligand and thereby inhibiting T cell activation. Autoimmune diseases involving T cell-mediated inflammation and/or tissue damage
15 would be amenable to this approach, for example type I diabetes. Knowledge of the specific peptide epitope presented by the relevant pMHC is required for this use.

Therapeutic or imaging high affinity TCRs in accordance with the invention will usually be supplied as part of a sterile, pharmaceutical composition which will normally include
20 a pharmaceutically acceptable carrier. This pharmaceutical composition may be in any suitable form, (depending upon the desired method of administering it to a patient). It may be provided in unit dosage form, will generally be provided in a sealed container and may be provided as part of a kit. Such a kit would normally (although not necessarily) include instructions for use. It may include a plurality of said unit dosage forms.

25 The pharmaceutical composition may be adapted for administration by any appropriate route, for example parenteral, transdermal or via inhalation, preferably a parenteral (including subcutaneous, intramuscular, or, most preferably intravenous) route. Such compositions may be prepared by any method known in the art of pharmacy, for example
30 by admixing the active ingredient with the carrier(s) or excipient(s) under sterile conditions.

Dosages of the substances of the present invention can vary between wide limits, depending upon the disease or disorder to be treated, the age and condition of the individual to be treated, etc. and a physician will ultimately determine appropriate dosages to be used.

The invention also provides a method for obtaining a high affinity TCR chain, which method comprises incubating such a host cell under conditions causing expression of the high affinity TCR chain and then purifying the polypeptide.

Preferred features of each aspect of the invention are as for each of the other aspects *mutatis mutandis*. The prior art documents mentioned herein are incorporated to the fullest extent permitted by law.

15 **Examples**

The invention is further described in the following examples, which do not limit the scope of the invention in any way.

Reference is made in the following to the accompanying drawings in which:

20 Figures 1a and 1b show respectively the nucleic acid sequences of a soluble A6 TCR α and β chains, mutated so as to introduce a cysteine codon. The shading indicates the introduced cysteine codons.

25 Figure 2a shows the A6 TCR α chain extracellular amino acid sequence, including the T₄₈ → C mutation (underlined) used to produce the novel disulphide inter-chain bond, and Figure 2b shows the A6 TCR β chain extracellular amino acid sequence, including the S₅₇ → C mutation (underlined) used to produce the novel disulphide inter-chain bond.

30

Figure 3 Outlines the cloning of TCR α and β chains into phagemid vectors. The diagram describes a phage display vector. RSB is the ribosome-binding site. S1 or S2 are signal peptides for secretion of proteins into periplasm of *E. coli*. The * indicates translation stop codon. Either of the TCR α chain or β chain can be fused to phage coat protein, however in this diagram only TCR β chain is fused to phage coat protein.

Figure 4 details the DNA sequence of phagemid pEX746:A6.

Figure 5 expression of phage particle fusions of bacterial coat protein and heterodimeric A6 TCR in *E. coli*. Fusion proteins of heterodimeric A6 TCR::gIII are detected using western blotting. Phage particles are prepared from *E. coli* XL-1-Blue and concentrated with PEG/NaCl. The samples are loaded in reducing or non-reducing sample buffers. Lane 1 is the sample of clone 7 containing correct sequence, and lane 2 is the sample of clone 14 containing a deletion in the α -chain encoding gene. The heterodimeric A6 TCR:gIII fusion protein was detected at 125kDa.

Figure 6 illustrates ELISA detection of pMHC peptide complex binding activity of a heterodimeric A6 TCR displayed on phage. Clone 7 binds specifically to HLA A2-Tax complex. Clone 14 cannot bind to any pMHC, as no TCR is attached to the phage particles.

Figure 7a schematic illustration of the single-chain A6 TCR-C-Kappa DNA ribosome display construct.

Figures 7b and 7c detail the complete DNA coding strand and amino acid sequence of the single-chain A6 TCR-C-Kappa DNA ribosome display construct encoded in pUC19 respectively.

Figure 8 details the DNA sequence of pUC19-T7.

Figure 9 details the DNA sequence of the single-chain A6 TCR-C-Kappa ribosome display construct that was cloned into pUC19-T7.

5 Figure 10 Western blot showing the detection of in-vitro translated single-chain A6 TCR-C-Kappa using Ambion rabbit reticulocyte lysates.

Figure 11 RT-PCR of the single-chain A6 TCR-C-Kappa mRNA on beads rescued from the ribosome display reactions.

10 Figure 12a details the DNA sequence of the A6 TCR Clone 9 mutated β chain; the mutated nucleic acid is indicated in bold.

Figure 12b details the amino acid sequence of the A6 TCR Clone 9 mutated β chain, the position corresponding to the introduced opal stop codon is indicated with an *.

15 Figure 13 details the DNA sequence of the A6 TCR Clone 49 mutated β chain; the mutated nucleic acid is indicated in bold. As this is a 'silent' mutation no change is introduced into the resulting amino acid sequence by this mutation.

20 Figure 14a details the DNA sequence of the A6 TCR Clone 134 mutated A6 TCR β chain; the mutated nucleic acids are indicated in bold.

25 Figure 14b details the amino acid sequence of the A6 TCR Clone 134 mutated A6 TCR β chain as tested by BIAcore assay; the mutated amino acids are indicated in bold.

Figure 14c details the amino acid sequence of the A6 TCR Clone 134 mutated A6 TCR β chain as tested by phage ELISA assay; the mutated amino acids are indicated in bold.

30 Figure 15 BIAcore data for the binding of A6 TCR clone 134 to HLA-A2 Tax and HLA-A2 NY-ESO

Figure 16 BIAcore data used to determine T_{OFF} for the binding of A6 TCR clone 134 to HLA-A2 Tax

5 Figures 17a and 17b show the DNA sequence of the mutated α and β chains of the NY-ESO TCR respectively

Figures 18a and 18b show the amino acid sequences of the mutated α and β chains of the NY-ESO TCR respectively

10 Figures 19a and 19b detail the DNA and amino acid sequence of the NY-ESO TCR β chain incorporated into the pEX746:NY-ESO phagemid respectively.

Figure 20 shows the specific binding of phage particles displaying the NY-ESO TCR to HLA-A2-NY-ESO in a phage ELISA assay.

15

Figure 21 shows the DNA sequence of the DR1 α chain incorporating codons encoding the Fos dimerisation peptide attached to the 3' end of the DRA0101 sequence. Shading indicates the Fos codons and the biotinylation tag codons are indicated by in bold text.

20 Figure 22 shows the DNA sequence of the pAcAB3 bi-cistronic vector used for the expression of Class II HLA-peptide complexes in Sf9 insect cells. The Bgl II restriction site (AGATCT) used to insert the HLA α chain and the BamHI restriction site (GGATCC) used to insert the HLA β chain are indicated by shading.

25 Figure 23 shows the DNA sequence of the DR1 β chain incorporating codons encoding the Jun dimerisation peptide attached to the 3' end of the DRB0401 sequence and codons encoding an HLA-loaded peptide attached to the 5' end of the DRB0401 sequence. Shading indicates the Jun codons, and the HLA-loaded Flu HA peptide codons are underlined.

30

Figure 24 shows a BIAcore trace of the binding of the high affinity A6 TCR clone 134 to flowcells coated as follows:

Flow-cell 1 (FC 1) - Blank

Flow-cell 2 (FC 2) - HLA-A2 (LLGRNSFEV) (SEQ ID 23)

Flow-cell 3 (FC 3) - HLA-A2 (KLVALGINAV) (SEQ ID 24)

Flow-cell 4 (FC 4) - HLA-A2 (LLGDLEFGV) (SEQ ID 25)

5

Figure 25 shows a BIAcore trace of the binding of the high affinity A6 TCR clone 134 to flowcells coated as follows:

Flow-cell 1 (FC 1) - Blank

Flow-cell 2 (FC 2) - HLA-B8 (FLRGRAYGL) (SEQ ID 26)

10 Flow-cell 3 (FC 3) - HLA-B27 (HRCQAIRKK) (SEQ ID 27)

Flow-cell 4 (FC 4) - HLA- Cw6 (YRSGIIAVV) (SEQ ID 28)

Figure 26 shows a BIAcore trace of the binding of the high affinity A6 TCR clone 134 to flowcells coated as follows:

15 Flow-cell 1 (FC 1) – Blank

Flow-cell 2 (FC 2) – HLA-A24 (VYGFVRACL) (SEQ ID 29)

Flow-cell 3 (FC 3) - HLA-A2 (ILAKFLHWL) (SEQ ID 30)

Flow-cell 4 (FC 4) - HLA-A2 (LTLGEFLKL) (SEQ ID 31)

20 Figure 27 shows a BIAcore trace of the binding of the high affinity A6 TCR clone 134 to flowcells coated as follows:

Flow-cell 1 (FC 1) – Blank

Flow-cell 2 (FC 2) – HLA-DR1 (PKYVKQNTLKLA) (SEQ ID 32)

Flow-cell 3 (FC 3) -HLA-A2 (GILGFVFTL) (SEQ ID 33)

25 Flow-cell 4 (FC 4) - HLA-A2 (SLYNTVATL) (SEQ ID 34)

Figure 28 shows a BIAcore trace of the binding of the high affinity A6 TCR clone 134 to flowcells coated as follows:

Flow-cell 1 (FC 1) – Blank

30 Flow-cell 4 (FC 4) - HLA-A2 (LLFGYPVYV) (SEQ ID 21)

Figures 29a and 29b show Biacore plots of the interaction between the soluble high affinity NY-ESO TCR and HLA-A2 NY-ESO.

5 Figures 30a and 30b show Biacore plots of the interaction between the soluble “wild-type” NY-ESO TCR and HLA-A2 NY-ESO.

Figures 31a and 31b show Biacore plots of the interaction between a mutant soluble A6 TCR (Clone 1) and HLA-A2 Tax.

10 Figures 32a and 32b show Biacore plots of the interaction between a mutant soluble A6 TCR (Clone 111) and HLA-A2 Tax.

Figures 33a and 33b show Biacore plots of the interaction between a mutant soluble A6 TCR (Clone 89) and HLA-A2 Tax.

15

Figure 34 shows a Biacore plot of the interaction between a mutant soluble A6 TCR (containing Clone 71 and Clone 134 mutations) and HLA-A2 Tax.

20 Figure 35 shows a Biacore plot of the interaction between a mutant soluble A6 TCR (containing Clone 1 and β G102→A mutations) and HLA-A2 Tax.

Figure 36a to 36c show Biacore plots of the interaction between a mutant soluble A6 TCR (containing Clone 89 and Clone 134 mutations) and HLA-A2 Tax.

25 Figure 37a and 37b show Biacore plots of the interaction between a mutant soluble A6 TCR (containing Clone 71 and Clone 89 mutations) and HLA-A2 Tax.

Figure 38 details the β chain variable domain amino acid sequences of the following A6 TCR clones:

30 38a – Wild-type, 38b - Clone 134, 38c - Clone 89, 38d - Clone 1 and 38e - Clone 111

The mutated residues are shown in bold, bracketed residues are alternative residues that may be present at a particular site.

Figures 39A and 39B I

5

Example 1 – Design of primers and mutagenesis of A6 Tax TCR α and β chains to introduce the cysteine residues required for the formation of a novel inter-chain disulphide bond

10 For mutating A6 Tax threonine 48 of exon 1 in TRAC*01 to cysteine, the following primers were designed (mutation shown in lower case):

5'-C ACA GAC AAA **tgT** GTG CTA GAC AT (SEQ ID 35)

5'-AT GTC TAG CAC **Aca** TTT GTC TGT G (SEQ ID 36)

15

For mutating A6 Tax serine 57 of exon 1 in both TRBC1*01 and TRBC2*01 to cysteine, the following primers were designed (mutation shown in lower case):

5'-C AGT GGG GTC **tGC** ACA GAC CC (SEQ ID 37)

20 5'-GG GTC TGT **Gca** GAC CCC ACT G (SEQ ID 38)

PCR mutagenesis:

Expression plasmids containing the genes for the A6 Tax TCR α or β chain were mutated using the α -chain primers or the β -chain primers respectively, as follows.

25 100 ng of plasmid was mixed with 5 μ l 10 mM dNTP, 25 μ l 10xPfu-buffer (Stratagene), 10 units Pfu polymerase (Stratagene) and the final volume was adjusted to 240 μ l with H₂O. 48 μ l of this mix was supplemented with primers diluted to give a final concentration of 0.2 μ M in 50 μ l final reaction volume. After an initial denaturation step of 30 seconds at 95°C, the reaction mixture was subjected to 15
30 rounds of denaturation (95°C, 30 sec.), annealing (55°C, 60 sec.), and elongation (73°C, 8 min.) in a Hybaid PCR express PCR machine. The product was then digested

for 5 hours at 37°C with 10 units of DpnI restriction enzyme (New England Biolabs). 10 µl of the digested reaction was transformed into competent XL1-Blue bacteria and grown for 18 hours at 37°C. A single colony was picked and grown over night in 5 ml TYP + ampicillin (16 g/l Bacto-Tryptone, 16 g/l Yeast Extract, 5 g/l NaCl, 2.5 g/l K₂HPO₄, 100 mg/l Ampicillin). Plasmid DNA was purified on a Qiagen mini-prep column according to the manufacturer's instructions and the sequence was verified by automated sequencing at the sequencing facility of Department of Biochemistry, Oxford University. The respective mutated nucleic acid and amino acid sequences are shown in Figures 1a and 2a for the α chain and Figures 1b and 2b for the β chain.

10

Example 2 – Construction of phage display vectors and cloning of A6 TCR α and β chains into the phagemid vectors.

In order to display a heterodimeric A6 TCR containing a non-native disulfide inter-chain bond on filamentous phage particles, phagemid vectors were constructed for expression of fusion proteins comprising the heterodimeric A6 TCR containing a non-native disulfide inter-chain bond with a phage coat protein. These vectors contain a pUC19 origin, an M13 origin, a bla (Ampicillin resistant) gene, Lac promoter/operator and a CAP-binding site. The design of these vectors is outlined in Figure 3, which describes vectors encoding for both the A6 TCR β chain-gp3 or A6 TCR β chain-gp8 fusion proteins in addition to the soluble A6 TCR α chain. The expression vectors containing the DNA sequences of the mutated A6 TCR α and β chains incorporating the additional cysteine residues required for the formation of a novel disulfide inter-chain bond prepared in Example 1 and as shown in figures 1a and 1b were used as the source of the A6 TCR α and β chains for the production of a phagemid encoding this TCR. The complete DNA sequence of the phagemid construct (pEX746) utilised is given in Figure 4.

25

The molecular cloning methods for constructing the vectors are described in “Molecular cloning: A laboratory manual, by J. Sambrook and D. W. Russell”.

30

Primers listed in table-1 are used for construction of the vectors. An example of the PCR programme is 1 cycle of 94°C for 2 minutes, followed by 25 cycles of 94°C for 5 seconds, 53°C for 5 seconds and 72°C for 90 seconds, followed by 1 cycle of 72°C for 10 minutes, and then hold at 4°C. The Expand high fidelity Taq DNA polymerase is purchased from Roche.

Table 1. Primers used for construction of the A6 TCR phage display vectors

Primer name	Sequence 5' to 3'
YOL1	TAATAATACGTATAATAATATTCATTTCAAG GAGACAGTC (SEQ ID 39)
YOL2	CAATCCAGCGGCTGCCGTAGGCAATAGGTATT TCATTATGACTGTCTCCTTGAAATAG (SEQ ID 40)
YOL3	CtaCGGCAGCCGCTGGATTGTTATTACTCGCG GCCAGCCGCCATGGCccag (SEQ ID 41)
YOL4	GTTCTGCTCCACTTCCTTCTGGGCCATGGCCG GCTGGGCCG (SEQ ID 42)
YOL5	CAGAAGGAAGTGGAGCAGAAC (SEQ ID 43)
YOL6	CTTCTTAAAGAATTCTTAATTAACCTAGGTTA TTAGGAACTTTCTGGGCTGGGGAAG (SEQ ID 44)
YOL7	GTTAATTAAGAATTCTTTAAGAAGGAGATATA CATATGAAAAAATTATTATTCGCAATTC (SEQ ID 45)
YOL8	CGCGCTGTGAGAATAGAAAGGAACAACATAAG GAATTGCGAATAATAATTTTTTCATATG (SEQ ID 46)
YOL9	CTTCTATTCTCACAGCGCGCAGGCTGGTGTC ACTCAGAC (SEQ ID 47)

YOL10	ATGATGTCTAGATGCGGCCGCTCTGCTCTAC CCCAGGCCTC (SEQ ID 48)
YOL11	GCATCTAGACATCATCACCATCATCACTAGAC TGTGTGAAAGTTGTTTAGCAAAAC (SEQ ID 49)
YOL12	CTAGAGGGTACCTTATTAAGACTCCTTATTAC GCAGTATG (SEQ ID 50)

Example 3 – Expression of fusions of bacterial coat protein and heterodimeric A6 TCR in E. coli.

5 In order to validate the construct made in Example 2, phage particles displaying the heterodimeric A6 TCR containing a non-native disulfide inter-chain bond were prepared using methods described previously for the generation of phage particles displaying antibody scFvs (Li *et al*, 2000, Journal of Immunological Methods **236**: 133-146) with the following modifications. *E. coli* XL-1-Blue cells containing

10 pEX746:A6 phagemid (i.e. the phagemid encoding the soluble A6 TCR α chain and an A6 TCR β chain fused to the phage gIII protein produced as described in Example 2) were used to inoculate 5 ml of Lbatg (Lennox L broth containing 100 μ g/ml of ampicillin, 12.5 μ g/ml tetracycline and 2% glucose), and then the culture was incubated with shaking at 37°C overnight (16 hours). 50 μ l of the overnight culture

15 was used to inoculate 5 ml of TYPatg (TYP is 16g/l of peptone, 16g/l of yeast extract, 5g/l of NaCl and 2.5g/l of K₂HPO₄), and then the culture was incubated with shaking at 37°C until OD_{600nm} = 0.8. Helper phage M13 K07 was added to the culture to the final concentration of 5 X 10⁹ pfu/ml. The culture was then incubated at 37°C stationary for thirty minutes and then with shaking at 200 rpm for further 30 minutes.

20 The medium of above culture was then changed to TYPak (TYP containing 100 μ g/ml of ampicillin, 25 μ g/ml of kanamycin), the culture was then incubated at 25°C with shaking at 250 rpm for 36 to 48 hours. The culture was then centrifuged at 4°C for 30 minutes at 4000 rpm. The supernatant was filtrated through a 0.45 μ m syringe filter and stored at 4°C for further concentration or analysis.

The fusion protein of filamentous coat protein and heterodimeric A6 TCR containing a non-native disulfide inter-chain bond was detected in the supernatant by western blotting. Approximately 10^{11} cfu phage particles were loaded on each lane of an SDS-PAGE gel in both reducing and non-reducing loading buffer. Separated proteins were primary-antibody probed with an anti-M13 gIII mAb, followed by a second antibody conjugated with Horseradish Peroxidase (HRP). The HRP activity was then detected with Opti-4CN substrate kit from Bio-Rad (Figure 5). These data indicated that disulfide-bonded A6 TCR of clone 1 is fused with filamentous phage coat protein, gIII protein.

10

Example 4 – Detection of functional heterodimeric A6 TCR containing a non-native disulfide inter-chain bond on filamentous phage particles

The presence of functional (HLA-A2-tax binding) A6 TCR displayed on the phage particles was detected using a phage ELISA method.

15

TCR-Phage ELISA

Binding of the A6 TCR-displaying phage particles to immobilised peptide-MHC in ELISA is detected with primary rabbit anti-fd antisera (Sigma) followed by alkaline phosphatase (AP) conjugated anti-Rabbit mAb (Sigma). Non specific protein binding sites in the plates can be blocked with 2% MPBS or 3% BSA-PBS

20

Materials and reagents

1. Coating buffer, PBS
2. PBS: 138mM NaCl, 2.7mM KCl, 10mM Na₂HPO₄, 2mM KH₂PO₄
3. MPBS , 3% marvel-PBS
4. PBS-Tween: PBS, 0.1% Tween-20
5. Substrate solution, Sigma FAST pNPP, Cat# N2770

25

Method

30

1. Rinse NeutrAvidin coated wells twice with PBS.

2. Add 25 μ l of biotin-HLA-A2 Tax or biotin-HLA-A2 NYESO in PBS at concentration of 10 μ g/ml, and incubate at room temperature for 30 to 60 min.
3. Rinse the wells twice with PBS
4. Add 300 μ l of 3% Marvel-PBS, and incubate at room temperature for 1hr. Mix
5 the TCR-phage suspension with 1 volume of 3% Marvel-PBS and incubate at room temperature.
5. Rinse the wells twice with PBS
6. Add 25 μ l of the mixture of phage-A6 TCR/Marvel-PBS, incubate on ice for 1hr
7. Rinse the wells three times with ice-cold PBStween, and three times with ice-cold PBS.
10
8. Add 25 μ l of ice cold rabbit anti-fd antibody diluted 1:1000 in Marvel-PBS, and incubate on ice for 1hr
9. Rinse the wells three times with ice-cold PBStween, and three times with ice-cold PBS.
15
10. Add 25 μ l of ice cold anti-rabbit mAb-Ap conjugate diluted 1:50,000 in Marvel-PBS, and incubate on ice for 1hr
11. Rinse the wells three times with ice-cold PBStween, and three times with ice-cold PBS.
12. Add 150 μ l of Alkaline phosphatase yellow to each well and read the signal at
20 405nm

The results presented in Figure 6 indicate clone 1 produced a phage particle displaying an A6 TCR that can bind specifically to its cognate pMHC. (HLA-A2 Tax)

Analysis of the DNA sequence of this displayed A6 TCR revealed the presence of an ‘opal’ stop codon in the TCR β chain not present in the corresponding sequence of the expression vector construct of Example 2. This codon is ‘read-through’ with low frequency by ribosomes of the *E. coli* strain utilised resulting in the insertion of a tryptophan residue at this site and a much-reduced overall level of full-length β chain expression. From this observation it was inferred that only cells expressing this mutated A6 TCR sequence had survived the culture rounds of Example 3, and that therefore the high levels of A6 TCR predicted to be expressed by the original expression vector were toxic to the host cells.

10

Example 5 – single- chain TCR (scTCR) ribosome display

Construction of Ribosome display scTCR vectors for use in generation of ribosome display PCR templates.

Ribosome display constructs were cloned into the readily available DNA plasmid pUC19 in order to generate an error free and stable DNA PCR template from which to conduct subsequent ribosome display experiments. Vector construction was undertaken in two steps so as to avoid the use of large oligonucleotide primers (with their associated error problems). The final A6 scTCR-C-Kappa DNA ribosome display construct is shown in a schematic form in figure 7a and both DNA and protein sequences are shown in Figure 7b. This construct can be excised from pUC19 as a Pst1/EcoR1 double digest.

15
20

The molecular cloning methods for constructing the vectors are described in “Molecular cloning: A laboratory manual, by J. Sambrook and D. W. Russell”. Primers listed in Table 2 are used for construction of the vectors. The PCR programme utilised was as follows – 1 cycle of 94°C for 2 minutes, followed by 25 cycles of 94°C for 30 seconds, 55°C for 20 seconds and 72°C for 120 seconds, followed by 1 cycles of 72°C for 5 minutes, and then hold at 4°C. The Pfu DNA polymerase is purchased from Strategene. Oligonucleotide primers used are described in table 2.

25
30

Construction of pUC19-T7- Step 1

The construction of pUC19-T7 is described below, the construction results in a pUC19 vector containing a T7 promoter region followed by a short space region and the an optimum eukaryotic Kozak sequence. This is an essential part of the ribosome display construct as it is required for the initiation of transcription of any attached sequence in rabbit reticulocyte lysates. Sequences for ribosome display such as the A6scTCR-Ckappa can be ligated into the pUC19-T7 vector between the Nco1 and EcoR1 restriction sites.

10

Equimolar amounts of the primer Rev-link and For-link were annealed by heating to 94°C for 10 min and slowly cooling the reaction to room temperature. This results in the formation of a double stranded DNA complex that can be seen below.

15

5 ' AGCTGCAGCTAATACGACTCACTATAGGAACAGGCCACCATGG
CGTCGATTATGCTGAGTGATATCCTTGTCCGGTGGTACCCTAG 3 '
(SEQ ID 51)

20

The 5' region contains an overhanging sticky end complimentary to a HindIII restriction site whilst the 3' end contains a sticky end that is complimentary to a BamHI restriction site.

25

The annealed oligonucleotides were ligated into Hind III/BamHI double-digested pUC19 which had been purified by agarose gel electrophoresis, excised and further purified with the Qiagen gel extraction kit. The ligations were transformed into *E. coli* XL1-BLUE. Individual pUC19-T7 clones were sequenced to confirm the presence of the correct sequence. The sequence is shown in Figure 8.

30

Construction of A6scTCR-C-Kappa vector – Step 2.

Construction of the single chain A6scTCR-C-Kappa DNA sequence requires the generation of three PCR fragments that must then be assembled into one A6scTCR-C-Kappa fragment. The fragments consist of (a.) the A6 TCR alpha chain variable region flanked by a Nco1 site in the 5' region and a section of Glycine Serine linker in the 3' region flanked by a BamH1 restriction site. This product was generated via a standard PCR of the vector pEX202 with the primers 45 and 50 (See Table 2). Fragment (b.) A6 TCR beta variable and constant region flanked by a BamH1 restriction site in the 5' region followed by a section of Glycine Serine linker. This product was generated via a standard PCR of the vector pEX207 with the primers 72 and 73 (See Table 2). Fragment (c.) Portion of a human C-kappa region generated by a standard PCR of the p147 vector with the primers 61-60 (See Table 2). All PCR products were run on a 1.6% TBE agarose gel and DNA bands of the correct size excised and purified using the Qiagen gel extraction kit.

Fragments (b.) and (c.) were fused by a standard overlap PCR via the complementarity in their primer sequences 73 and 61(See Table 2). The PCR was carried out via the primers 72 and 60 (See Table 2). The PCR products were run on a 1.6% TBE agarose gel and DNA bands of the correct size excised and purified using the Qiagen gel extraction kit. This fragment is termed (d.).

Fragment (a.) was double digested with Nco1 and BamH1 whilst fragment (d.) was double digested with BamH1 and EcoR1. pUC19-T7 was double digested with Nco1 and EcoR1. All digested DNA products were run on a 1.2% TBE agarose gel and DNA bands of the correct size were excised and purified using the Qiagen gel extraction kit. The digested pUC19-T7, fragments (a.) and (d.) were ligated and transformed into E. coli XL1-BLUE. Transformants were sequenced to confirm the correct sequence. The sequence of the A6scTCR-C-Kappa ribosome display construct that was cloned into pUC19 is shown in Figure 9 flanked by its Pst1 and EcoR1 sites.

30 Table 2.

Oligonucleotides used (Purchased from MWG).

Rev-Link	5' GATCCCATGGTGGCCTGTTCCCTATAGTGAGTCGTATTAGCTGC (SEQ ID 52)
For-Link	5' AGCTGCAGCTAATACGACTCACTATAGGAACAGGCCACCATGG (SEQ ID 53)
45-A6	5' CCACCATGGGCCAGAAGGAAGTGGAGCAGAACTC (SEQ ID 54)
7 A6-Beta(RT-PCR)(a)	5' CGAGAGCCCGTAGAACTGGACTTG (SEQ ID 55)
49-A6-BamH1-F	5' GTGGATCCGGCGGTGGCGGGTCGAACGCTGGTGTCA CTCAGACCCC (SEQ ID 56)
50-A6-BamH1-R	5' CCGGATCCACCTCCGCCTGAACCGCCTCCACCGGTGACCACAAC CTGGGTCCCTG (SEQ ID 57)
60-Kappa-rev-EcoR1	5' CTGAGAATTCTTATGACTCTCCGCGGTTGAAGCTC (SEQ ID 58)
61-Beta-Kappa-for1	5' TGACGAATTCTGACTCTCCGCGGTTGAAGCTC (SEQ ID 59)
71 T7-Primer	5' AGCTGCAGCTAATACGACTCACTATAGG (SEQ ID 60)
72 A6-beta	5' GGCCACCATGGGCAACGCTGGTGTCACTCAGACCCC (SEQ ID 61)
73-A6-cons-rev	5' TGAACCGCCTCCACCGTCTGCTCTACCCCAGGCCTCGGCG (SEQ ID 62)
75 Kappa-rev	5' TGACTCTCCGCGGTTGAAGCTC (SEQ ID 63)

5

10

Demonstration of the production of sc A6 TCR-C-Kappa by In vitro transcription translation.

Preparation of scA6 TCR-C-Kappa PCR product for In vitro transcription translation.

Here we describe the synthesis of sc A6 TCR-C-Kappa via *In vitro* transcription translation in the presence of biotinylated lysine and its subsequent detection by western blotting and detection with alkaline phosphatase labelled streptavidin.

The sc A6 TCR-C-Kappa PCR product was prepared in a standard PCR reaction using the vector sc A6 TCR-C-Kappa as template and PCR primers 71 and 60. Primer 60 contains a stop codon to allow the release of the scTCR from the ribosome. Pfu polymerase (Stratagene) was used for increased fidelity during PCR synthesis. The PCR products were run on a 1.6% TBE agarose gel and DNA bands of the correct size excised and purified using the Qiagen gel extraction kit.

The transcription translation reactions were carried out using the Ambion PROTEINscript II Linked transcription translation kit Cat 1280-1287 with 300ng of the above described PCR product. Three transcription translation reactions were set up according to the manufactures protocol. The one modification was the addition of biotinylated lysine from the Transcend™ Non-Radioactive Translation Detection System.

Reaction 1 sc A6 TCR-C-Kappa 300ng with 2µl biotinylated lysine
Reaction 2 sc A6 TCR-C-Kappa 300ng without 2µl biotinylated lysine
Reaction 3 No DNA control with 2µl biotinylated lysine.

Two microliters of each reaction was run on a 4-20% Novex gradient SDS-PAGE gel (Invitrogen). Additionally a number of dilutions of a control biotinylated TCR were also run. The gel was blotted and the proteins detected with streptavidin alkaline phosphatase and subsequently colometrically developed with Western Blue® Stabilized Substrate for Alkaline Phosphatase as described in the Transcend™ Non-Radioactive Translation Detection System protocol. The western blot is shown in Figure 10.

In the no DNA control and A6scTCR-C-Kappa reaction without biotinylated lysine no band of approximately the correct size can be seen as expected whilst in the A6scTCR-C-Kappa reaction in the presence of biotinylated lysine a band of approximately the correct size can be seen. This demonstrates the synthesis of the sc
5 A6 TCR-C-Kappa TCR by *In vitro* transcription translation.

Preparation of sc A6 TCR-C-Kappa ribosome display PCR product.

The sc A6 TCR-C-Kappa PCR product was prepared in a standard PCR reaction using
10 the vector A6scTCR-C-Kappa as template and PCR primers 71 and 75 (See Table 2). Primer 75 does not contain a stop codon. Pfu polymerase (Stratagene) was used for increased fidelity during PCR synthesis. The PCR products were run on a 1.6% TBE agarose gel and DNA bands of the correct size were excised and purified using the Qiagen gel extraction kit.

15

Ribosome Display Process

Transcription and translation of sc A6 TCR-C-Kappa

The transcription / translation reactions were carried out using the Ambion
20 PROTEINscript II Linked transcription translation kit (Cat No. 1280-1287)

25

30

Transcription reactions

The following transcription reactions were set up in Ambion 0.5 ml non stick tubes (Cat No. 12350).

Contents	Tube 1 (Normal A6)	Tube 2 (Control)
<i>Water</i>	4.53 μ l	5.7 μ l
Template (PCR product)	Sc A6 TCR-C-Kappa PCR product 1.17 μ l (300 ng)	No DNA
5X transcription mix	2 μ l	2 μ l
Enzyme mix	2 μ l	2 μ l
Supersasin <small>Rnase inhibitor</small> <small>ambion</small>	0.3 μ l	0.3 μ l
Final volume	10 μ l	10 μ l

5

The tubes were incubated at 30°C for 60 min on a PCR block with the hot lid off.

Translation reactions

The following translation reactions were set up in Ambion 0.5 ml non stick tubes.

10

Contents	1 (Normal A6)	2 (Control)
Reticulocyte Lysate	105 μ l	105 μ l
25mM Mg-Acetate	3 μ l	3 μ l
Translation Mix	7.5 μ l	7.5 μ l
Methionine	7.5 μ l	7.5 μ l
Water	18 μ l	18 μ l
Supersasin <small>Rnase inhibitor</small>	3 μ l	3 μ l
Transcription reaction	6 μ l tube 1 above	6 μ l tube 2 above

Each tube contains enough for 3x50 μ l selections. The tubes were mixed and incubated at 30°C for 60 min on a PCR block with the hot lid off. After 30 min 3 Unit of RQ1 Rnase free Dnase (Promega) was added to destroy the original DNA template in tube 1

and 3 Unit RQ1 Rnase free Dnase (Promega) in tube 2. After 60 min 18µl of Heparin solution was added to translation reaction 2 and 18µl of Heparin solution was added to translation reaction 1. Samples were stored on ice ready for selection against HLA-coated beads.

5

Coating of magnetic beads.

20µl of resuspended Streptavidin Magnetic Particles (Roche Cat. No. 1641778) were transferred into a sterile Rnase free 1.5 ml eppendorf tube. The beads were immobilised with a Magnetic Particle Separator (Roche Cat. No. 1641794) and the supernatant was removed. The beads were then washed with 100 µl of Rnase free 1 X PBS (10 x PBS Ambion Cat No. 9624, Ambion H₂O Cat No. 9930) the beads were immobilised and the supernatant was removed. A total of 3 PBS washes were carried out.

10

The beads were resuspended in 20µl of PBS and the contents split evenly between two tubes (10µl each). One tube will be used to produce control-blocked beads and the other tubes to produce HLA-A2-Tax coated beads.

15

To the control beads tube 80µl of BSA/Biotin solution was added and mixed. The BSA/Biotin solution was made up as follows. 10µl of a 0.2M Tris base 0.1M Biotin solution was added to 990µl of PBS 0.1 % BSA (Ambion Ultrapure Cat No. 2616). Also 20 µl of Heparin solution (138 mg/ml Heparin (Sigma H-3393) in 1 x PBS) was added and the solution mixed. The beads were incubated at room temperature for 1 hour with intermittent mixing. The beads were then washed three times with 100µl of PBS and were resuspended in 10 µl of PBS, 0.1% BSA.

20

25

The HLA-TAX coated beads were prepared as follows. 40 µl of HLA-A2-Tax(1.15 mg/ml prepared as described in WO99/60120) was added to the 10 µl of beads and mixed. The beads were incubated at room temperature for 15 min and then 20 µl of BSA 50mg/ml Ambion Cat 2616 and 20 µl of heparin solution (see above) were added and mixed. The beads were incubated for a further 45 min and then 20 µl of

30

BSA/Biotin solution was added. The beads were then washed three times with 100 μ l of PBS and were re-suspended in 10 μ l of PBS, 0.1% BSA.

Panning with magnetic beads

- 5 The sc A6 TCR translation reaction was split into three 50 μ l aliquots and each aliquot received either 2 μ l of the following beads:

Control (no HLA)

HLA-A2-Tax

- 10 HLA-A2-Tax plus 10 μ g soluble scA6 TCR

A control translation reaction was also carried out and split into three 50 μ l aliquots and each aliquot received either 2 μ l of the following beads

- 15 Control (no HLA)

HLA-A2-Tax

HLA-A2-Tax plus 10 μ g soluble sc A6 TCR

- 20 This gave a total of six tubes. The tubes were incubated on a PCR block at 5°C for 60 min with intermittent mixing.

- The beads were then washed three times with 100 μ l ice cold buffer (PBS, 5mM Mg-acetate, 0.2% Tween 20(Sigma Rnase free). Each aliquot of beads were then re-suspended in 50 μ l of 1 x RQ1 Dnase digestion buffer containing 1 μ l (40 U) of Supersasin and 1 μ l (1U) of RQ1 Dnase. The beads were incubated on a PCR block for
25 30 min at 30°C.

The beads were then washed three times with 100 μ l ice cold buffer (PBS, 5mM Mg-acetate, 0.2% Tween 20) and once with ice cold H₂O. The beads were re-suspended in 10 μ l of Rnase free H₂O. The beads were then frozen ready for RT-PCR.

RT-PCR of sc A6 TCR-C-Kappa mRNA on beads rescued from the ribosome display reactions.

The RT PCR reactions on the beads were carried out using the Titan one tube RT-PCR
5 kit cat 1855476 as described in the manufacturers protocols. Two microliters of beads
were added into each RT-PCR reaction along with the primers 45 and 7 and 0.3 μ l of
Supersasin Rnase inhibitor.

For each RT-PCR reaction a second PCR only reaction was set up which differed only
by the fact that no reverse transcriptase was present just Roche high fidelity
10 polymerase. This second reaction served as a control for DNA contamination.
Additionally a RT-PCR positive control control was set up using 1ng of the vector sc
A6 TCR-C-Kappa.

The reactions were cycled as follows. An RT-PCR step was carried out by incubation
15 of the samples at 50°C for 30 min followed by the inactivation of the reverse
transcriptase by incubation at 94°C for 3 min on a PCR block.

The reactions were PCR cycles as follows for a total of 38 cycles:

94°C 30 seconds
20 55°C 20 seconds
68°C 130 seconds.

The PCR reaction was finished by incubation at 72°C for 4 minutes.

Great care was taken during all ribosome display steps to avoid Rnase contamination.
25 The RT-PCR and PCR reactions were run on a 1.6% TBE agarose gel which can be
seen in Figure 11. Analysis of the gel shows that there is no DNA contamination and
that all PCR products are derived from mRNA. The DNA band of the correct size in
lane 2 demonstrates that ribosome displayed sc A6 TCR-C-Kappa was selected out by
HLA-A2-Tax coated beads. Lane 3 shows that we can inhibit this specific selection of
30 ribosome-displayed sc A6 TCR-C-Kappa by the addition of soluble sc A6 TCR. The
significant reduction in the band intensity in lane 3 relative to the uninhibited sample

in lane 2 demonstrates this. No binding of ribosome-displayed sc A6 TCR-C-Kappa could be shown against control non-HLA coated beads.

Example 6 – Sequence Analysis of A6 TCR clones displayed on phage particles and methods to improve display characteristics

5 After the construction of vectors for displaying A6 TCR on phage by PCR and molecular cloning, bacterial clones that can produce phage particles displaying A6 TCR were screened by phage ELISA as described in Example 4. Three different clones were identified that gave specific binding to HLA-A2-tax in the ELISA binding
10 assay. These clones all contained mutations in the ‘wild-type’ A6 TCR DNA or in the associated regulatory sequences, which are described in the following table:

Functional clones from screening TCR A6 displayed on phage

Name	Feature	
Clone 7	The third ribosome-binding site, which is located in front of $v\beta$ gene, is mutated from <u>AAGGAGA</u> to <u>AAGGGGA</u> .	
Clone 9	An opal codon is introduced in $v\beta$ CDR3.	Full DNA and amino acid sequence in Figures 12a & 12b
Clone 49	An amber codon is introduced in $v\beta$ FR1. This mutation introduces a ‘silent’ mutation that does not affect the resulting amino acid sequence	Full DNA sequence in Figures 13a

15 These clones all contained mutations that are likely to cause a reduction in the expression levels of the A6 TCR β chain. It was inferred that low expression clones were selected over high expression clones as a result of cell toxicity caused by high expression levels of TCR.

YOL63	TGTGCCTCGAGGCCGGGANNKNNKNNKNNKNNKNNKNNKGGGGCGACCAGAGCAGTAC (SEQ ID 74)
YOL68	TGTGCCTCGAGGNKNNKNNKNNKNNKNNKNNKNNKNNKCCAGAGCAGTACTTCGggc (SEQ ID 75)
YOL69	TGTGCCTCGAGGNKNNKNNKNNKNNKNNKNNKNNKNNKNGAGCAGTACTTCGggccg (SEQ ID 76)
YOL70	TGTGCCTCGAGGNKNNKNNKNNKNNKNNKNNKNNKNNKNCAGTACTTCGggccgggc (SEQ ID 77)
YOL71	TGTGCCTCGAGGccgNNKNNKNNKNNKNNKNNKggCGACCAGAGCAGTACTTCG (SEQ ID 78)
YOL58	AAACTGAAGCTTMMNNMNNMNNMNNMNNMNT GTAACGGCACAGAGGTAG (SEQ ID 79)
YOL72	AAACTGAAGCTTMMNNMNNgctgtcMNNNT GTAACGGCACAGAGGTAG (SEQ ID 80)
YOL73	AAACTGAAGCTTMMNNMNNMNNgctgtcM NNTGTAACGGCACAGAGGTAG (SEQ ID 81)
YOL74	AAACTGAAGCTTMMNNMNNgctgtcMNNA ACGGCACAGAGGTAG (SEQ ID 82)

α -chain fragments were digested with *Nco I* and *HindIII* and re-purified using a Qiagen kit and vector was prepared by digesting clone 9 with *Nco I* and *HindIII* followed by gel purification using a Qiagen kit. β -chain fragments were digested with *Xho I* and *Not I* and re-purified using a Qiagen kit and vector was prepared by digesting clone 9 with *Xho I* and *Not I* followed by gel purification using a Qiagen kit. Purified inserts and vectors at 3:1 molar ratio were mixed with T4 ligase buffer, T4 ligase and nuclease-free water. The ligations were carried out at 16°C water bath overnight. For each mutation-library, a total of 0.5 to 1 μ g purified ligated products were electroporated into *E. coli* TG1 at ratio of 0.2 μ g DNA per 40 μ l of electroporation-competent cells (Stratagen) following the protocols provided by the manufacturer. After electroporation, the cells were re-suspended immediately with 960 μ l of SOC medium at 37°C and plated on a 244mm x244mm tissue culture plate containing YTE (15g Bacto-Agar, 8g NaCl, 10g Tryptone, 5g Yeast Extract in 1 litre)

supplemented with 100µg/ml ampicillin and 2% glucose. The plate was incubated at 30°C over night. The cells were then scraped from the plates with 5 ml of DYT (16g Trytone, 10g Yeast extract and 5g NaCl in 1 litre, autoclaved at 125°C for 15 minutes) supplemented with 15% glycerol.

5

In order to make phage particles displaying the A6 TCR, 500 ml of DYTag (DYT containing 100 µg/ml of ampicillin and 2% glucose) was inoculated with 500 to 1000 µl of the library stocks. The culture was grown until OD(600nm) reached 0.5. 100 ml of the culture was infected with helper phage (M13 K07 (Invitrogen), or HYPER PHAGE (Progen Biotechnik, GmbH 69123 Heidelberg), and incubated at 37°C water bath for 30 minutes. The medium was replaced with 100 ml of DYTak (DYT containing 100 µg/ml ampicillin and 25 µg/ml of kanamycin). The culture was then incubated with shaking at 300 rpm and 25°C for 20 to 36 hours.

15 *Example 8 – Isolation of high affinity A6 TCR mutants*

The isolation of high affinity A6 TCR mutants was carried out using two different methods.

20 The first method involves selecting phage particles displaying mutant A6 TCRs capable of binding to HLA-A2 Tax complex using Maxisorp immuno-tubes (Invitrogen) The immuno-tubes were coated with 1 to 2 ml 10µg/ml streptavidin in PBS overnight at room temperature. The tubes were washed twice with PBS, and then 1 ml of biotinylated HLA-A2 Tax complex at 5µg/ml in PBS was added and incubated
25 at room temperature for 30 minutes. The rest of the protocol for selection of high affinity binders is as described previously (Li *et al.* (2000) *Journal of Immunological Methods* 236: 133-146), except for the following modifications. The selection was performed over three or four rounds. The concentrations of biotinylated HLA-A2 Tax complex were 5µg/ml for the first round of selection, 0.5 µg/ml for the second, 0.05
30 µg/ml for the third and 0.005 µg/ml for the fourth round of selection. M13 K07 helper

phage were used in rounds one and two, and hyper phage were used in subsequent rounds, for the selection.

The second method utilised was the selection of phage particles displaying mutant A6
5 TCRs capable of binding to HLA-A2 Tax complex in solution. Streptavidin-coated
paramagnetic beads (Dynal M280) were pre-washed according to manufacturer's
protocols. Phage particles, displaying mutated A6 TCR at a concentration of 10^{12} to
 10^{13} cfu, were pre-mixed with biotinylated HLA-A2 Tax complex at concentrations of
 2×10^{-8} M, 2×10^{-9} M, 2×10^{-10} M and 2×10^{-11} M for first, second, third and fourth-round of
10 selections respectively. The mixture of A6 TCR-displaying phage particles and HLA-
A2 Tax complex was incubated for one hour at room temperature with gentle rotation,
and A6 TCR-displaying phage particles bound to biotinylated HLA-A2 Tax complex
were captured using 200 μ l (round 1) or 50 μ l (round 2, 3, and 4) of streptavidin-coated
M280 magnetic beads. After capture of the phage particles, the beads were washed a
15 total of ten times (three times in PBStween20, twice in PBStween 20 containing 2%
skimmed milk powder, twice in PBS, once in PBS containing 2% skimmed milk
powder, and twice in PBS) using a Dynal magnetic particle concentrator. After final
wash, the beads was re-suspended in 1ml of freshly prepared 100mM triethylamine
pH11.5, and incubated for 5 to 10 minutes at room temperature with gentle rotation.
20 Phage particles eluted from the beads were neutralized immediately with 300 μ l of 1M
tris-HCl pH7.0. Half of the eluate was used to infect 10 ml of *E.coli* TG1 at
OD(600nm)=0.5 freshly prepared for the amplification of the selected phage particles
according to the methods previously described (Li *et al.*, (2000) *Journal of*
Immunological Methods 236: 133-146).

25

After the third or fourth round of selection, 95 colonies were picked from the plates
and used to inoculate 100 μ l of DYTag in a 96-well microtiter plate. The culture was
incubated at 37°C with shaking overnight. 100 μ l of DYTag was then sub-inoculated
with 2 to 5 μ l of the overnight cultures, and incubated at 37°C with shaking for 2 to 3
30 hours or until the culture became cloudy. To infect the cells with helper phage, the
culture was infected with 25 μ l of DYTag containing 5×10^9 pfu helper phages, and

incubated at 37°C for 30 minutes. The medium was replaced with DYTak. The plates were incubated at 25°C for 20 to 36 hours with shaking at 300 rpm. The cells were precipitated by centrifugation at 3000g for 10 minutes at 4°C. Supernatants were used to screen for high affinity A6 TCR mutants by competitive phage ELISA as follows.

5

Nunc-Immuno Maxisorp wells coated with streptavidin were rinsed twice with PBS. 25 µl 5 µg/ml biotinylated HLA-A2-Tax complex was added to each well and these were incubated at room temperature for 30 to 60 minutes, and followed by two PBS rinses. Non-specific protein binding sites in the wells were blocked by the addition of 10 300 µl 3% skimmed milk in PBS followed by incubation at room temperature for 2 hours. In order to prepare phage particles displaying the heterodimeric A6 TCR, phage particles were mixed with 3% skimmed milk in PBS containing 0, 20, and 200 nM HLA-A2-Tax, followed by incubated at room temperature for 1 hour. The phage is added to the wells coated with HLA-A2-Tax and incubated at room temperature for 15 1 hour, followed by 3 washes with PBS containing 0.1% tween 20 and then 3 washes with PBS. The bound TCR-dispalying phage particles are detected with an anti-fd antibody (Sigma) as described in Example 4.

Several putative high affinity A6 TCR mutants were identified, and the CDR3 sequences are listed in the two following tables along with the correspondding wild-20 type sequences. Amber stop codons (**x**) were found in all β chain mutants and one α chain mutant.

25 A6 TCR β chain mutants

clone	CDR3 sequence
Wild Type	GCCTCGAGGCCGGGACTAGCGGGAGGGCGACCAGAGCAGTAG (SEQ ID 83) A S R P G L A G G R P E Q Y (SEQ ID 84)
134	GCCTCGAGGCCGGGGCTGATGAGTGCGTAGCCAGAGCAGTAC (SEQ ID 85) A S R P G L M S A X P E Q Y (SEQ ID 86)

86	GCCTCGAGGCCGGGGCTGAGGTCGGCGTAGCCAGAGCAGTAC (SEQ ID 87) A S R P G L R S A X P E Q Y (SEQ ID 88)
87	GCCTCGAGGCCGGGACTAGCGGGAGGGCGACCAGAGGCGTAG (SEQ ID 89) A S R P G L A G G R P E A X (SEQ ID 90)
89	GCCTCGAGGCCGGGACTAGCGGGAGGGCGACCAGAGGATTAG (SEQ ID 91) A S R P G L A G G R P E D X (SEQ ID 92)
85	GCCTCGAGGCCGGGACTAGCGGGAGGGCGACCAGATCAGTAG (SEQ ID 93) A S R P G L A G G R P D Q X (SEQ ID 94)
83	GCCTCGAGGCCGGGTCTGTAGGCTGGGCGACCAGAGCAGTAC (SEQ ID 95) A S R P G L X A G R P E Q Y (SEQ ID 96)
1	GCCTCGAGGCCGGGGCTGGTTCCGGGGCGACCAGAGCAGTAG (SEQ ID 97) A S R P G L V P G R P E Q X (SEQ ID 98)
2	GCCTCGAGGCCGGGGCTTGTGTCTGCTTAGCCAGAGCAGTAC (SEQ ID 99) A S R P G L V S A X P E Q Y (SEQ ID 100)
111	GCCTCGAGGCCGGGACTAGCGGGAGGGCGACCACATCCGTAG (SEQ ID 101) A S R P G L A G G R P H P X (SEQ ID 102)
125	GCCTCGAGGCCGGGACTAGCGGGAGGGCGACCAGATGCGTAG (SEQ ID 103) A S R P G L A G G R P D A X (SEQ ID 104)
133	GCCTCGAGGCCGGGTCTGATTAGTGCTTAGCCAGAGCAGTAC (SEQ ID 105) A S R P G L I S A X P E Q Y (SEQ ID 106)

A6 TCR α chain mutants

Clone	CDR3
Wild Type	GCCGTTACAACCTGACAGCTGGGGGAAGCTTCAG (SEQ ID 107) A V T T D S W G K L Q (SEQ ID 108)
149	GCCGTTACAACCTGACAGCTGGGGGCCGCTTCAG (SEQ ID 109) A V T T D S W G P L Q (SEQ ID 110)
65	GCCGTTACAACCTGACAGCTGGGGGAAGATGCAG (SEQ ID 111) A V T T D S W G K M Q (SEQ ID 112)
66	GCCGTTACAACCTGACAGCTGGGGGAAGTTGCAT (SEQ ID 113) A V T T D S W G K L H (SEQ ID 114)
153	GCCGTTACAACCTGACAGCTGGGGGTAGCTTCAT (SEQ ID 115) A V T T D S W G X L H (SEQ ID 116)
71	GCCGTTACAACCTGACAGCTGGGGGGAGCTTCAT (SEQ ID 117) A V T T D S W G E L H (SEQ ID 118)
70	GCCGTTACAACCTGACAGCTGGGGGAGGCTGCAT (SEQ ID 119) A V T T D S W G R L H (SEQ ID 120)
121	GCCGTTACAACCTGACAGCTGGGGGCAGCTTCAT (SEQ ID 121) A V T T D S W G Q L H (SEQ ID 122)
117	GCCGTTACAACCTGACAGCTGGGGGAAGGTTCAT (SEQ ID 123) A V T T D S W G K V H (SEQ ID 124)
72	GCCGTTACAACCTGACAGCTGGGGGAAGGTGAAT (SEQ ID 125) A V T T D S W G K V N (SEQ ID 126)
150	GCCGTTACAACCTGACAGCTGGGGGAAGCTTCTG (SEQ ID 127) A V T T D S W G K L L (SEQ ID 128)

5 *Example 9 – Production of soluble heterodimeric A6 TCR with non-native disulfide bond between constant regions, containing CDR3 mutations*

Phagemid DNA encoding the high affinity A6 TCR mutants identified in Example 8 was isolated from the relevant *E.coli* cells using a Mini-Prep kit (Quiagen, UK)

10 PCR amplification using the phagemid DNA as a target and the following primers was used to amplify the soluble TCR α and β chain DNA sequences.

A6 TCR alpha chain forward primer
ggaattc atcgatg cagaaggaagtggagcag (SEQ ID 129)
ClaI restriction site is underlined)

15 Universal TCR alpha chain reverse primer
gtacacggccgggtcagggttctggatatac (SEQ ID 130)
(EagI restriction site is underlined)

20 A6 beta chain forward primer
Tctctcattaatgaatgctggtgtcactcagacccc (SEQ ID 131)
(AseI restriction site is underlined)

25 Universal beta chain reverse primer
Tagaaaccgggtggccagggcacaccagtgtggc (SEQ ID 132)
(AgeI restriction site is underlined)

In the case of the TCR β chain a further PCR stitching was carried out to replace the
30 amber stop codon in the CDR3 region with a codon encoding glutamic acid. When an
amber stop codon is suppressed in *E.coli*, a glutamine residue is normally introduced
instead of the translation being stopped. Therefore, when the amber codon-containing
TCR is displayed on the surface of phage, it contains a glutamine residue in this
position. However, when the TCR β –chain gene was transferred into the expression
35 plasmid, a glutamic acid residue was used as an alternative to glutamine. The primers
used for this PCR stitching were as follows.

YOL124 CTGCTCTGGTTCCGCACTC
(SEQ ID 133)

YOL125 GAGTGCGGAACCAGAGCAG
(SEQ ID 134)

5 The DNA sequence of the mutated soluble A6 TCR β chain was verified by automated sequencing (see Figure 14a for the mutated A6 TCR β chain DNA sequence and 14b for the amino acid sequence encoded thereby). Figure 14c shows the mutated A6 TCR β chain amino acid sequence without the glutamine to glutamic acid substitution, i.e. the sequence that was present in Clone 134 as isolated by phage-ELISA.

10 These A6 TCR α and β DNA sequences were then used to produce a soluble A6 TCR as described in WO 03/020763. Briefly, the two chains are expressed as inclusion bodies in separate *E.coli* cultures. The inclusion bodies are then isolated, de-natured and re-folded together *in vitro*.

15 *Example 10 – BIAcore surface plasmon resonance characterisation of a high affinity A6 TCR binding to HLA-A2 Tax.*

20 A surface plasmon resonance biosensor (BIAcore 3000™) was used to analyse the binding of the high affinity clone 134 A6 TCR (See Figures 15a & 15b for the full DNA and amino acid sequences of the mutated TCR β chain respectively) to the HLA-A2 Tax ligand. This was facilitated by producing pMHC complexes (described below) which were immobilised to a streptavidin-coated binding surface in a semi-oriented fashion, allowing efficient testing of the binding of a soluble T-cell receptor to up to four different pMHC (immobilised on separate flow cells) simultaneously.
25 Manual injection of HLA complex allows the precise level of immobilised class I molecules to be manipulated easily.

Biotinylated class I HLA-A2 tax complexes were refolded *in vitro* from bacterially-expressed inclusion bodies containing the constituent subunit proteins and synthetic

peptide, followed by purification and *in vitro* enzymatic biotinylation (O'Callaghan *et al.* (1999) *Anal. Biochem.* **266**: 9-15). HLA-heavy chain was expressed with a C-terminal biotinylation tag which replaces the transmembrane and cytoplasmic domains of the protein in an appropriate construct. Inclusion body expression levels of ~75
5 mg/litre bacterial culture were obtained. The HLA light-chain or β 2-microglobulin was also expressed as inclusion bodies in *E.coli* from an appropriate construct, at a level of ~500 mg/litre bacterial culture.

E. coli cells were lysed and inclusion bodies were purified to approximately 80%
10 purity. Protein from inclusion bodies was denatured in 6 M guanidine-HCl, 50 mM Tris pH 8.1, 100 mM NaCl, 10 mM DTT, 10 mM EDTA, and was refolded at a concentration of 30 mg/litre heavy chain, 30 mg/litre β 2m into 0.4 M L-Arginine-HCl, 100 mM Tris pH 8.1, 3.7 mM cystamine, mM cysteamine, 4 mg/ml peptide (e.g. tax 11-19), by addition of a single pulse of denatured protein into refold buffer at < 5°C.
15 Refolding was allowed to reach completion at 4°C for at least 1 hour.

Buffer was exchanged by dialysis in 10 volumes of 10 mM Tris pH 8.1. Two changes of buffer were necessary to reduce the ionic strength of the solution sufficiently. The protein solution was then filtered through a 1.5 μ m cellulose acetate filter and loaded
20 onto a POROS 50HQ anion exchange column (8 ml bed volume). Protein was eluted with a linear 0-500 mM NaCl gradient. HLA-A2-peptide complex eluted at approximately 250 mM NaCl, and peak fractions were collected, a cocktail of protease inhibitors (Calbiochem) was added and the fractions were chilled on ice.

25 Biotinylation tagged HLA-A2 complexes were buffer exchanged into 10 mM Tris pH 8.1, 5 mM NaCl using a Pharmacia fast desalting column equilibrated in the same buffer. Immediately upon elution, the protein-containing fractions were chilled on ice and protease inhibitor cocktail (Calbiochem) was added. Biotinylation reagents were then added: 1 mM biotin, 5 mM ATP (buffered to pH 8), 7.5 mM MgCl₂, and 5 μ g/ml
30 BirA enzyme (purified according to O'Callaghan *et al.* (1999) *Anal. Biochem.* **266**: 9-15). The mixture was then allowed to incubate at room temperature overnight.

Biotinylated HLA-A2 complexes were purified using gel filtration chromatography. A Pharmacia Superdex 75 HR 10/30 column was pre-equilibrated with filtered PBS and 1 ml of the biotinylation reaction mixture was loaded and the column was developed with PBS at 0.5 ml/min. Biotinylated HLA-A2 complexes eluted as a single peak at approximately 15 ml. Fractions containing protein were pooled, chilled on ice, and protease inhibitor cocktail was added. Protein concentration was determined using a Coomassie-binding assay (PerBio) and aliquots of biotinylated HLA-A2 complexes were stored frozen at -20°C . Streptavidin was immobilised by standard amine coupling methods.

10

The interactions between the high affinity A6 Tax TCR containing a novel inter-chain bond and the HLA-A2 Tax complex or an irrelevant HLA-A2 NY-ESO combination, the production of which is described above, were analysed on a BIAcore 3000TM surface plasmon resonance (SPR) biosensor. SPR measures changes in refractive index expressed in response units (RU) near a sensor surface within a small flow cell, a principle that can be used to detect receptor ligand interactions and to analyse their affinity and kinetic parameters. The probe flow cells were prepared by immobilising the individual HLA-A2 peptide complexes in separate flow cells via binding between the biotin cross linked onto $\beta 2\text{m}$ and streptavidin which have been chemically cross linked to the activated surface of the flow cells. The assay was then performed by passing sTCR over the surfaces of the different flow cells at a constant flow rate, measuring the SPR response in doing so. Initially, the specificity of the interaction was verified by passing soluble A6 TCR at a constant flow rate of $5 \mu\text{l min}^{-1}$ over four different surfaces; one coated with ~ 1000 RU of HLA-A2 Tax complex, the second coated with ~ 1000 RU of HLA-A2 NY-ESO complex, and two blank flow cells coated only with streptavidin (see Figure 15).

25

The increased affinity of the mutated soluble A6 TCR made calculation of the k_d for the interaction of this moiety with the HLA-A2 Tax complex difficult. However, the half-life ($t_{1/2}$) for the interaction was calculated to be 51.6 minutes (see Figure 16), which compares to a $t_{1/2}$ for the wild-type interaction of 7.2 seconds.

30

Example 11 – Production of vector encoding a soluble NY-ESO TCR containing a novel disulphide bond.

5 The β chain of the soluble A6 TCR prepared in Example 1 contains in the native sequence a BglII restriction site (AAGCTT) suitable for use as a ligation site.

PCR mutagenesis was carried as detailed below to introduce a BamHI restriction site (GGATCC) into the α chain of soluble A6 TCR, 5' of the novel cysteine codon. The
10 sequence described in Figure 2a was used as a template for this mutagenesis. The following primers were used:

| BamHI |

5' -ATATCCAGAACCCgGATcCTGCCGTGTA-3' (SEQ ID 135)

15 5' -TACACGGCAGGAaTCcGGGTTCTGGATAT-3' (SEQ ID 136)

100 ng of plasmid was mixed with 5 μ l 10 mM dNTP, 25 μ l 10xPfu-buffer (Stratagene), 10 units Pfu polymerase (Stratagene) and the final volume was adjusted to 240 μ l with H₂O. 48 μ l of this mix was supplemented with primers diluted to give a
20 final concentration of 0.2 μ M in 50 μ l final reaction volume. After an initial denaturation step of 30 seconds at 95°C, the reaction mixture was subjected to 15 rounds of denaturation (95°C, 30 sec.), annealing (55°C, 60 sec.), and elongation (73°C, 8 min.) in a Hybaid PCR express PCR machine. The product was then digested for 5 hours at 37°C with 10 units of DpnI restriction enzyme (New England Biolabs).
25 10 μ l of the digested reaction was transformed into competent XL1-Blue bacteria and grown for 18 hours at 37°C. A single colony was picked and grown over night in 5 ml TYP + ampicillin (16 g/l Bacto-Tryptone, 16 g/l Yeast Extract, 5 g/l NaCl, 2.5 g/l K₂HPO₄, 100 mg/l Ampicillin). Plasmid DNA was purified on a Qiagen mini-prep column according to the manufacturer's instructions and the sequence was verified by
30 automated sequencing at the sequencing facility of Department of Biochemistry, Oxford University.

cDNA encoding NY-ESO TCR was isolated from T cells according to known techniques. cDNA encoding NY-ESO TCR was produced by treatment of the mRNA with reverse transcriptase.

5

In order to produce vectors encoding a soluble NY-ESO TCR incorporating a novel disulphide bond, A6 TCR plasmids containing the α chain BamHI and β chain BglII restriction sites were used as templates. The following primers were used:

10

| NdeI |

5' -GGAGATATACATATGCAGGAGGTGACACAG -3' (SEQ ID 137)

5' -TACACGGCAGGATCCGGTTCTGGATATT-3' (SEQ ID 138)

| BamHI |

15

|NdeI |

5' -GGAGATATACATATGGGTGTCACTCAGACC-3' (SEQ ID 139)

5' -CCCAAGCTTAGTCTGCTCTACCCCAGGCCTCGGC -3' (SEQ ID 140)

|BglII |

20

NY-ESO TCR α and β -chain constructs were obtained by PCR cloning as follows. PCR reactions were performed using the primers as shown above, and templates containing the native NY-ESO TCR chains. The PCR products were restriction digested with the relevant restriction enzymes, and cloned into pGMT7 to obtain expression plasmids. The sequence of the plasmid inserts were confirmed by

25 automated DNA sequencing. Figures 17a and 17b show the DNA sequence of the mutated NY-ESO TCR α and β chains respectively, and Figures 18a and 18b show the resulting amino acid sequences.

30

Example 12 - Construction of phage display vectors and cloning of DNA encoding NY-ESO TCR α and β chains into the phagemid vectors.

DNA encoding soluble NY-ESO TCR α and β chains incorporating novel cysteine codons to facilitate the formation of a non-native disulfide inter-chain bond, produced as described in Example 11 were incorporated into the phagemid vector pEX746 as follows.

5

The DNA encoding the two NY-ESO TCR chains were individually subjected to PCR in order to introduce cloning sites compatible with the pEX746 phagemid vector (containing DNA encoding A6 TCR clone 7) using the following primers:

10 *For the NY-ESO TCR alpha chain*

TRAV21

GCCGGCCATGGCCAAACAGGAGGTGACGCAGATTCCT (SEQ ID 141)

YOL6

15 CTTCTTAAAGAATTCTTAATTAACCCTAGGTTATTAGGAACTTTCTGGGCTG
GGGAAG (SEQ ID 142)*For the NY-ESO TCR beta chain*

TRBV6-1/2/3/5/6/7/8/9

20 TCACAGCGCGCAGGCTGGTGTCACTCAGACCCCAA (SEQ ID 143)

RT1

CGAGAGCCCGTAGAACTGGACTTG (SEQ ID 144)

25 The molecular cloning methods for constructing the vectors are described in "Molecular cloning: A laboratory manual, by J. Sambrook and D. W. Russell". Primers listed in table-1 are used for construction of the vectors. An example of the PCR programme is 1 cycle of 94°C for 2 minutes, followed by 25 cycles of 94°C for 5 seconds, 53°C for 5 seconds and 72°C for 90 seconds, followed by 1 cycle of 72°C
30 for 10 minutes, and then hold at 4°C. The Expand high fidelity Taq DNA polymerase is purchased from Roche.

DNA encoding the clone 7 A6 TCR β chain was removed from pEX746 by digestion with restriction enzymes BssHIII and BglII. The correspondingly digested PCR DNA

encoding the NY-ESO β chain was then substituted into the phagemid by ligation. The sequence of the cloning product was verified by automated sequencing.

5 Similarly, DNA encoding the clone 7 A6 TCR α chain was removed from pEX746 by digestion with restriction enzymes NcoI and AvrII. The correspondingly digested PCR DNA encoding the NY-ESO α chain was then substituted into the phagemid already containing DNA encoding the NY-ESO TCR β chain by ligation. The sequence of the cloning product was verified by automated sequencing.

10 Figures 19a and 19b detail respectively the DNA and amino acid sequence of the NY-ESO TCR α and β chain as well as surrounding relevant sequence incorporated in the phagemid (pEX746:NY-ESO). The sequence preceding the NcoI site is the same as pEX746.

15 *Example 13 – Expression of fusions of bacterial coat protein and heterodimeric NY-ESO TCR in E. coli.*

Phage particles displaying the heterodimeric NY-ESO TCR containing a non-native disulfide inter-chain bond were prepared using methods described previously for the generation of phage particles displaying antibody scFvs (Li *et al*, 2000, Journal of
20 Immunological Methods **236**: 133-146) with the following modifications. *E. coli* TG 1 cells containing pEX746:NY-ESO phagemid (i.e. the phagemid encoding the soluble NY-ESO TCR α chain and an NY-ESO TCR β chain fused to the phage gIII protein produced as described in Example 12) were used to inoculate 10 ml of 2x TY (containing 100 μ g/ml of ampicillin and 2% glucose), and then the culture was
25 incubated with shaking at 37°C overnight (16 hours). 50 μ l of the overnight culture was used to inoculate 10 ml of 2x TY (containing 100 μ g/ml of ampicillin and 2% glucose), and then the culture was incubated with shaking at 37°C until OD_{600nm} = 0.8. HYPERPHAGE Helper phage was added to the culture to the final concentration of 5 X 10⁹ pfu/ml. The culture was then incubated at 37°C stationary for thirty minutes and
30 then with shaking at 200 rpm for further 30 minutes. The medium of above culture was then made up to 50 ml with 2x TY (containing 100 μ g/ml of ampicillin and 25 μ g/ml of kanamycin), the culture was then incubated at 25°C with shaking at 250 rpm

for 36 to 48 hours. The culture was then centrifuged at 4°C for 30 minutes at 4000 rpm. The supernatant was filtrated through a 0.45 µm syringe filter and stored at 4°C for further concentration. The supernatant was then concentrated by PEG precipitation and re-suspended in PBS at 10% of the original stored volume.

5

Example 14 – Detection of functional heterodimeric NY-ESO TCR containing a non-native disulfide inter-chain bond on filamentous phage particles

The presence of functional (HLA-A2-NY-ESO binding) NY-ESO TCR displayed on
10 the phage particles in the concentrated suspension prepared in Example 13 was detected using the phage ELISA methods described in Example 4. Figure 20 shows the specific binding of phage particles displaying the NY-ESO TCR to HLA-A2-NY-ESO in a phage ELISA assay.

15 *Example 15 - Construction of plasmids for cellular expression of HLA-DRA genes.*

DNA sequences encoding the extracellular portion of HLA-DRA chains are amplified from cDNA isolated from the blood of a healthy human subject, using the polymerase chain reaction (PCR), with synthetic DNA primer pairs that are designed to include a
20 Bgl II restriction site.

PCR mutagenesis is then used to add DNA encoding the Fos leucine zipper to the 3' end of the amplified sequence.

25 DNA manipulations and cloning described above are carried out as described in Sambrook, J *et al*, (1989). Molecular Cloning - A Laboratory Manual. Second Edition. Cold Spring Harbor Laboratory Press, USA.

Figure 21 provides the DNA sequence of the HLA-DR β chain ready for insertion into
30 the bi-cistronic expression vector. This figure indicates the position of the codons encoding the Fos leucine zipper peptide and the biotinylation tag.

Amino acid numbering is based on the mouse sequence (Kabat, 1991, Sequences of Proteins of Immunological Interest, 5th edition, US Dept of Health & Human Services, Public Health Service, NIH, Bethesda, MD 1-1137)

5 This DNA sequence is then inserted into a bi-cistronic baculovirus vector pAcAB3 (See Figure 22 for the sequence of this vector) along with DNA encoding the corresponding Class II HLA β chain for expression in Sf9 insect cells. This vector can be used to express any Class II HLA-peptide complex in insect cells.

10 *Example 16. Construction of plasmids for cellular expression of HLA-DRB wild type and mutant genes.*

DNA sequences encoding the extracellular portion of HLA-DRB chains are amplified from cDNA isolated from the blood of a healthy human subject, using the polymerase
15 chain reaction (PCR), with synthetic DNA primer pairs that are designed to include a BamH1 restriction site.

PCR mutagenesis is then used to add DNA encoding the Jun leucine zipper to the 3' end of the amplified sequence and DNA encoding the Flu HA peptide loaded by the
20 HLA-DR1 molecule to the 5' end of the sequence.

DNA manipulations and cloning described above are carried out as described in Sambrook, J *et al*, (1989). Molecular Cloning - A Laboratory Manual. Second Edition. Cold Spring Harbor Laboratory Press, USA.

25

Figure 23 provides the DNA sequence of the HLA-DR β chain ready for insertion into the bi-cistronic expression vector. This figure indicates the position of the codons encoding the Jun leucine zipper peptide and the Flu HA peptide.

Amino acid numbering is based on the mouse sequence (Kabat, 1991, Sequences of Proteins of Immunological Interest, 5th edition, US Dept of Health & Human Services, Public Health Service, NIH, Bethesda, MD 1-1137)

5 This DNA sequence is then inserted into a bi-cistronic baculovirus vector pAcAB3 (See Figure 22 for the sequence of this vector) along with DNA encoding the corresponding Class II α chain for expression in Sf9 insect cells. This vector can be used to express any Class II HLA-peptide complex in insect cells.

10 *Example 17 Expression and refolding of Class II HLA-DR1-Flu HA complexes*

Class II MHC expression is carried out using the bi-cistronic expression vectors produced as described in Examples 15 and 16 containing the Class II HLA-DR1 α and β chains and the Flu HA peptide. The expression and purification methods used are as described in (Gauthier (1998) PNAS USA **95** p11828-11833). Briefly, soluble HLA-DR1 is expressed in the baculovirus system by replacing the hydrophobic transmembrane regions and cytoplasmic segments of DR α and β chains with leucine zipper dimerization domains from the transcription factors Fos and Jun. In the expression construct, the required Class MHC-loaded Flu HA peptide sequence is covalently linked to the N terminus of the mature DR β chain and the DR α chain contains a biotinylation tag sequence to facilitate bifunctional ligand formation utilizing the biotin / strepavidin multimerisation methodology. The recombinant protein is secreted by Sf9 cells infected with the recombinant baculovirus, and purified by affinity chromatography. The protein is further purified by anion-exchange HPLC.

25

Example 18 –Construction of Class I soluble peptide-HLA molecules

In order to investigate further the specificity of the high affinity A6 TCR clone 134 the following soluble class I peptide-HLA molecules were produced:

30

HLA-A2 – peptide (LLGRNSFEV) (**SEQ ID 23**)

HLA-A2 – peptide (KLVALGINAV) (**SEQ ID 24**)

HLA-A2 – peptide (LLGDLFGV) (SEQ ID 25)

HLA-B8 - peptide (FLRGRAYGL) (SEQ ID 26)

HLA-B27 – peptide (HRCQAIRKK) (SEQ ID 27)

HLA - Cw6 – peptide (YRSGIIAVV) (SEQ ID 28)

5 HLA-A24 – peptide (VYGFVRACL) (SEQ ID 29)

HLA-A2 – peptide (ILAKFLHWL) (SEQ ID 30)

HLA-A2 – peptide (LTLGEFLKL) (SEQ ID 31)

HLA-A2 – peptide (GILGFVFTL) (SEQ ID 33)

HLA-A2 – peptide (SLYNTVATL) (SEQ ID 34)

10

These soluble peptide-HLAs were produced using the methods described in Example 10.

Example 19 – BIAcore surface plasmon resonance measurement of the specificity of
15 *Clone 134 high affinity A6 TCR binding to peptide-HLA.*

A surface plasmon resonance biosensor (BIAcore 3000™) was used to analyse the binding specificity of the high affinity clone 134 A6 TCR. (See Figures 15a & 15b for the full DNA and amino acid sequences of the mutated TCR β chain respectively)

20 This was carried out using the Class II HLA-DR1-peptide, produced as described in Examples 15 –17, and the Class I peptide-HLA complexes listed in Example 18, produced using the methods detailed in Example 10. The following table lists the peptide-HLA complexes utilised:

- 25
1. HLA-A2 – peptide (LLGRNSFEV) (SEQ ID 23)
 2. HLA-A2 – peptide (KLVALGINAV) (SEQ ID 24)
 3. HLA-A2 – peptide (LLGDLFGV) (SEQ ID 25)
 4. HLA-B8 - peptide (FLRGRAYGL) (SEQ ID 26)
 5. HLA-B27 – peptide (HRCQAIRKK) (SEQ ID 27)
 - 30 6. HLA - Cw6 – peptide (YRSGIIAVV) (SEQ ID 28)
 7. HLA-A24 – peptide (VYGFVRACL) (SEQ ID 29)

8. HLA-A2 – peptide (ILAKFLHWL) (SEQ ID 30)
9. HLA-A2 – peptide (LTLGEFLKL) (SEQ ID 31)
10. HLA-DR1- peptide (PKYVKQNTLKLA) (SEQ ID 32)
11. HLA-A2 – peptide (GILGFVFTL) (SEQ ID 33)
- 5 12. HLA-A2 – peptide (SLYNTVATL) (SEQ ID 34)

The above peptide HLAs were immobilised to streptavidin-coated binding surfaces in of the flow cells of a BIAcore 3000™ in a semi-oriented fashion.

10 The BIAcore 3000™ allows testing of the binding of the soluble T-cell receptor to up to four different pMHC (immobilised on separate flow cells) simultaneously. For this experiment three different HLA-peptides were immobilised in flowcells 2-4 and flowcell 1 was left blank as a control. Manual injection of HLA-peptide complexes allowed the precise level of immobilised molecules to be manipulated.

15 After the ability of the high affinity A6 TCR clone 134 to bind to the first 3 HLA-peptide complexes in the above list had been assessed the next three were immobilised onto these flowcells directly on top of the previous ones. This process was continued until the binding of the high affinity A6 TCR clone 134 to all 12 HLA-peptide
20 complexes had been assessed.

Ten injections of 5 µl of the high affinity A6 TCR clone 134 were passed over each flowcell at at 5 µl/min at concentrations ranging from 4.1 ng/ml to 2.1 mg/ml. (See Figures 24-28)

25 As a final control the high affinity A6 TCR clone 134 was passed over a flowcell containing immobilised HLA-A2 Tax (LLFGYPVYV)(SEQ ID 21), the cognate ligand for this TCR.

30 Specific binding of the high affinity A6 TCR clone 134 was only noted to its cognate ligand. (HLA-A2 Tax (LLFGYPVYV) (SEQ ID 21)) These data further demonstrate the specificity of the high affinity A6 TCR clone 134. (See Figures 24-28)

Example 20 – Mutagenesis of NY-ESO TCR CDR3 regions

The CDR3 regions of the NY-ESO TCR were targeted for the introduction of mutations to investigate the possibility of generating high affinity mutants. This was
5 achieved using NY-ESO TCR-specific PCR primers in combination with methods substantially the same as those detailed in Example 7.

Example 21 – Isolation of high affinity A6 TCR mutants

10 The isolation of high affinity NY-ESO TCR mutants was carried out using the first of the two methods described in Example 8.

A single high affinity NY-ESO TCR mutant was identified.

15 *Example 22 – Production of soluble high affinity heterodimeric NY-ESO TCR with non-native disulfide bond between constant regions, containing variable region mutations*

Phagemid DNA encoding the high affinity NY-ESO TCR mutant identified in
20 Example 21 was isolated from the relevant *E.coli* cells using a Mini-Prep kit (Quiagen, UK)

PCR amplification using the phagemid DNA as a target and the following primers were used to amplify the mutated soluble NY-ESO TCR β chain variable region DNA
25 sequence.

NY-ESO beta chain forward primer
Tctctccattaatgaatgctggtgtcactcagacccc (SEQ ID 145)
(AseI restriction site is underlined)

30 Universal beta chain reverse primer
Tagaaaccggtggccaggcacaccagtgtgg (SEQ ID 146)
(AgeI restriction site is underlined)

The PCR product was then digested with Age1/Ase1 and cloned into pEX821 (Produced as described in Example 11) cut with Nde/Age1.

5 The mutated NY-ESO TCR β chain DNA sequence amplified as described above, and the NY-ESO TCR α chain produced as described in Example 11 were then used to produce a soluble high affinity NY-ESO TCR as described in WO 03/020763. Briefly, the two chains are expressed as inclusion bodies in separate *E. coli* cultures. The inclusion bodies are then isolated, de-natured and re-folded together *in vitro*.

10 *Example 23 – BIAcore surface plasmon resonance characterisation of a high affinity NY-ESO TCR binding to HLA-A2 NY-ESO.*

A surface plasmon resonance biosensor (Biacore 3000™) was used to analyse the binding of the high affinity NY-ESO TCR to the HLA-A2 NY-ESO ligand. This was
15 facilitated by producing pMHC complexes (as described in Example 10) which were immobilised to a streptavidin-coated binding surface in a semi-oriented fashion, allowing efficient testing of the binding of a soluble T-cell receptor to up to four different pMHC (immobilised on separate flow cells) simultaneously. Manual injection of HLA complex allows the precise level of immobilised class I molecules to
20 be manipulated easily.

The interactions between the high affinity NY-ESO TCR containing a novel inter-chain bond and the HLA-A2 NY-ESO complex or an irrelevant HLA-A2 Tax combination, the production of which is described in Example 10, were analysed on a
25 Biacore 3000™ surface plasmon resonance (SPR) biosensor, again as described in Example 10.

The k_d for the interaction of the soluble high affinity NY-ESO with the HLA-A2 NY-ESO was calculated to be 4.1 μM , (See Figures 29a and 29b) which compares to a k_d
30 of 15.7 μM for the wild-type interaction. (See Figures 30a and 30b)

Example 24 – Production and testing of further High Affinity A6 TCRs

Soluble TCRs containing the following mutations corresponding to those identified in clones 89, 1, 111 and 71 (see Example 8) were produced using the methods detailed in Example 9. The binding of these soluble TCRs to HLA-A2 Tax was then assessed using the Biacore assay detailed in Example 10.

A6 TCR β chain mutants

Clone	CDR3 sequence
Wild Type	GCCTCGAGGCCGGGACTAGCGGGAGGGCGACCAGAGCAGTAG (SEQ ID 83) A S R P G L A G G R P E Q Y (SEQ ID 84)
89	GCCTCGAGGCCGGGACTAGCGGGAGGGCGACCAGAGGATTAG (SEQ ID 91) A S R P G L A G G R P E D X (SEQ ID 92)
1	GCCTCGAGGCCGGGGCTGGTTCCGGGGCGACCAGAGCAGTAG (SEQ ID 97) A S R P G L V P G R P E Q X (SEQ ID 98)
111	GCCTCGAGGCCGGGACTAGCGGGAGGGCGACCACATCCGTAG (SEQ ID 101) A S R P G L A G G R P H P X (SEQ ID 102)

10 A6 TCR α chain mutant

Clone	CDR3
Wild Type	GCCGTTACAACCTGACAGCTGGGGGAAGCTTCAG (SEQ ID 107) A V T T D S W G K L Q (SEQ ID 108)
71	GCCGTTACAACCTGACAGCTGGGGGGAGCTTCAT (SEQ ID 117) A V T T D S W G E L H (SEQ ID 118)

Combined mutations used as a basis for the production of mutated soluble A6 TCRs:

Clone 89 mutations + Clone 134 mutations

Clone 71 mutations + Clone 134 mutations

Clone 71 mutations + Clone 89 mutations

Clone 1 mutations + β G102 \rightarrow A mutation

Results:

- 5 The following table compares the HLA-A2 Tax affinity of the above soluble mutated A6 TCRs to that obtained using a soluble A6 TCR containing unmutated variable regions. Note that the affinity of the highest affinity mutants is expressed as the half-life for the interaction. ($T_{1/2}$) These soluble mutant A6 TCRs exhibited higher affinity for HLA-A2 Tax than the unmutated soluble A6 TCR as demonstrated by their lower
- 10 kd or longer $T_{1/2}$ for the interaction.

Figures 31 – 37 show the Biacore traces used to calculate the affinity for HLA-A2 Tax of these soluble mutated TCRs. Figures 38a-e show the amino acid sequence of the mutated A6 TCR chains.

15

A6 TCR	Kd (μ M)	$T_{1/2}$ (Secs)
Wild-type	1.9	7
Clone 1		810
Clone 89	0.41	
Clone 111	1.18	
Clone 71	1.37	
Clone 89 + Clone 134 mutations		114 (phase 1) 4500 (phase 2)
Clone 71 + Clone 134 mutations		882
Clone 71 + Clone 89 mutations	0.35	
Clone 1 + β G102 \rightarrow A mutation		738

Example 25 – Cell staining using High affinity A6 TCR tetramers and monomers

T2 antigen presenting cells were incubated with β 2m (3 μ g/ml) pulsed with Tax peptide at a range of concentrations (10^{-5} – 10^{-9} M) for 90 minutes at 37°C. Controls, also using T2 cells incubated with β 2m (3 μ g/ml), were pulsed with 10^{-5} M Flu peptide or incubated without peptide (unpulsed). After pulsing the cells were washed in serum-free RPMI and 2×10^5 cells were incubated with either strepavidin-linked high affinity Clone 134 A6 TCR tetramer labelled with phycoerythrin (PE). (Molecular probes, The Netherlands) (10 μ g/ml) or high affinity Clone 134 A6 TCR monomers labelled with Alexa 488 (Molecular probes, The Netherlands) for 10 minutes at room temperature. After washing the cells, the binding of the labelled TCR tetramers and monomers was examined by flow cytometry using a FACSVantage SE (Becton Dickinson).

15

Results

As illustrated in Figure 39a specific staining of T2 cells by high affinity A6 TCR tetramers could be observed at Tax peptide concentrations of down to 10^{-9} M.

20

As illustrated in Figure 39b specific staining of T2 cells by high affinity A6 TCR monomers could be observed at Tax peptide concentrations of down to 10^{-8} M.

25

30

Claims:

1. A proteinaceous particle displaying on its surface a T-cell receptor (TCR), characterised in that

5

(i) the proteinaceous particle is a ribosome and the TCR is a single chain TCR (scTCR) polypeptide, or dimeric TCR (dTCR) polypeptide pair, or

10

(ii) the proteinaceous particle is a phage particle, or a cell with cell surface protein or polypeptide molecules to which the TCR is covalently linked, and the TCR is a human scTCR or a human dTCR polypeptide pair, or

15

(iii) the proteinaceous particle is a phage particle, or a cell with cell surface protein or polypeptide molecules to which the TCR is covalently linked, and the TCR is a non-human dTCR polypeptide pair, or

20

(iv) the proteinaceous particle is a phage particle, or a cell with cell surface protein or polypeptide molecules to which the TCR is covalently linked, and the TCR is a scTCR polypeptide comprising TCR amino acid sequences corresponding to extracellular constant and variable domain sequences present in native TCR chains and a linker sequence, the latter linking a variable domain sequence corresponding to that of one chain of a native TCR to a constant domain sequence corresponding to a constant domain sequence of another native TCR chain, and a disulfide bond which has no equivalent in native T cell receptors links residues of the constant domain sequences.

25

2. A proteinaceous particle, displaying on its surface a dimeric T-cell receptor (dTCR) polypeptide pair, or a single chain T-cell receptor (scTCR) polypeptide wherein

30

the dTCR polypeptide pair is constituted by TCR amino acid sequences corresponding to extracellular constant and variable domain sequences present

in native TCR chains, and the scTCR is constituted by TCR amino acid sequences corresponding to extracellular constant and variable domain sequences present in native TCR chains and a linker sequence, the latter linking a variable domain sequence corresponding to that of one chain of a native TCR to a constant domain sequence corresponding to a constant domain sequence of another native TCR chain;

wherein the variable domain sequences of the dTCR polypeptide pair or scTCR polypeptide are mutually orientated substantially as in native TCRs, and

in the case of the scTCR polypeptide a disulfide bond which has no equivalent in native T cell receptors links residues of the polypeptide.

3. A proteinaceous particle as claimed in claim 1 or claim 2, which is a filamentous phage particle.
4. A proteinaceous particle as claimed in claim 1 or claim 2, which is a cell with cell surface protein or polypeptide molecules to which the TCR is covalently linked.
5. A proteinaceous particle as claimed in claim 1 or claim 2, which is a ribosome.
6. A proteinaceous particle as claimed in any of the preceding claims wherein the C-terminus of one member of the dTCR polypeptide pair, or the C-terminus of the scTCR polypeptide, is linked by a peptide bond to a surface exposed residue of the proteinaceous particle.
7. A proteinaceous particle as claimed in any of claims 1 to 4 wherein the C-terminus of one member of the dTCR polypeptide pair, or the C-terminus of the

scTCR polypeptide, is linked by a disulfide bond to a surface exposed cysteine residue of the proteinaceous particle.

8. A proteinaceous particle as claimed in any of the preceding claims wherein a
5 scTCR polypeptide is displayed which comprises

a first segment constituted by an amino acid sequence corresponding to a TCR
 α or δ chain variable domain

10 a second segment constituted by an amino acid sequence corresponding to a
TCR β or γ chain variable domain sequence fused to the N terminus of an
amino acid sequence corresponding to a TCR β chain constant domain
extracellular sequence, and

15 a linker sequence linking the C terminus of the first segment to the N terminus
of the second segment,

PROVIDED THAT where the proteinaceous particle is a phage, the scTCR
corresponds to a human TCR.

20

9. A proteinaceous particle as claimed in any of claims 1 to 7 wherein a scTCR
polypeptide is displayed which comprises

25 a first segment constituted by an amino acid sequence corresponding to a TCR
 β or γ chain variable domain

a second segment constituted by an amino acid sequence corresponding to a
TCR α or δ chain variable domain sequence fused to the N terminus of an
amino acid sequence corresponding to a TCR α chain constant domain
30 extracellular sequence, and

a linker sequence linking the C terminus of the first segment to the N terminus of the second segment

PROVIDED THAT where the proteinaceous particle is a filamentous phage, the
5 scTCR corresponds to a human TCR.

10. A proteinaceous particle as claimed in any of claims 1 to 7 wherein a scTCR polypeptide is displayed which has

10 a first segment constituted by an amino acid sequence corresponding to a TCR α or δ chain variable domain sequence fused to the N terminus of an amino acid sequence corresponding to a TCR α chain constant domain extracellular sequence,

15 a second segment constituted by an amino acid sequence corresponding to a TCR β or γ chain variable domain fused to the N terminus of an amino acid sequence corresponding to TCR β chain constant domain extracellular sequence,

20 a linker sequence linking the C terminus of the first segment to the N terminus of the second segment, or vice versa, and

a disulfide bond between the first and second chains, said disulfide bond being one which has no equivalent in native $\alpha\beta$ or $\gamma\delta$ T cell receptors,

25 the length of the linker sequence and the position of the disulfide bond being such that the variable domain sequences of the first and second segments are mutually orientated substantially as in native $\alpha\beta$ or $\gamma\delta$ T cell receptors.

30

11. A proteinaceous particle as claimed in claim 10 wherein the linker sequence has the formula -P-AA-P- wherein P is proline and AA represents an amino acid sequence wherein the amino acids are glycine and serine.
- 5 12. A proteinaceous particle as claimed in claim 10 or claim 11 wherein the linker sequence links the C terminus of the first segment to the N terminus of the second segment.
- 10 13. A proteinaceous particle as claimed in claim 12 wherein the linker sequence consists of from 26 to 41 amino acids.
14. A proteinaceous particle as claimed in claim 13 wherein the linker sequence consists of 29, 30, 31 or 32 amino acids.
- 15 15. A proteinaceous particle as claimed in claim 13 wherein the linker sequence consists of 33, 34, 35 or 36 amino acids.
- 20 16. A proteinaceous particle as claimed in claim 13 wherein the linker sequence has the formula -PGGG-(SGGGG)₅-P- wherein P is proline, G is glycine and S is serine.
- 25 17. A proteinaceous particle as claimed in claim 13 wherein the linker sequence has the formula -PGGG-(SGGGG)₆-P- wherein P is proline, G is glycine and S is serine.
- 30 18. A proteinaceous particle as claimed in any of claims 1 to 7 wherein a dTCR polypeptide pair is displayed which is constituted by
- a first polypeptide wherein a sequence corresponding to a TCR α or δ chain variable domain sequence is fused to the N terminus of a sequence corresponding to a TCR α chain constant domain extracellular sequence, and

a second polypeptide wherein a sequence corresponding to a TCR β or γ chain variable domain sequence fused to the N terminus a sequence corresponding to a TCR β chain constant domain extracellular sequence,

5

the first and second polypeptides being linked by a disulfide bond which has no equivalent in native $\alpha\beta$ or $\gamma\delta$ T cell receptors.

19. A proteinaceous particle as claimed in any preceding claim wherein the displayed dTCR polypeptide pair or scTCR polypeptide have amino acid sequences corresponding to $\alpha\beta$ TCR extracellular constant and variable domain sequences.

10

20. A proteinaceous particle as claimed in any of claims 1 to 19 wherein the displayed dTCR polypeptide pair or scTCR polypeptide have amino acid sequences corresponding to extracellular $\alpha\beta$ TCR constant domain sequences and $\gamma\delta$ TCR variable domain sequences.

15

21. A proteinaceous particle as claimed in any preceding claim wherein the displayed dTCR polypeptide pair or scTCR polypeptide have amino acid sequences corresponding to non-human extracellular $\alpha\beta$ TCR constant domain sequences and human TCR variable domain sequences.

20

22. A proteinaceous particle as claimed in any of the preceding claims wherein an amino acid sequence of one member of the displayed dTCR polypeptide pair, or an amino acid sequence of the displayed scTCR, corresponds to a native TCR extracellular constant chain Ig domain sequence.

25

23. A proteinaceous particle as claimed in any of claims 1 to 22 wherein the displayed dTCR polypeptide pair or displayed scTCR, includes sequences corresponding to native TCR extracellular constant chain Ig domain sequences.

30

24. A proteinaceous particle as claimed in claim 23 wherein a disulfide bond links amino acid residues of the said constant chain Ig domain sequences, which disulfide bond has no equivalent in native TCRs.
- 5 25. A proteinaceous particle as claimed in claim 24 wherein the said disulfide bond is between cysteine residues corresponding to amino acid residues whose β carbon atoms are less than 0.6 nm apart in native TCRs.
- 10 26. A proteinaceous particle as claimed in claim 24 wherein the said disulfide bond is between cysteine residues substituted for Thr 48 of exon 1 of TRAC*01 and Ser 57 of exon 1 of TRBC1*01 or TRBC2*01 or the non-human equivalent thereof.
- 15 27. A proteinaceous particle as claimed in claim 24 wherein the said disulfide bond is between cysteine residues substituted for Thr 45 of exon 1 of TRAC*01 and Ser 77 of exon 1 of TRBC1*01 or TRBC2*01 or the non-human equivalent thereof.
- 20 28. A proteinaceous particle as claimed in claim 24 wherein the said disulfide bond is between cysteine residues substituted for Tyr 10 of exon 1 of TRAC*01 and Ser 17 of exon 1 of TRBC1*01 or TRBC2*01 or the non-human equivalent thereof.
- 25 29. A proteinaceous particle as claimed in claim 24 wherein the said disulfide bond is between cysteine residues substituted for Thr 45 of exon 1 of TRAC*01 and Asp 59 of exon 1 of TRBC1*01 or TRBC2*01 or the non-human equivalent thereof.
- 30 30. A proteinaceous particle as claimed in claim 24 wherein the said disulfide bond is between cysteine residues substituted for Ser 15 of exon 1 of TRAC*01 and Glu 15 of exon 1 of TRBC1*01 or TRBC2*01 or the non-human equivalent thereof.
31. A proteinaceous particle as claimed in any of claims 23 to 30 wherein the sequences corresponding to native TCR extracellular constant chain Ig domain

sequences are truncated at their C-termini relative to said native sequences such that the cysteine residues which form the native interchain disulphide bond are excluded.

5 32. A proteinaceous particle as claimed in any of claims 23 to 30 wherein in the sequences corresponding to native TCR extracellular constant chain Ig domain sequences the cysteine residues which form the native interchain disulphide bond are substituted by non-cysteine residues.

10 33. A proteinaceous particle as claimed in claim 32 wherein the cysteine residues which form the native interchain disulfide bond are substituted by serine or alanine.

34. A proteinaceous particle as claimed in any of the preceding claims wherein in the displayed dTCR or scTCR there is no unpaired cysteine residue corresponding an unpaired cysteine residue present in a native TCR.

15 35. A proteinaceous particle as claimed in any of claims 23 to 34 wherein the sequences corresponding to native TCR extracellular constant chain Ig domain sequences are truncated N-terminal to residues corresponding to those which form the non-native interchain disulphide bond.

20 36. A proteinaceous particle as claimed in claim 1 which is a filamentous phage particle displaying on its surface a dimeric T-cell receptor (dTCR) polypeptide pair, the said pair being constituted by

25 a first polypeptide wherein a sequence corresponding to a TCR α chain variable domain sequence is fused to the N terminus of a sequence corresponding to a TCR α chain constant domain extracellular sequence, and

30 a second polypeptide wherein a sequence corresponding to a TCR β chain variable domain sequence is fused to the N terminus a sequence corresponding to a TCR β chain constant domain extracellular sequence,

the first and second polypeptides being linked by a disulfide bond between cysteine residues substituted for Thr 48 of exon 1 of TRAC*01 and Ser 57 of exon 1 of TRBC1*01 or TRBC2*01 or the non-human equivalent thereof,

5

the C-terminus of one member of the dTCR polypeptide pair being linked by a peptide bond to a coat protein of the phage.

37. A diverse library of dTCR polypeptide pairs or scTCR polypeptides displayed on proteinaceous particles said dTCR polypeptide pairs or scTCR polypeptides having the structural features defined in any of claims 8 to 36.

10

38. A diverse library as claimed in claim 37 wherein the diversity resides in the variable domain(s) of the dTCR or scTCR polypeptides.

15

39. A diverse library as claimed in any of claims 37 to 39 wherein the proteinaceous particles are filamentous phage particles.

20

40. A diverse library of filamentous phage particles as claimed in claim 35, wherein the diversity resides in one or more of the complementarity determining regions of the variable domain(s) of the dTCR or scTCR polypeptides and/or in one or more of the framework regions of the complementarity determining regions of the displayed dTCR or scTCR polypeptides.

25

41. Nucleic acid encoding (a) one chain of a dTCR polypeptide pair and (b) the other chain of a dTCR polypeptide pair fused to a nucleic acid sequence encoding a protein capable of forming part of the surface of a proteinaceous particle; or nucleic acid encoding a scTCR polypeptide fused to a nucleic acid sequence encoding a protein capable of forming part of the surface of a proteinaceous particle, the dTCR pair or scTCR having the structural features defined in any of claims 8 to 36.

30

42. An expression vector comprising nucleic acid as claimed in claim 41, or a composition comprising a first vector comprising nucleic acid (a) as defined in claim 42 and a second vector comprising nucleic acid (b) as defined in claim 42.
- 5 43. An expression system comprising phagemid or phage genome vectors expressing nucleic acid as claimed in claim 41.
44. An expression system as claimed in claim 43 wherein the phagemid or phage genome vectors is (are) derived from a filamentous phage
- 10 45. An expression system as claimed in claim 44 wherein the phagemid or phage genome vectors encode(s) bacteriophage gIII or gVIII coat proteins.
46. An expression system as claimed in any of claims 43 to 45 where a vector
- 15 contains a sequence or sequences which limit constitutively or inducibly the amount of TCR polypeptide expressed by the vector to a desired level.
47. An expression system as claimed in claim 46 wherein the said sequence(s) is (are) weak promoter sequence(s)
- 20 48. An expression system as claimed in claim 46 wherein the said sequence(s) is (are) mutated ribosome binding site(s).
49. An expression system as claimed in claim 46 wherein the said sequence(s) is
- 25 (are) miss-sense suppressor stop codon(s).
50. An expression system as claimed in claim 46 wherein the said sequence(s) is (are) mutated start codon(s).

51. An expression system as claimed in claim 46 wherein the said sequence(s) is (are) promoter sequence(s) amenable to metabolite-mediated modification of promoter strength.
- 5 52. An expression system as claimed in claim 46 wherein the said sequence(s) contain(s) a number of codons less preferred by the expression system being utilised.
53. A host cell comprising nucleic acid as claimed in claim 41, an expression vector as claimed in claim 42 or an expression system as claimed in any of claims 43
10 to 52.
54. A host cell harbouring a phagemid expression system as claimed in any of claims 43 to 52, and a helper phage.
- 15 55. A method for the identification of TCRs with a specific characteristic, said method comprising subjecting a diverse library of TCRs displayed on proteinaceous particles as claimed in any of claims 37 to 40 to
- 20 a selection process which selects for said characteristic, and isolating proteinaceous particles which display a TCR having said characteristic, and optionally to an amplification process to multiply the isolated particles.
- and/or
- 25 a screening process which measures said characteristic, identifying those proteinaceous particles which display a TCR with the desired characteristic and isolating these proteinaceous particles, and optionally to an amplification process to multiply the isolated particles.
- 30 56. A method as claimed in claim 57 wherein the specific characteristic is increased affinity for a TCR ligand.

57. A method for detecting TCR ligand complexes, which comprises:
- (i) providing a TCR-displaying proteinaceous particle(s) as claimed in any of claims 1 to 41;
 - (ii) contacting said TCR-displaying proteinaceous particle(s) with a putative ligand complex; and
 - (iii) detecting binding of the said TCR-displaying proteinaceous particle(s) to the putative ligand complexes.
- 58 A method as claimed in claim 57 wherein the putative TCR ligand complexes are peptide-MHC complexes.
59. A method of identifying an inhibitor of the interaction between a TCR-displaying proteinaceous particle(s) as claimed in any one of claims 1 to 41, and a TCR-binding ligand comprising contacting the TCR-displaying proteinaceous particle with a TCR-binding ligand, in the presence of and in the absence of a test compound, and determining whether the presence of the test compound reduces binding of the TCR-displaying proteinaceous particle(s) to the TCR-binding ligand, such reduction being taken as identifying an inhibitor.
60. A TCR specific for a given TCR ligand, which (i) has the structural features defined in any of claims 8 to 36, (ii) is mutated in the variable domain(s) relative to the native TCR specific for said TCR ligand and which (iii) has a K_d for the said TCR ligand less than that of the native TCR.
61. A TCR specific for a given TCR ligand, which (i) has the structural features defined in any of claims 8 to 36, (ii) is mutated in the variable domain(s) relative to the native TCR specific for said TCR ligand and which (iii) has a K_d for the said TCR ligand less than that of the native TCR as measured by Surface Plasmon Resonance.
62. A TCR specific for a given TCR ligand, which (i) has the structural features defined in any of claims 8 to 36, (ii) is mutated in the variable domain(s) relative to the

native TCR specific for said TCR ligand and which (iii) has an off-rate (k_{off}) for the said TCR ligand less than that of the native TCR

5 63. A TCR specific for a given TCR ligand, which (i) has the structural features defined in any of claims 8 to 36, (ii) is mutated in the variable domain(s) relative to the native TCR specific for said TCR ligand and which (iii) has an off-rate (k_{off}) for the said TCR ligand less than that of the native TCR as measured by Surface Plasmon Resonance.

10 64. A dimeric TCR as claimed in any of claims 60 to 63 which has the structural features of an $\alpha\beta$ heterodimeric TCR defined in any of claims 18 to 36.

15 65. A TCR as claimed in any of claims 60 to 64 which is mutated relative to the native TCR in at least one complementarity determining region and/or framework region thereof.

66. A TCR as claimed in any of claims 60 to 65 which is specific for a given MHC type or types.

20 67. A TCR as claimed in any of claims 60 to 65 which is specific for a given pMHC.

68. A TCR as claimed in any of claims 60 to 65 or 67 which is specific for the HLA-A2 Tax peptide (LLFGYPVYV) (SEQ ID 21) complex.

25 69. A TCR as claimed in claim 68 comprising the beta chain variable domain amino acids shown in SEQ IDs 172, 173, 174, or 175.

30 70. A TCR as claimed in claim 68 comprising one of more of beta chain variable domain amino acids 99M, 99V, 100S, 100P, 101A, 102E, 102Q, 104H, 105P, 105D and 106Q using the numbering shown in SEQ ID 171.

71. A TCR as claimed in claim 68 comprising beta chain variable domain amino acids 99M, 100S and 101A, using the numbering shown in SEQ ID 171.
- 5 72. A TCR as claimed in claim 68 comprising beta chain variable domain amino acid 105D, using the numbering shown in SEQ ID 171
73. A TCR as claimed in claim 68 comprising beta chain variable domain amino acids 99V and 100P, using the numbering shown in SEQ ID 171.
- 10 74. A TCR as claimed in claim 68 comprising beta chain variable domain amino acids 104H and 105P, using the numbering shown in SEQ ID 171.
75. A TCR as claimed in any of claims 60 to 65 or 67 which is specific for the
15 HLA-A2 NY-ESO peptide (SLLMITQC) (SEQ ID 22) complex.
76. Nucleic acid encoding a TCR as claimed in any of claims 60 to 78.
77. A TCR as claimed in any of claims 60 to 75 associated with a therapeutic
20 compound.
78. A TCR as claimed in any of claims 60 to 75 associated with an imaging compound.
- 25 79. A TCR as claimed in any of claims 60 to 75 associated with a cytotoxic compound.
80. A TCR as claimed in claims 77 or 79 wherein the TCR is specific for the HLA-A2 Tax peptide (LLFGYPVYV) (SEQ ID 21) complex.
- 30

81. A TCR as claimed in claims 77 or 79 wherein the TCR is specific for the HLA-A2 NY-ESO peptide (SLLMITQC) (**SEQ ID 22**) complex.
82. A method of treatment of HTLV-1 infection comprising administering to a
5 subject suffering such infection an effective amount of a TCR as claimed in any of claims 68 to 74, or claim 79.
83. The use of a TCR as claimed in any of claims 68 to 74, or claim 79 in the
preparation of a composition for the treatment of HTLV-1 infection.
10
84. A method of treatment of cancer comprising administering to a subject
suffering such cancer an effective amount of a TCR as claimed in claim 75 or claim
81.
- 15 85. The use of a TCR as claimed in claim 75 or claim 81 in the preparation of a composition for the treatment of cancer.

Figure 1a

Atgcagaaggaagtggagcagaactctggacccctcagtgttccagagggagccatt
gcctctctcaactgcacttacagtgaccgaggttcccagtccttcttctggtacaga
caatattctgggaaaagccctgagttgataatgtccatatactccaatggtgacaaa
gaagatggaaggtttacagcacagctcaataaagccagccagtatgtttctctgctc
atcagagactcccagcccagtgattcagccacctacctctgtgccgttacaactgac
agctgggggaaattgcagtttggagcagggaccaggttgtgggtcaccagataatc
cagaaccctgaccctgccgtgtaccagctgagagactctaaatccagtgacaagtct
gtctgcctattcaccgattttgattctcaacaaatgtgtcacaagtaaggattct
gatgtgtatatcacagacaaaatggtgtgctagacatgaggtctatggacttcaagagc
aacagtgctgtggcctggagcaacaaatctgactttgcatgtgcaaacgccttcaac
aacagcattattccagaagacaccttcttccccagcccagaaagtctcctaa

(SEQ ID 147)**Figure 1b**

atgaacgctgggtgtcactcagacccccaaaattccaggtcctgaagacaggacagagc
atgacactgcagtggtgccaggatatgaaccatgaatacatgtcctgggtatcgacaa
gaccagggcatggggctgaggctgattcattactcagttgggtgctgggtatcactgac
caaggagaagtccccaatggctacaatgtctccagatcaaccacagaggatttcccg
ctcaggctgctgtcggctgctccctcccagacatctgtgtacttctgtgccagcagg
ccgggactagcgggagggcgaccagagcagtgacttcgggcccgggcaccaggctcacg
gtcacagaggacctgaaaaacgtgttcccacccgaggtcgctgtgtttgagccatca
gaagcagagatctcccacacccaaaaggccacactgggtgtgcctggccacaggcttc
taccocgaccacgtggagctgagctgggtgggtgaatgggaaggaggtgcacagtggg
gtctgacagacccgcagcccctcaaggagcagcccgcctcaatgactccagatac
gctctgagcagccgcctgagggctctcggccaccttctggcaggacccccgcaaccac
tccgctgtcaagtcagttctacgggctctcggagaatgacgagtgaccagggat
agggccaaaccctcaccagatcgtcagcgcggaggcctggggtagagcagactaa

(SEQ ID 148)

Figure 2a

MQ

KEVEQNSGPL SVPEGAIASL NCTYSDRGSQ SFFWYRQYSG KSPELIMSIY
SNGDKEDGRF TAQLNKASQY VLLIRDSQP SDSATYLCAV TTDSWGKLOF
GAGTQVVVTP DIQNPDPAVY QLRDSKSSDK SVCLFTDFDS QTNVSQSKDS
DVYITDKCVL DMRSMDFKSN SAVAWSNKSD FACANAFNNS IIPEDTFFPS
PESS*

(SEQ ID 149)**Figure 2b**

M

NAGVTQTPKF QVLKTGQSMT LQCAQDMNHE YMSWYRQDPG MGLRLIHYSV
GAGITDQGEV PNGYNVSRST TEDFPLRLLS AAPSQTSVYF CASRPGLAGG
RPEQYFGPGT RLTVTEDLKN VFPPEVAVFE PSEAEISHTQ KATLVCLATG
FYPDHVELSW WVNGKEVHSG VCTDPQPLKE QPALNDSRYA LSSRLRVSAT
FWQDPRNHFR CQVQFYGLSE NDEWTQDRAK PVTQIVSAEA WGRAD*

(SEQ ID 150)

Figure 3




Figure 4

```

1  gttaactacg tcaggtggca cttttcgggg aaatgtgcg c ggaacccta tttgtttatt
61  tttctaaata cattcaaata tgtatccgct catgagacia taaccctgat aaatgcttca
121 ataatatga aaaaggaaga gtatgagtat tcaacatttc cgtgtcgccc ttattcctt
181 ttttgccgca ttttgccctt cgttttttgc tcaccagaa acgctgggta aagtaaaaga
241 tgctgaagat cagttgggtg cacgagtggg ttacatcgaa ctggatctca acagcggtaa
301 gatccttgag agttttcgcc ccgaagaacg ttctccaatg atgagcactt ttaaagtctt
361 gctatgtggc gcggtattat ccggtgttga cgccgggcaa gagcaactcg gtcgcccgat
421 acaactattct cagaatgact tgggtgagta ctcaccagtc acagaaaagc atcttacgga
481 tggcatgaca gtaagagaat tatgcagtg cgtccataacc atgagtgata acactgcccg
541 caacttactt ctgacaacga tcggaggacc gaaggagcta accgctttt tgcaacaacat
601 gggggatcat gtaactcgcc ttgatcgttg ggaaccggag ctgaatgaag ccataccaaa
661 cgacgagcgt gacaccacga tgctgttagc aatggcaaca acggtgcgca aactattaac
721 tggcgaaacta cttactctag cttcccggca acaattaata gactggatgg aggcggataa
781 agttgcagga ccacttctgc gctcggccct tccggctggc tggtttattg ctgataaatc
841 tggagccggt gagcgtgggt ctcgcccgtt cattgcagca ctggggccag atggtaaagc
901 ctcccgtatc gtagttatct acacgacggg gagtcaggca actatggatg aacgaaatag
961 acagatcgct gagatagggt cctcactgat taagcattgg taactgtcag accaagtta
1021 ctcatatata ctttagattg atttacccc gttgataatc agaaaagccc caaaaacagg
1081 aagattgtat aagcaaatat ttaaattgta aacgttaata ttttgtaaa attcgctt
1141 aatttttggt aaatcagctc attttttaac caataggccg aaatcggcaa aatccctat
1201 aaatcaaaag aatagcccga gatagggttg agtgttgttc cagtttgga caagagtcca
1261 ctattaaaga acgtggactc caacgtcaaa gggcgaaaaa ccgtctatca gggcatggc
1321 cactacgtg aaccatcacc caaatcaagt tttttgggt cgaggtgccg taaagcacta
1381 aatcgaacc ctaaaggag ccccgattt agagcttgac ggggaaagc aacgtggcga
1441 gaaaggaagg gaagaaagcg aaaggagcgg gcgctagggc gctggcaagt gtagcgtca
1501 cgetgcgct aaccaccaca cccgcccgc ttaatgcgc gctacagggc gcgtaaaagg
1561 atctagggtg agatcctttt tgataatctc atgacaaaa tccctaacg tgagtttctg
1621 tccactgag cgtcagacc cgtagaaaag atcaaggat cttcttgata tcctttttt
1681 ctgctgtaa tctgctgctt gcaaacaaaa aaaccaccgc taccagcggg ggtttgtttg
1741 ccgatcaag agctaccaac tctttttccg aaggtaactg gcttcagcag agcgcagata
1801 ccaataactg ttcttctagt gtagccgtag ttaggccaac acttcaagaa ctctgtagca
1861 ccgctacat acctcgctct gctaactctg ttaccagtgg ctgctgccag tggcgataag
1921 ctctgtctta ccgggttgg ctaagacga tagttaccgg ataaggcga gcggtcgggc
1981 tgaacggggg gttcgtgac acagcccagc ttggagcgaa cgactacac cgaactgaga
2041 tacctacagc gtgagctatg agaaagcgc acgcttcccg aaggagaaa ggcggacagg
2101 tatccggtaa gcggcagggt cggaacagga gagcgcacga gggagcttc agggggaaac
2161 gcttggtatc tttatagtcc tgtcgggttt cgcacactct gacttgagcg tcatttttg
2221 tgatgctcgt caggggggcg gagcctatgg aaaaacgcca gcaacgggc ctttttacgg
2281 ttctggcct tttgctggc ttttctcag atgtaatgtg agttagctca ctcattaggc
2341 acccaggct ttacacttta tgcttccggc tcgtatgttg tgtggaattg tgagcgata
2401 acaatttcac acaggaaaca gctatgacca tgattacgcc aagctacgta taataatatt
2461 ctatttcaag gagacagtca taatgaaata cctattgcct acggcagccg ctggattggt
2521 attactcgcg gccagcccg ccatggcca gaaggaaagt gagcagaact ctggaccctt
2581 cagtgttcca gagggagcca ttgctctct caactgcact tacagtgacc gaggttccca
2641 gtcttcttc tggtacagac aatattctgg gaaaagcct gagttgataa tgtccatata
2701 ctccaatggt gacaagaag atggaaggtt tacagcacag ctcaataaag ccagccagta
2761 tgtttctctg ctcatcagag actcccagcc cagtgattca gccacctacc tctgtgcgt
2821 tacaactgac agctggggga aattgcagtt tggagcaggg acccaggttg tggcaccctt
2881 agatatccag aaccctgacc ctgcccgtga ccagctgaga gactcctaat ccagtgaca
2941 gtctgtctgc ctattcaccg attttgattc tcaaaaaat gtgtcaciaa gtaaggattc
3001 tgatgtgtat atcacagaca aatgtgtgct agacatgagg tctatggact tcaagagcaa
3061 cagtctgtg gcctggagca acaaatctga ctttgcatgt gcaaacgctt caacaacag
3121 cattattcca gaagacacct tcttcccag cccagaaagt tctaataaac ctagggtta
3181 taagaattct ttaagaagga gatatacata tgaaaaaatt attattcgca atctcttag
3241 ttgttctctt ctattctcac agcgcgagc ctggtgtcac tcagacccta aattccagg
3301 tctgaagac aggacagagc atgacactgc agtgtccca ggatagaac catgaatata
3361 tgtcctggta tcgacaagac ccaggcatgg ggctgaggct gattcattac tcagttggtg

```

3421 ctggtatcac tgaccaagga gaagtcccca atgggtacaa tgtctccaga tcaaccacag
3481 aggatttccc gctcaggctg ctgtcggctg ctccctccca gacatctgtg tacttctgtg
3541 ccagcaggcc gggactagcg ggagggcgac cagagcagta cttcggggccg ggcaccaggc
3601 tcacggtcac agaggacctg aaaaacgtgt tcccaccga ggtcgcctgtg tttgagccat
3661 cagaagcaga gatctcccac acccaaaagg ccacactggt gtgcctggcc acaggcttct
3721 accccgacca cgtggagctg agctggtggg tgaatgggaa ggaggtgcac agtggggctt
3781 gcacagacc gcagcccctc aaggagcagc ccgccctcaa tgactccaga tacgctctga
3841 gcagccgctt gagggtctcg gccaccttct ggcaggacc cgcgaaccac ttccgctgtc
3901 aagtccagtt ctacgggctc tcggagaatg acgagtggtg ccaggatagg gccaaaccgg
3961 tcaccagat cgtcagcgcg gaggcctggg gtagagcaga cgcggccgca tctagacatc
4021 atcacatca tccactagact gttgaaagtt gtttagcaaa accccataca gaaaattcat
4081 ttactaacgt ctggaaagac gacaaaactt tagatcgtaa cgtaactat gagggtgtgtc
4141 tgtggaatgc tacaggcgtt gtagtttgta ctggtgacga aactcagtg tactggtacat
4201 gggttcctat tgggcttget atccctgaaa atgaggggtgg tggctctgag ggtggcggtt
4261 ctgaggggtg cggttctgag ggtggcggta ctaaactctc tgagtacggg gatacaccta
4321 ttccgggcta tacttataatc aaccctctcg acggcactta tccgcctggt tccgacaaa
4381 accccgctaa tcctaactct tctcttgagg agtctcagcc tcttaatact ttcagttttc
4441 agaataatag gttccgaaat aggcaggggg cattaactgt ttatacgggc actgttactc
4501 aaggcactga ccccgtaaa acttattacc agtacactcc tgtatcatca aaagccatgt
4561 atgacgctta ctggaacggt aaattcagag actgcgcttt ccattctggc tttaatgagg
4621 atccattcgt ttgtgaatat caaggccaat cgtctgacct gcctcaacct cctgtcaatg
4681 ctggcgggcg ctctggtggt ggttctggtg cggctctga ggggtggtgg tctgagggtg
4741 gcggttctga ggggtggcggc tctgagggag gcggttccgg tgggtggctc ggttccggtg
4801 attttgatta tgaaaagatg gcaaacgcta ataagggggc tatgaccgaa aatgccgatg
4861 aaaacgcgct acagtctgac gctaaaggca aacttgattc tgtcgctact gattacggtg
4921 ctgctatcga tggtttcatt ggtgacgttt ccggccttgc taatggtaat ggtgctactg
4981 gtgattttgc tggctctaat tcccaaatgg ctcaagtcgg tgacggtgat aattcacctt
5041 taatgaataa tttccgtcaa tattacctt ccctccctca atcggttgaa tgtcgccctt
5101 ttgtcttttag cgctggtaaa ccatatgaat ttctattga ttgtgacaaa ataaacttat
5161 tccgtggtgt ctttgcgttt cttttatatg ttgccacctt tatgtatgta ttttctacgt
5221 ttgctaacat actgcgtaat aaggagtctt aataaggtac cctctagtca aggcctatag
5281 tgagtcgtat tacggactgg ccgtcgtttt acaacgctcg gactgggaaa accctggcgt
5341 taccacactt aatcgcttgg cagcacatcc ccctttcgcc agctggcgta atagcgaaga
5401 ggcccgcacc gatcgccctt cccaacagtt gcgcagcctg aatggcgaat ggcgcttcgc
5461 ttgtaataa agcccgttcc ggcgggcttt ttttt

(SEQ ID 151)

Figure 5




Figure 6




Figure 7a

Schematic diagram of the A6 scTCR-C-Kappa ribosome display construct




Figure 7b

```

agctgcagct aatacgactc actataggaa caggccacca tgggccagaa
ggaagtggag cagaactctg gaccctcag tgttcagag ggagccattg
cctctctcaa ctgcacttac agtgaccgag gttcccagtc cttcttctgg
tacagacaat attctgggaa aagccctgag ttgataatgt ccatatactc
caatggtgac aaagaagatg gaaggtttac agcacagctc aataaaagcca
gccagtatgt ttctctgctc atcagagact cccagcccag tgattcagcc
acctacctct gtgccgttac aactgacagc tgggggaaat tgcagtttgg
agcagggacc caggttgtgg tcaccggtgg aggcggttca ggcggaggtg
gatccggcgg tggcgggtcg aacgctgggtg tcaactcagac cccaaaatc
caggtcctga agacaggaca gagcatgaca ctgcagtggtg cccaggatat
gaacatgaa tacatgtcct ggtatcgaca agaccaggc atggggctga
ggctgattca ttactcagtt ggtgctggtg tcaactgacca aggagaagtc
cccaatggct acaatgtctc cagatcaacc acagaggatt tcccgtcag
gctgctgtcg gctgctcctt cccagacatc tgtgtacttc tgtgccagca
ggccgggact agcgggaggg cgaccagagc agtacttcgg gccgggcacc
aggetcacgg tcacagagga cctgaaaaac gtgttccac ccgaggctgc
tgtgtttgag ccatcagaag cagagatctc ccacacccaa aaggccacac
tgggtgtcct ggcacagggc ttctaccccg accacgtgga gctgagctgg
tgggtgaaat ggaaggaggt gcacagtggg gtcagcacag acccgcagcc
cctcaaggag cagcccggcc tcaatgactc cagatacgtt ctgagcagcc
gcctgagggg ctgggccacc ttctggcagg acccccgcaa ccaactccgc
tgtcaagtcc agttctacgg gctctcggag aatgacgagt ggaccagga
tagggccaaa cccgtcacc cagatcgtcag cggcgaggcc tggggtagag
cagacgggtg aggcgggttca ctcagcagca ccctgacgct gagcaaagca
    
```

gactacgaga aacacaaagt ctacgcctgc gaagtcaccc atcagggcct
 gagttcgccc gtcacaaaga gcttcaaccg cggagagtca taagaattct
 cag

(SEQ ID 152)

Figure 7C

M G Q K E V E Q N S G P L S V P E G A I A S L
 N C T Y S D R G S Q S F F W Y R Q Y S G K S P
 E L I M S I Y S N G D K E D G R F T A Q L N K
 A S Q Y V S L L I R D S P S D S A T Y L C A V
 T T D S W G K L Q F G A G T Q V V V T G G G G
 S G G G G S G G G G S N A G V T Q T P K F Q V
 L K T G Q S M T L Q C A Q D M N H E Y M S W Y
 R Q D P G M G L R L I H Y S V G A G I T D Q G
 E V P N G Y N V S R S T T E D F P L R L L S A
 A P S Q T S V Y F C A S R P G L A G G R P E Q
 Y F G P G T R L T V T E D L K N V F P P E V A
 V F E P S E A E I S H T Q K A T L V C L A T G
 F Y P D H V E L S W W V N G K E V H S G V S T
 D P Q P L K E Q P A L N D S R Y A L S S R L R
 V S A T F W Q D P R N H F R C Q V Q F Y G L S
 E N D E W T Q D R A K P V T Q I V S A E A W G
 R A D G G G G S L S S T L T L S K A D Y E K H
 K V Y A C E V T H Q G L S S P V T K S F N R G
 E S

(SEQ ID: 153)

Figure 8

pUC19-T7 sequence

```

1  ctgctttccc ggagcactat gcggataaaa atatccaatt acagtactat tattaccaaa gaatctgcag
71  tccaccgtga aaagcccctt tacacgcgcc ttggggataa acaataaaaa agatttatgt aagtttatac
141 ataggcgagt actotgttat tgggactatt tacgaagtta ttataacttt ttocttctca tactcataag
211 ttgtaaaggc acagcgggaa taagggaaaa aacgccgtaa aacggaagga caaaaacgag tgggtctttg
281 cgaccacttt cttttctac gacttctagt caaccacgt gtcacccaa thtagcttga cctagagttg
351 tcgccattct aggaactctc aaaagcgggg cttcttgcaa aaggttacta ctogtgaaaa tttcaagacg
421 atacaccgag ccataatagg gcataactgc ggcccgttct cgttgagcca cggcgtatg tgataaagat
491 cttactgaac caactcatga gtggtcagtg tcttttcgta gaatgcctac cgtactgtca ttctcttaat
561 acgtcacgac ggtattggta ctcactattg tgacgccggt tgaatgaaga ctggtgctag cctcctggct
631 tcctcgattg gcgaaaaaac gtgttgtagc ccctagtaca ttgagcggaa ctagcaacct ttggcctcga
701 cttacttcgg tatggtttgc tgctcgcact gtgttgctac ggacatcggt accgttgttg caacgcgttt
771 gataattgac cgcttgatga atgagatcga agggccgttg ttaattatct gacctacctc cgcctatttc
841 aacgtcctgg tgaagacgag agccgggaag gccgaccgac caataacga ctatthagac ctcggccact
911 cgcaccaga gcgccatagt aacgtcgtga ccccggtcta ccattcggga gggcatagca tcaatagatg
981 tgctgccctt cagtccgttg atacctactt ccttatctgt tctagcgaact ctatccacgg agtgactaat
1051 tcgtaacat tgacagtctg gttcaaatga gtatatatga aatctaacta aattttgaag taaaaattaa
1121 attttctctag atccacttct agggaaaaact attagagtac tggttttagg gaattgcaact caaaagcaag
1191 gtgactcgca gtctggggca tcttttctag tttcttagaa gaactctagg aaaaaagac gccgattaga
1261 cgacgaacgt ttgttttttt ggtggcgatg gtcgccacca acaaacggc ctagtctcag atggttgaga
1331 aaaaggcttc cattgaccga agtctctctc cgtctatggt ttatgacagg aagatcaaat cggcatcaat
1401 ccggtgggta agttcttgag acatctgggc ggtatgatgg agcggagaca ttaggacaat ggtcaccgac
1471 gacggtcacc gctattcagc acagaatggc ccaacctgag ttctgtatc aatggcctat tccgcgtcgc
1541 cagcccgaact tgcccccaa gcacgtgtgt cgggtcgaac ctgcttctg ggtatggct tgactctatg
1611 gatgtcgcac tcgatactct ttcgcggtgc gaaggcttc cctcttccg cctgtccata ggccattcgc
1681 cgtcccagcc ttgtcctctc gcgtgtctcc tcgaaggctc ccctttcgg accatagaaa tatcaggaca
1751 gcccaaagcg gtggagactg aactcgcagc taaaacact acgagcagtc ccccgcctc ggataccttt
1821 ttgcggtcgt tgcgcccgaa aaatgccaa gaccggaaaa cagccgaaa acgagtgtac aagaaggac
1891 gcaatagggg actaagacac ctattggcat aatggcgaa actcactcga ctatggcgag cggcgtcggc
1961 ttgctggctc gcgtcgtcga gtcactcgct ccttcgctt ctgcggggt atgcgtttgg cggagagggg
2031 cgcgcaaccg gctaagtaat tacgtcgacc gtgctgtcca aagggtgac ctttcgccc tcaactcgct
2101 tgcgttaatt aactcaatc gactgagtaa tccgtggggt ccgaaatgtg aaatacgaag gccgagcata
2171 caacacacct taacactcgc ctattgttaa agtgtgtcct ttgtcgatac tggtaactaa gccgttcgac
2241 gtcgattatg ctgagtgata tccttctcgg gtggtaccct aggggcccat ggctcgagct taagtaccg
2311 gcagcaaaat gttgcagcac tgaccctttt gggaccgcaa tgggttgaat tagcggaacg tcgtgtaggg
2381 ggaagcgggt cgaccgcatt atcgttctc cggcgtggc tagcgggaa ggttgtcaac gcgtcggact
2451 taccgcttac cgcggactac gccataaaag aggaatcgt agacacgcca taaagtgtgg cgtataccac
2521 gtgagagtca ttttagacga gactacggcg tatcaattcg gtcggggctg tgggcggttg tgggcgactg
2591 cgcgggactg ccggaacaga cgaggccct agcgaatgt ctgttcgaca ctggcagagg ccctcgactg
2661 acacagtctc caaaagtggc agtagtggct ttgcgctc

```

(SEQ ID 154)

Figure 9

A6 scTCR-C-kappa cloned into pUC19-T7


```

1  ccatggggcca gaaggaagtg gagcagaact ctggaccct cagtgttcca
51  gagggagcca ttgcctctct caactgcact tacagtgacc gaggttccca
101 gtccttcttc tggtagagac aatattctgg gaaaagccct gagttgataa
151 tgtccatata ctccaatggt gacaaagaag atggaagggt tacagcacag
201 ctcaataaag ccagccagta tgtttctctg ctcatcagag actcccagcc
251 cagtgattca gccacctacc tctgtgccgt tacaactgac agctggggga
301 aattgcagtt tggagcaggg acccaggttg tggtcaccgg tggaggcggg
351 tcaggcggag gtggatccgg cgggtgcccgg tcgaacgctg gtgtcactca
401 gaccccaaaa ttccaggtcc tgaagacagg acagagcatg aactgagctg
451 gtgccagga tatgaacat gaatacatgt cctggtatcg acaagacca
501 ggcattggggc tgaggctgat tcattactca gttggtgctg gtatcactga
551 ccaaggagaa gtccccaatg gctacaatgt ctccagatca accacagagg
601 atttcccgtc caggctgctg tccgctgctc cctcccagac atctgtgtac
651 ttctgtgcca gcaggcccgg actagcggga gggcgaccag agcagtactt
701 cgggcccgggc accaggctca cggtcacaga ggacctgaaa aactgtttcc
751 caccgaggt cgctgtgttt gagccatcag aagcagagat ctcccacacc
801 caaaaggcca cactggtgtg cctggccaca ggcttctacc ccgaccagct
851 ggagctgagc tggtaggtga atgggaagga ggtgcacagt ggggtcagca
901 cagacccgca gccctcaag gagcagcccg ccctcaatga ctccagatc
951 gctctgagca gccgcctgag ggtctcggcc accttctggc aggacccccg
1001 caaccacttc cgctgtcaag tccagttcta cgggctctcg gagaatgacg
1051 agtggaccca ggataggccc aaacccgtca cccagatcgt cagcggccgag
1101 gcctggggta gagcagacgg tggaggcggg tcaactcagca gcacctgac
1151 gctgagcaaa gcagactacg agaaacacaa agtctacgcc tgccaagtca
1201 cccatcaggg cctgagttcg cccgtcacia agagttcaa ccgaggagag
1251 tcataagaat tc

```


(SEQ ID 155)

Figure 10



The A6 scTCR-C-Kappa protein is shown in the above western blot with an arrow.

Figure 11



- Lane 1 Bioline 100bp DNA marker
- Lane 2 A6scTCR-C-Kappa reaction selected against HLA-A2 TAX beads
- Lane 3 A6scTCR-C-Kappa reaction selected against HLA-A2 TAX beads in the presence of 10 microgrammes of soluble A6scTCR
- Lane 4 A6scTCR-C-Kappa reaction selected against control beads
- Lane 5 Control no DNA reaction selected against HLA-A2-TAX beads
- Lane 6 Control no DNA reaction selected against HLA-A2 TAX beads in the presence of 10 microgrammes of soluble A6scTCR
- Lane 7 Control no DNA reaction selected against control beads
- Lanes 8-12 and lane 13 are as lanes 2-7 except no reverse transcriptase was added just Roche high fidelity taq. These are the DNA contamination controls.
- Lane 13 RT-PCR positive control.

Figure 12a

Clone 9 Mutated A6 TCR β chain DNA sequence

```
gctggtgcactcagacccccaaaattccaggtcctgaagacaggacagagcatgacactgcagtggtgccaggatatgaacat
gaatacatgtcctggatcgacaagaccaggcatggggctgaggctgattcattactcagttggtgctggatcactgaccaagga
gaagtcccaatggctacaatgtctccagatcaaccacagaggattcccgctcaggctgctgctggctgctccctcccagacatct
gtgacttctgtgccagcaggccgggactagcgggaggggtgaccagagcagtactcgggccggggcaccaggctcacggtcac
agaggacctgaaaaacgtgttccaccgggctgctgtgtttgagccatcagaagcagagatctccacacccaaaaggcca
cactggtgtgctggccacaggcttaccaccgaccacgtggagctgagctggtgggtgaatgggaaggaggtgcacagtgggg
tctgcacagaccgcagcccctcaaggagcagcccgcctcaatgactccagatacgtctgagcagccgcctgagggtctcgg
ccacctctggcaggacccccgcaaccactccgctgtcaagtcagttctacgggctctcgggagaatgacgagtgaccagga
tagggccaaaccgtcaccagatcgtcagcgcggaggcctgggtagagcagac
```

(SEQ ID 156)

Figure 12b

Clone 9 Mutated A6 TCR β chain amino acid sequence

```
AGVTQTPKFQVLKTGQSMTLQCAQDMNHEYMSWYRQDPGMGLRLIHYSVGAGITDQGEVP
NGYNVSRSTTEDFPLRLLSAAPSQTSVYFCASRPGLAGGXPEQYFGPGTRLTVTEDLKNVF
PPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPA
LNDSRYALSSRLRVSATFWQDPRNHFRQVQFYGLSENDEWTQDRAKPVTVQIVSAEAWGR
AD
```

(SEQ ID 157)

X - Denotes the position of the amino acid corresponding to the introduced 'opal' stop codon, this will generally result in the substitution of a tryptophan (w) residue into the TCR β chain at this point.

Figure 13Clone 49 Mutated A6 TCR β chain DNA sequence

```
gctgggtcactcagaccccaaaattccaggtcctgaagacaggacagagcatgacactgtagtgtgccaggatatgaacat  
gaatacatgtcctggtatcgacaagaccaggcatggggctgaggctgattactcagttgggtggtatcactgaccaagga  
gaagtcccaatggctacaatgtctccagatcaaccacagaggattcccgtcaggctgctgtcggctgtcctcccagacatct  
gtgtacttctgtccagcaggccgggactagcgggagggcgaccagagcagtactcgggcccgggaccaggctcacggtcac  
agaggacctgaaaaacgtgtcccacccgaggtcgtgtgttgagccatcagaagcagagatctcccaccccaaaaggcca  
cactgggtgctcctggccacaggcttaccacccgaccacgtggagctgagctgggtgggtgaatgggaaggaggtgcacagtgggg  
tctgcacagaccgcagcccctcaaggagcagcccgcctcaatgactccagatacgtctgagcagccgcctgagggtctcgg  
ccaccttctggcaggacccccgcaaccacttccgtgtcaagtcagttctacgggctctcgggagaatgacgagtggaaccagga  
tagggccaaaccgctaccagatcgtcagcgcgaggcctggggtagagcagac
```

(SEQ ID 158)

Figure 14a

Clone 134 Mutated A6 TCR β chain DNA sequence

gctgggtgcactcagaccccaaaattccaggctcctgaagacaggacagagcatgacactgcagtggtcccaggatgaacat
 gaatacatgtcctggatcgacaagaccaggcatggggctgaggctgattcattactcagttggctggtatcactgaccaagga
 gaagtcccaatggctacaatgtctccagatcaaccacagaggattcccgcctcaggctgctgctggctgctccctcccagacatct
 gtgacttctgtgctcagggccggggctgatgagtgcggaaccagagcagctactcgggcccggcaccaggctcacgggtcac
 agaggacctgaaaaacgtgtcccacccgaggctcgtgtgtttgagccatcagaagcagagatctcccacacccaaaaggcca
 cactggtgtgctggccaccggttctaccccgaccacgtggagctgagctggtgggtgaatgggaaggaggtgcacagtggggt
 ctgcacagaccgcagcccctcaaggagcagcccgcctcaatgacccagatcagctctgagcagccgcctgagggtctcgg
 ccacctctggcaggacccccgcaaccactccgctgcaagtccagttctacgggctctcggagaatgacgagtggaaccagga
 tagggccaaaccgctacccagatcgtcagcgcggaggcctgggtagagcagactaagctgaattc
 (SEQ ID 159)

Figure 14b

Clone 134A Mutated A6 TCR β chain amino acid sequence (BIAcore)

MNAGVTQTPKFQVLKTGQSMTLQCAQDMNHEYMSWYRQDPGMGLRLIHYSVGAGITDQG
 EVPNGYNVSRSTTEDFPLRLLSAAPSQTSVYFCASRPGLMSAEPEQYFGPGTRLTVTEDLK
 NVFPPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKE
 QPALNDSRYALSSRLRVSATFWQDPRNHFRQCQVQFYGLSENDEWTQDRAKPVTQIVSAEA
 WGRAD*
 (SEQ ID 160)

Figure 14c

Clone 134 Mutated A6 TCR β chain amino acid sequence (ELISA)

AGVTQTPKFQVLKTGQSMTLQCAQDMNHEYMSWYRQDPGMGLRLIHYSVGAGITDQGEVP
 NGYNVSRSTTEDFPLRLLSAAPSQTSVYFCASRPGLMSAQPEQYFGPGTRLTVTEDLKNVF
 PPEVAVFEPSEAEISHTQKATLVCLATGFYPDHVELSWWVNGKEVHSGVCTDPQPLKEQPA
 LNSRYALSSRLRVSATFWQDPRNHFRQCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGR
 AD
 (SEQ ID 161)

Figure 15

A6 TCR clone 134




Figure 16




Figure 17a

atgcaggaggtgacacagattcctgcagctctgagtggtccagaaggagaaaactggttctcaactgcagttcactgata
 gcgctatttacaacctccagtggttaggcaggaccctgggaagggtctcacatctctgttgcttattcagtcaagtacagaga
 gagcaacaagtggaagacttaatgcctcgctggataaatcatcaggacgtagtactttatacattgcagcttctcagcctgg
 tgactcagccacctctctgtgctgtgaggccacatcaggaggaagctacatacctacattggaagaggaaccagcct
 tattgtcatccgtatatccagaacctgacctgccgtgtaccagctgagagactctaaatccagtgacaagtctgtctgct
 attcaccgattttgatttcaacaatgtgtcacaagaaggattctgatgtgtatatcacagacaaatgtgtgctagacatg
 aggtctatggacttcaagagcaacagtgtgtggcctggagcaacaatctgactttgcatgtgcaaacgccttcaacaaca
 gcattattccagaagacaccttctccccagcccagaaagttcctaa
 (SEQ ID 162)

Figure 17b

atgggtgtcactcagacccccaaattccaggtcctgaagacaggacagagcatgacactgcagtggtcccaggatatgaa
 ccatgaatacatgtcctggtatcgacaagaccaggcatggggctgaggctgattcattactcagttggtgctggtatcactg
 accaaggagaagtcccaatggctacaatgtctccagatcaaccacagaggattcccgcctcaggtgctgtcggctgctc
 cctcccagacatctgtgtacttctgtgccagcagttactcgtgggaacaccggggagctgtttttggagaaggctctaggctg
 accgtactggaggacctgaaaaacgtgttcccaccgaggtcgtgtgtttgagccatcagaagcagagatctcccacacc
 caaaaggccacactggtgtgcttggccacaggtcttaccaccgaccacgtggagctgagctggtgggtgaatgggaagg
 aggtgcacagtggggtctgcacagaccgcagcccctcaaggagcagcccgcctcaatgactccagatacgtctctgag
 cagccgctgagggctctggccaccttctggcaggacccccgcaaccacttccgctgtcaagtccagttctacgggctctc
 ggagaatgacgagtggtgaccaggatagggccaaccgtcaccagatcgtcagcggcaggcctggggttagagcag
 actaa
 (SEQ ID 163)

Figure 18a

MQEV TQIP AALS VPEGENLVLNCSFTDS AIYNLQWFRQ
 DPGKGLTSLLLIQSSQREQTSGRLNASLDKSSGRSTLYI
 AASQPGDSATYLC AVRPTSGGSYIPTFGRGTS LIVHPYI
 QNPDP AVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDS
 DVIITDKCVLDMRSMDFKSN SAVAWSNKSD FACANAF
 NNSIIPEDTFFPSPSS Stop
 (SEQ ID 164)

Figure 18b

MGVTQTPKFQVLKTGQSM TLQCAQDMNHEYMSWYRQ
 DPGMGLRLIHYSVGAGITDQGEVPNGYNVSRSTTEDFP
 LRLLSAAPSQTSVYFCASSYVGN TGELFFGEGSRLTVLE
 DLKNVFPPEVA VFEPSEAEISHTQKATLVCLATGFYPDH
 VELSWWVNGKEVHSGVCTDPQPLKEQPALNDSRYALS
 SRLRVSATFWQDPRNHFRCQVQFYGLSENDEWTQDRA
 KPVTQIVSAEAWGRAD Stop (SEQ ID 165)

Figure 19a

TTCTGGCCCT TTTGCTGGCC TTTTGGCTCAC ATGTAATGTG AGTTAGCTCA
AAGGACCCGG AAAACGACCCG AAAACGAGTG TACATTACAC TCAATCGAGT
CTCATFAGGC ACCCCAGGCT TTACACTTFA TGCTTCCGGC TCGTATGTTG
GAGTAATCCG TGGGGTCCGA AATGTGAAAT ACGAAGCCG AGCATACAAC
TGTGGAAATG TGAGCGGATA ACAATTTTAC ACAGGAAACA GCTATGACCA
ACACCTTAAC ACTCGCCTPAT TGTAAAAGTG TGTCCCTTGT CGATACTGGT
TGATTACGCC AAGTACGTA CTTAAGTATT CTATTTCAAG GAGACAGTCA
ACTAATGCCG TTCGATGCAT GAATTCATAA GATAAAGTTC CTCGTGCTAGT
TAATGAAATA CCTATTGCCT ACGGCAGCCG CTGGATTGTT ATTACTCGCG
ATTACTTTTAT GGATAACCGA TGCCGTCCGG GACCTAACAA TAATGAGCCG
GCCCAGCCGG CCATGGCCAA ACAGGAGGTG ACGCAGATT CTGCAGCTCT
CGGGTCGGCC GGTACCCGTT TGTCCCTCAC TGCGTCTAAG GACGTCGAGA
GAGTGTCCCA GAAGGAGAAA ACTTGGTTCT CAACTGCAGT TTCACTGATA
CTCACAGGGT CTTCCTCTTT TGAACCAAGA GTTGACGTC AAGTGACTAT
GCGCTAATTA CAACCTCCAG TGGTTTAGGC AGGACCCTGG GAAAGGCTCT
CGCGATAAAT GTTGGAGGTC ACCAAATCCG TCCTGGGACC CTTTCCAGAG
ACATCACTGT GTCTTATTCA GTCAAGTCAG AGAGAGCAAA CAAGTGGAA
TGTAGAGACA ACGAATAAGT CAGTTCAGTC TCTCTCGTTT GTTCACCTTC
ACTTAATGCC TCGTGGATA AATCATCAGG ACGTAGTACT TTATACATTG
TGAATFACCG AAGGACCTAT TTAGTAGTCC TGCATCATGA AATATGTAAC
CAGCTTCTCA GCCTGGTGAC TCAGCCACCT ACCTCTGTGC TGTGAGGCC
GTCGAAGAGT CCGACCACTG AGTCGGTGG TGGAGACAG ACACTCCGGG
ACATCAGGAG GAAGCTACAT ACCTACATTT GGAAGAGGAA CCAGCCTTAT
TGTAGTCCCT CTTCGATGTA TGGATGTAAA CCTTCCTCTT GGTCCGAATA
TGTTTCATCCG TATATCCAGA ACCCGGATCC TGCCGTGTAC CAGCTGAGAG
ACAAAGTAGG ATATAGGTCT TGGCCCTAGG ACGGCACATG GTGACTCTC
ACTCTAAATC CAGTGACAAG TCTGTCTGCC TATTCACCGA TTTTGTATTCT
TGAGATTTAG GTCACTGTTC AGACAGACGG ATAAGTGGCT AAAACTAAGA
CAAAACAAATG TGTCACAAAG TAAGGATTC GATGTGTATA TCACAGACAA
GTTTGTTTAC ACAGTGTTC ATTCCTAAGA CTACACATAT AGTGTCTGTT
ATGTTGTGTA GACATGAGGT CTATGGACT CAAGAGCAAC AGTGTCTGTGG
TACACACGAT CTGTACTCCA GATACCTGAA GTTCTCGTTG TCACGACACC
CCTGGAGCAA CAATCTGAC TTTGCATGTG CAAACGCCTT CAACAACAGC
GGACCTCGTT GTTTAGACTG AAACGTACAC GTTTGCGGAA GTTGTGTGTC
ATTAATCCAG AAGACACCTT CTTCCTCCAG CCAGAAAGTT CCTAATAACC
TAATAAGGTC TTCTGTGGAA GAAGGGTCCG GGTCTTTCAA GGATTTATTGG
TAGGTTAATT AAGAATTCCT TAAGAAGGGG ATATACATAT GAAAAATTA
ATCCAAATTA TTCTTAAGAA ATCTTCCCT TATATGTATA CTTTTTTAA
TTATTCGCAA TTCTTTAGT TGTTCCTTTC TATTCACACA GCGCGCAGGC
AATAAGCGTT AAGGAAATCA ACAAGGAAAG ATAAGAGTGT CCGCGTCCG
TGTTCTCACT GACACCCCAA AATTCAGGT CCTGAAGACA GGACAGAGCA
ACCACAGTGA GTCTGGGGTT TTAAGGTCCA GGACTTCTGT CCTGTCTCGT
TGACACTGCA GTGTGCCAG GATATGAACC ATGAATFACAT GTCCTGGTAT
ACTGTGACGT CACACGGGTC CTATACTTGG TACTTATGTA CAGGACCATA
CGACAAGAC CAGGCATGGG GCTGAGGCTG ATTCATTACT CAGTGTGGTC
GCTGTCTGCG GTCCGTACCC GACTCCGAC TAAGTAATGA GTCACCCAG
TGGTATCACT GACCAAGGAG AAGTCCCAA TGGCTACAAT GTCTCCAGAT
ACCATAGTGA CTGTTCTCTC TTCAGGGGTT ACCGATGTTA CAGAGGTCTA
CAACCACAGA GGATTTCCCG CTCAGGCTGC TGTCCGGTGC TCCCTCCAG
GTTGGTGTCT CCTAAAGGGC GAGTCCGACG ACAGCCGACG AAGGAGGGTC
ACATCTGTGT ACTTCTGTGC CAGCAGTTAC GTCGGGAACA CCGGGGAGCT
TGTAGACACA TGAAGACACG GTCGTCAATG CAGCCCTTGT GGCCCTCGA
GTTTTTTTGA GAAGGCTCTA GGCTGACCGT ACTGGAGGAC CTGAAAAACG
CAAAAAACCT CTTCGAGAT CCGACTGGCA TGACCTCCTG GACTTTTTTC
TGTTCACCAC CAGGGTCCGT GTGTTTGAGC CATCAGAAGC AGAGATCTCC
ACAAGGGTGG GCTCCAGCGA CACAACTCG GTAGTCTTCC TCTCTAGAGG
CACACCCAAA AGGCCACACT GGTGTGCCTG GCCACAGGCT TCTACCCCGA
GTGTGGGTTT TCCGGTGTGA CCACACGGAC CCGGTGTCCGA AGATGGGGCT
CCACGTGGAG CTGAGCTGGT GGTGAATGG GAAGGAGGTG CACAGTGGGG
GGTGCACCTC GACTCGACCA CCCACTTACC CTTCCTCCAC GTGTACCCCC
TCTGCACAGA CCGCAGCCC CTCAAGGAGC AGCCCGCCCT CAATGACTCC
AGACGTGTCT GGGCGTCGGG GAGTTCCTCG TCGGGCGGGA GTTACTGAGG
AGATACGCTC TGAGCAGCCG CCTGAGGGTC TCGGCCACCT TCTGGCAGGA
TCTATGCCGAG ACTCGTCCGC GGACTCCAG AGCCGGTGGG AGACCGTCTC
CCCCGCAAC CACTTCCGCT GTCAAGTCCA GTTCTACGGG CTCCTCGGAG
GGGGCGTTG GTGAAGGGCA CAGTTCAGGT CAAGATGCCC GAGAGCCCTCT
ATGACGAGTG TACCAGGAT AGGGCCAAAC CCGTCAACCA GATCGTCCAG
TACTGCTCAC CTGGTCTTA TCCCGTTTG GGCAGTGGGT CTAGCAGTCC
GCCGAGGCC TGGGTAGAGC AGACCGGGCC GCA
CGGCTCCGGA CCCCATCTCG TCTGCGCCGG CGT

(SEQ ID 166)

Figure 19b

K Y L L P T A A A G L L L L A A Q P
 A M A K Q E V T Q I P A A L S V P E
 G E N L V L N C S F T D S A I Y N L
 Q W F R Q D P G K G L T S L L L I Q
 S S Q R E Q T S G R L N A S L D K S
 S G R S T L Y I A A S Q P G D S A T
 Y L C A V R P T S G G S Y I P T F G
 R G T S L I V H P Y I Q N P D P A V
 Y Q L R D S K S S D K S V C L F T D
 F D S Q T N V S Q S K D S D V Y I T
 D K C V L D M R S M D F K S N S A V
 A W S N K S D F A C A N A F N N S I
 I P E D T F F P S P E S S M K K L L
 F A I P L V V P F Y S H S A Q A G V
 T Q T P K F Q V L K T G Q S M T L Q
 C A Q D M N H E Y M S W Y R Q D P G
 M G L R L I H Y S V G A G I T D Q G
 E V P N G Y N V S R S T T E D F P L
 R L L S A A P S Q T S V Y F C A S S
 Y V G N T G E L F F G E G S R L T V
 L E D L K N V F P P E V A V F E P S
 E A E I S H T Q K A T L V C L A T G
 F Y P D H V E L S W W V N G K E V H
 S G V C T D P Q P L K E Q P A L N D
 S R Y A L S S R L R V S A T F W Q D
 P R N H F R C Q V Q F Y G L S E N D
 E W T Q D R A K P V T Q I V S A E A
 W G R A D A A A

(SEQ ID 167)

Figure 20




Figure 21

DRA0101

```

1 ggatccatgg ccataagtgg agtcacctgtg ctaggatttt tcatcatagc tgtgctgatg
61 agcgctcagg aatcatgggc tatcaaagaa gaacatgtga tcatccaggc cgagttctat
121 ctgaatcctg accaatcagg cgagtttatg tttgactttg atgggtgatga gattttccat
181 gtggatatgg caaagaagga gacggctctgg cggcttgaag aatttggacg atttgccagc
241 tttgaggctc aaggtgcatt ggccaacata gctgtggaca aagccaacct ggaaatcatg
301 acaaagcgct ccaactatac tccgatcacc aatgtacctc cagaggtaac tgtgctcagc
361 aacagccctg tggaaactgag agagcccaac gtccctcatct gtttcatcga caagttcacc
421 ccaccagtgg tcaatgtcac gtggcttcga aatggaaaac ctgtcaccac aggagtgtca
481 gagacagtct tcctgccag ggaagaccac cttttccgca agttccacta tctccccttc
541 ctgccctcaa ctgaggacgt ttacgactgc aggggtggagc actggggcctt ggatgagcct
601 cttctcaagc actgggagtt tgatgctcca agccctctcc cagagactac agagaacgtg
661 gatgggggtc tgactgatac actccaagcg gagacagatc aacttgaaga caagaagtct
721 gcgttgcaga cagagattgc caatctactg aaagagaagg aaaaactaga gttcatcctg
781 gcagcttacg gatctggtgg tggctctgaac gatatttttg aagctcagaa aatcgaatgg
841 catgagtagg atcc

```

(SEQ ID 168)

xxx - Fos Leucine zipper codons
xxx - Biotinylation tag codons

Figure 22

```

1 aattctactc gtaaagcgag ttgaaggatc atatthtagtt gcgthttatga gataagattg
61 aaagcacgtg taaaatgttt cccgcgcggt ggcacaacta tttacaatgc ggccaagtta
121 taaaagattc taatctgata tgthtttaaaa cacctthtgcg gcccgagttg tthgctgacg
181 tgactagcga agaagatgtg tggaccgcag aacagatagt aaaacaaaac cctagtattg
241 gagcaataat cgatttaacc aacacgtcta aatattatga tgggtgtgcat thttthgctggg
301 cgggcctgth atacaaaaaa attcaagtac ctggccagac thtgccgctt gaaagcatag
361 ttcaagaatt tattgacacg gtaaaagaat ttacagaaaa gtgtcccggc atgttggtgg
421 gcgtgcactg cacacacggt attaatcgca ccggttacat ggtgtgcaga tathtaatgc
481 acaccctggg tattgcccgg caggaagcca tagatagatt cgaaaaagcc agaggtcaca
541 aaattgaaag acaaaattac gttcaagatt tathaatthta athaatatta thtgcatctt
601 ttaacaaata cthtatccta thttcaaath gthgctgctt thccagcgaa ccaaaactat
661 gcttcgcttg ctccgthtag ctgtgacccg atcagtgggc thgtthccaat cgacggtagg
721 attaggccgg atathctcca ccacaatgth ggcaacgthg atgttacgtht tatgctthtg
781 gththccacg tacgtcttht ggccgthaat agccgthaac gtagtgccgt cgcgcgtcac
841 gcacaacacc ggatgthtgc gctgtcccgc ggggtattga accgcgcgat ccgacaaatc
901 caccactthg gcaactaaat cgggtgacct gcgctcttht thctgcatta thtctcttht
961 cththgcatg gthtccctgga agccggtgta catgcccgtht agatcagthca tgacgcgcgt
1021 gacctgcaaa thctthggcct cgatctgctt gctcttgatg gcaacgatgc gthcaataaa
1081 ctcttgthtth ttaacaagth cctcggthtth thgcccacc accgctgca cgcgctthgt
1141 gtgctcggth aatgtcgcaa thcagcttagt caccaactgt thgctctcct cctcccgttg
1201 thtgatcgcg ggatcgtact thcoccgthgca gagcactthga ggaathactt cthctaaaag
1261 ccathctthgt aathctatgg chtaaggcaa ththggactt ataathcagct gaathcagcc
1321 ggathtagta atgagcactg thtgccgctg caaathacagc gggthgcccc ththcagcag
1381 gctgttagag gtagggcccc caththggat ggtctgctca aathacgatt thgaththt
1441 gtctacatga acacgtatag cthtatcaca aactgtatath ththaaactgt tagcgcagthc
1501 cthggccacg aaccggacct gthggthcgc ctctagcacg thaccgcaggt tgaacgtatc
1561 thctccaaat thaaathctc caaththaac gcgagccatt thgathacag thgtgctgatt
1621 thgcaacaac ththgthtth taacgcaaac thaaactath gthgthaagca athaathaaat
1681 atgggggaac atgcccgcgt acaacactcg thgthtatgaa cgcagacggc gccggtctcg
1741 gcgcaagcgg cthaaaacgth thgcccgtht aacgcccga acatcgcaa agccaatgth
1801 acagththga thtgcatath aacggcgatt ththaaatha thctththaa thaaatgthta
1861 tgacgcctac aactccccgc ccgctthgac thgctgcacc thgagcagtht cgtthgacgc
1921 thctccgthg thgcccgaaca cgtcgcgagc gthggthgatg accagcggcg thcccgcagc
1981 gacgcacaag thctctgtaca ccgaatgatg gthcggcgaa ggcagctcg cctccaagthg
2041 gcaaththgg caaathctgaa aathatataca gththggthgt thgctcathat ctathcgtggc
2101 ththggcatg thcgtcccga cgtthgathth catgcaagcc gaaathaaat cathcgcatt
2161 agthcgtatta aaacgththg thctctcgt ththaatcath cgcgthatta aathcgcgcaa
2221 thcagthcaag thgathcaagth gthggaathaat gththctthg ththcccag thcaagcgcag
2281 cgcgththth aacaaactag ccatctthgta agthtagtht aththaatgca actththtcca
2341 athaatathat atgthacgca cgtcaagaath thaaathgcg cccgthgthc cathctcaaca
2401 cgactathgat agagathcaaa thaaagcgcga aththaatagc thgctgacgca acgthgacga
2461 thctgtgcagc cgtthccggca cgcgctthga thgthaatag thththacgaa ggcathgacath
2521 gacccccgth gthgacaacga thcagcccaa aagaactgccc gactacaaaa thaccgagth
2581 thctcggthgac gththaaacta thaaagccatc caathcagacc thagthcgaath caggaccgct
2641 ggtgcgagaa gccgcgaagth atggcgaathg cathctgthaa cgtgtggagth ccgctcathth
2701 gagcgtcathg ththgacaagth aaagctacath aththaatgth thccgathgat ththattgath
2761 aathgaccct aactccathac accgththct acaathggcgg gthththggthc aathththccg
2821 gactgcgathg thcathgctg thaacggctc cgcctactath thathgaaath aathththcca
2881 athththaaaa acgcagcaagth agaaacathth gthathgaaag thcgtagaa gthaaagaaaa
2941 atgthcgtcga cathgctgaa aacaagathth athathcctcc gthgthataaaa aathaththga
3001 acgaththgaa agaaaacathg thaccgcgcg gcgthathgth caggaaagag thththactha
3061 actgththacath thgcaaacgth gththctgthg ccaagthgthg aacccgathg ththathcaag
3121 ctctgacgca ththctacaac cagactcca agthgthgthg thgaaagcath caththththaa
3181 thaaathccca agathgthgath aaaccaccaa actgccaath aathgaaact gthcgaacg

```

3241 tctgtccggt tgctggcaac tgcaagggtc tcaatcctat ttgtaattat tgaataataa
 3301 aacaattata aatgctaaat ttgtttttta ttaacgatac aaaccaaacy caacaagaac
 3361 atttgtagta ttatctataa ttgaaaacgc gtagttataa tcgctgaggt aatattttaa
 3421 atcattttca aatgattcac agttaatttg cgacaatata attttttttt cacataaaat
 3481 agacgccttg tcgtcttctt cttcgtattc cttctctttt tcattttttt cctcataaaa
 3541 attaacatag ttattatcgt atccatataat gtatctatcg tatagagtaa attttttgtt
 3601 gtcataaata tatatgtctt ttttaatggg gtgtatagta ccgctgagca tagtttttct
 3661 gtaatttaca acagtgctat tttctggtag ttcttcggag tgtgttgctt taattattaa
 3721 atttatataa tcaatgaatt tgggatcgtc ggttttgtac aatatgttgc cggcatagta
 3781 cgcagcttct tctagttaa ttacaccatt ttttagcagc accggattaa cataacttc
 3841 caaaatgttg tacgaaccgt taaacaaaaa cagttcacct ccttttcta tactatttc
 3901 tgcgagcagt tgtttgttgt taaaaataac agccattgta atgagacgca caaactaata
 3961 tcacaaactg gaaatgtcta tcaatataa gttgctgatg atccagcatg ataagataca
 4021 ttgatgagtt tggacaaacc acaactagaa tgcagtgaaa aaaatgcttt atttgtgaaa
 4081 tttgtgatgc tattgcttta tttgtaacca ttataagctg caataaacia gttccgagtt
 4141 tgtcagaaag cagacaaac agcggttgga ataataagcga gaacagagaa atagcggcaa
 4201 aaataatacc cgtatcactt ttgctgatat tgcctgagaa ggttgatgct atcgggaaaa
 4261 acgggaagta ggctcccatg ataaaaagt aaaagaaaaa gaataaacgy aacatccaaa
 4321 agtttgtgtt ttttaaatag tacataatgg atttccttac gcgaaatacgy ggcagacatg
 4381 gcctgcccgy ttattattat tttgacacc agaccaactg gtaatggtag cagccggcgc
 4441 tcagctggaa ttcagatctg tgattgtaaa taaaatgtaa tttacagtat agtattttaa
 4501 ttaatataca aatgatttga taataattct tatttaacta taatatattg tgttgggttg
 4561 aattaaaggt cccggcatcc tcaaatgcat aatttcatag tccccctgtg tgaagtgtag
 4621 gcgtatttct gaatctttgt aaaaatagcac acaagactcc aacgcgtttg cgtttttatt
 4681 ttcttgcctg actctagttt attaggcctc tagagatccg tttttatagg tttttttatt
 4741 acaaaactgt tacgaaaaca gtaaaatact tttttatttg cgagatggtt atcattttaa
 4801 ttatctccat gatccaataa acctagaata aagggcccga cctttaattc aacccaacac
 4861 aatatattat agttaaataa gaattattat caaatcattt gtatattaat taaaatacta
 4921 tactgtaaat tacattttat ttacaatcac agatccccgg gatccgggta ttagtaccatt
 4981 tattaagcgc tagattctgt gcgttgttga tttacagaca attgtgttac gtattttaat
 5041 aattcattaa atttataatc tttaggggtgg tatgttagag cgaaaatcaa atgattttca
 5101 gcgtctttat atctgaattt aaatattaaa tcctcaatag atttgtaaaa taggtttcga
 5161 ttagtttcaa acaaggggtg tttttccgaa ccgatggctg gactatctaa tggattttcg
 5221 ctcaacgcca caaaacttgc caaatcttgt agcagcaatc tagctttgtc gatattcggt
 5281 tgtgttttgt tttgtaataa aggttcgacg tcggtcaciaa tattattcgc ttttgtattt
 5341 ctttcatcac tgtcgttagt gtacaattga ctgcagctaa acacgttaaa taaagcttgg
 5401 acataattaa catcgggctg gttagcttta ttaggccgat tatcgtcgtc gtcccaaccc
 5461 tcgtcgttag aagttgcttc cgaagacgat tttgccatag ccacacgacg cctattaatt
 5521 gtgtcggccta acacgtccgc gatcaaaatt gttagttgagc tttttggaat ttttctgat
 5581 tgcgggctgt tttgggctgg ttcaatcta actgtgcccg attttaattc agacaacacg
 5641 ttagaaaagc atggtgcagg cgggtgtaac atttcagacg gcaaatctac taatggcggc
 5701 ggtggtggag ctgatgataa atctaccatc ggtggaggcg caggcggggc tggcggcgga
 5761 ggcggaggcg gaggtggtgg cgggtgatgca gacggcgggt taggctcaaa tgtctcttta
 5821 ggcaacacag tcggcacctc aactattgta ctggtttcgg gcgccgtttt tggtttgacc
 5881 ggtctgagac gagtgcgatt tttttcgttt ctaatagctt ccaacaattg ttgtctgtcg
 5941 tctaaaggtg cagcgggttg aggttccgtc ggcattggtg gagcggggcg caattcagac
 6001 atcgatggtg gtgggtggtg tggagggcgt ggaatgttag gcacgggaga aggtggtggc
 6061 ggcgggtgcc ceggtataat ttgttctggt ttagtttgtt cgcgcacgat tgtgggcacc
 6121 ggcgcaggcg ccgctggctg cacaacggaa ggtcgtctgc ttcgaggcag cgcttggggg
 6181 ggtggcaatt caatattata attggaatac aaatcgtaaa aatctgctat aagcattgta
 6241 atttcgtat cgtttaccgt gccgatattt aacaaccgct caatgtaagc aattgtattg
 6301 taaagagatt gtctcaagct cggatcgcac ccgcacgccc ataacaagcc ttttcaattt
 6361 tactacagca ttgtagtgcc gagacacttc gctgtcgtcg acgtacatgt atgctttggt
 6421 gtcaaaaacg tcgttggcaa gctttaaaat atttaaaaga acatctctgt tcagccacc
 6481 tgtgttctgc taaatgttgt ttttgataat ttgcgcttc gcagtatcga cacgttcaaa

6541 aaattgatgc gcatcaatth tgttgttcct attattgaat aaataagatt gtacagattc
6601 atatctacga ttcgtcatgg ccaccacaaa tgctacgctg caaacgctgg tacaatttta
6661 cgaaaactgc aaaaacgtca aaactcggta taaaataatc aacgggctgt ttggcaaaat
6721 atctatttta tcgcacaagc ccactagcaa attgtatttg agcgaccacc tttcggcgca
6781 caattttaac gctgacgaaa taaaagtcca ccagttaatg agcgaccacc caaattttat
6841 aaaaatctat tttaatcacg gttccatcaa caaccaagtg atcgtgatgg actacattga
6901 ctgtcccgat ttatttgaaa cactacaaat taaaggcgag ctttcgtacc aacttgtag
6961 caatattatt agacagctgt gtgaagcgct caacgatttg cacaagcaca atttcataca
7021 caacgacata aaactcgaac atgtcttata tttcgaagca cttgatcgcg tgtatgtttg
7081 cgattacgga ttgtgcaaac acgaaaactc acttagcgtg cacgacggca cgttggagta
7141 ttttagtccg gaaaaaatc gacacacaac tatgcacgtt tcgtttgact ggtacgcggc
7201 gtgttaacat acaagttgct aaccggcggc cgacacccat ttgaaaaaag cgaagacgaa
7261 atgttggact tgaatagcat gaagcgtcgt cagcaatata atgacattgg cgttttaaaa
7321 cacgttcgta acgttaacgc tcgtgacttt gtgtactgcc taacaagata caacatagat
7381 tgtagactca caaattacaa acaattata aaacatgagt ttttgcgta aaaatgccac
7441 ttgttttacg agtagaattc ccagcttggc actggcctgc gttttacaac gtcgtgactg
7501 gaaaaaccct ggcgttaacc aacttaatcg ccttgacgca catcccctt tcgacagctg
7561 gcgtaatagc gaagaggccc gcaccgatcg cccttcccaa cagttgcgca gcctgaatgg
7621 cgaatggcgc ctgatgcggg attttctcct tacgcatctg tgcggatatt cacaccgcat
7681 atggtgcact ctacgtacaa tctgctctga tgccgcatag ttaagccagc cccgacacc
7741 gccaacacc gctgacgcgc cctgacgggc ttgtctgctc ccggcatccg cttacagaca
7801 agctgtgacc gtctccggga gctgcatgtg tcagaggttt tcaccgtcat caccgaaacg
7861 gcggaacgaa agggcctcgt gatacgccta tttttatagg ttaatgcat gataataatg
7921 gtttcttaga cgtcaggtgg cacttttcgg ggaaatgtgc gcggaacccc tattgttta
7981 ttttctaaa tacattcaaa tatgtatccg ctcatgagac aataaccctg ataaatgctt
8041 caataatatt gaaaaaggaa gagtatgagt attcaacatt tccgtgtcgc ccttattccc
8101 tttttgagg cattttgcct tcctgttttt gctcaccag aaacgctggg gaaagtaaaa
8161 gatgctgaag atcagttggg tgcacgagtg ggttacatcg aactggatct caacagcggg
8221 aagatccttg agagttttcg cccgaagaa cgttttccaa tgatagcac ttttaaggtt
8281 ctgctatgtg gcgcggtatt atcccgtatt gacgcccggc aagagcaact cggcgcgc
8341 atacactatt ctacagaatga cttgggtgag tactcaccag tcacagaaaa gcattctacg
8401 gatggcatga cagtaagaga attatgcagt gctgccataa ccatgagtga taacactgcy
8461 gccaaactac ttctgacaac gatcggagga ccgaaggagc taaccgctt tttgcacaac
8521 atgggggac atgtaactcg ccttgatcgt tgggaaccgg agctgaatga agccatacca
8581 aacgacgagc gtgacaccac gatgcctgta gcaatggcaa caacgttgcg caaactatta
8641 actggcgaac tacttactct agcttcccgg caacaattaa tagactggat ggaggcggat
8701 aaagttgcag gaccacttct gcgctcggcc cttccggctg gctggtttat tgcgataaa
8761 tctggagccg gtgagcgtgg gtctcgcggt atcattgcag cactggggcc agatggtaag
8821 ccctcccgtc tcgtagttat ctacacgacg gggagtcagg caactatgga tgaacgaaat
8881 agacagatcg ctgagatagg tgccctactg attaagcatt ggtaactgtc agaccaagtt
8941 tactcatata tacttttagat tgatttataaa cttcattttt aattttaaag gatctagggt
9001 aagatccttt ttgataatct catgacaaa atcccctaac gtgagttttc gttccactga
9061 gcgtcagacc ccgtagaaaa gatcaaagga tcttcttgag atcctttttt tctgcgcgta
9121 atctgctgct tgcaaacaaa aaaaccaccg ctaccagcgg tggtttggtt gccggatcaa
9181 gagtaccaa ctctttttcc gaaggtaact ggcttcagca gagcgcagat accaaatact
9241 gtcttcttag ttagaccgta gttaggccac cacttcaaga actctgtagc accgcctaca
9301 tacctcgtc tgctaactct gttaccagt gctgctgcca gtggcgataa gtcgtgtctt
9361 accgggttgg actcaagacg atagttaccg gataaggcgc agcggctggg ctgaacgggg
9421 ggttcgtgca cacagcccag cttggagcga acgacctaca ccgaactgag atacctacag
9481 cgtgagcatt gagaaagcgc cacgcttccc gaaggagaa agcggacag gtatccggta
9541 agcggcaggg tcggaacagg agagcgcacg agggagctc cagggggaaa cgcctggtat
9601 ctttatagtc ctgtcgggtt tcgccacctc tgacttgagc gtcgattttt gtgatgctc
9661 tcaggggggc ggagcctatg gaaaaacgcc agcaacgcgg ctttttacg gttcctggcc
9721 ttttctggc cttttgctca catgttcttt cctgctgtat cctcgattc tgtggataac
9781 cgtattaccg cttttgagtg agctgatacc gctcgcgca gccgaacgac cgagcgcagc
9841 gagtcaagtga gcgaggaagc ggaagagcgc ccaatacgc aaccgcctc ccccgccgt
9901 tggccgatcc ataatgcag ctggcagcag aggttcccag actggaaagc gggcagtgag
9961 cgcaacgcaa ttaatgtgag ttagctcact cattaaggca cccaggctt acactttatg

10021 cttccggctc gtatgttggtg tggattgtg agcggataac aatttcacac aggaaacagc
10081 tatgaccatg attacg

(SEQ ID 169)



- Restriction enzyme sites

Figure 23

```

1 ggtaccggat ccagcatggt gtgtctgaag ctccctggag gctcctgcat gacagcgtg
61 acagtgcac tgatggtgct gagctcccca ctggctttgt cgggagacac cggacctaag
121 tacgtcaagc agaacacact gaaactggct tccggtggcg gatctctagt tccacgcggt
181 agtggaggcg gtggttccgg agacacgcgt ccacgtttct tgtggcagct taagttttaa
241 tgtcatttct tcaatgggac ggagcgggtg cggttgctgg aaagatgcat ctataaccaa
301 gaggagtccg tgcgcttoga cagcgcgtg ggggagtacc gggcggtgac ggagctgggg
361 cggcctgatg ccgagtactg gaacagccag aaggacctcc tggagcagag gcgggcccgg
421 gtggacacct actgcagaca caactacggg gttggtgaga gttcacagt gcagcggcga
481 gttgagccta aggtgactgt gtatccttca aagaccagc ccctgcagca ccacaacctc
541 ctggtctgct ctgtgagtgg tttctatcca ggcagcattg aagtcaggtg gttccggaac
601 ggccaggaag agaaggctgg ggtggtgtcc acaggcctga tccagaatgg agattggacc
661 ttccagaccc tggatgatgct ggaaacagtt cctcggagtg gagaggttta cacctgcaa
721 gtggagcacc caagtgtgac gagccctctc acagtggaat ggagagcacg gtctgaatct
781 gcacagagca aggtcgacgg aggcgggtggg ggtagaatcg cccggctgga ggaaaagtg
841 aaaaccttga agctcagaa ctcggagctg gggtccacgg ccaacatgct cagggaaacag
901 gtggcacagc ttaaacagaa agtcgatgaac tactaggatc c

```

(SEQ ID 170)

xxx

- Jun Leucine zipper codons

xxx

- HLA-loaded peptide

Figure 24




Figure 25




Figure 26




Figure 27




Figure 28




Figure 29a




Figure 29b




Figure 30a




Figure 30b




Figure 31a




Figure 31b




Figure 32a

Response RU




Figure 32b

Response
RU




Figure 33a




Figure 33b




Figure 34




Figure 35




Figure 36






Figure 37a




Figure 37b




Figure 38a

MNAGVTQTPKF QVLKTGQSMT LQCAQDMNHE YMSWYRQDPG
MGLRLIHYSV GAGITDQGEV PNGYNVSRST TEDFPLRLLS AAPSQTSVYF
CASRPGLAGG RPEQYFGPGT RLTVT (SEQ ID 171)

Figure 38b

MNAGVTQTPKF QVLKTGQSMT LQCAQDMNHE YMSWYRQDPG
MGLRLIHYSV GAGITDQGEV PNGYNVSRST TEDFPLRLLS AAPSQTSVYF
CASRPGLMSAXPEQYFGPGT RLTVT (SEQ ID 172)

X denotes a position at which amino acids E, Q or R can be inserted.

Figure 38c

MNAGVTQTPKF QVLKTGQSMT LQCAQDMNHE YMSWYRQDPG
MGLRLIHYSV GAGITDQGEV PNGYNVSRST TEDFPLRLLS AAPSQTSVYF
CASRPGLAGG RPE**D**QYFGPGT RLTVT (SEQ ID 173)

Figure 38d

MNAGVTQTPKF QVLKTGQSMT LQCAQDMNHE YMSWYRQDPG
MGLRLIHYSV GAGITDQGEV PNGYNVSRST TEDFPLRLLS AAPSQTSVYF
CASRPGL**V**PG RPEQ**Q**FGPGT RLTVT (SEQ ID 174)

Figure 38e

MNAGVTQTPKF QVLKTGQSMT LQCAQDMNHE YMSWYRQDPG
MGLRLIHYSV GAGITDQGEV PNGYNVSRST TEDFPLRLLS AAPSQTSVYF
CASRPGLAGG R**HP**QFGPGT RLTVT (SEQ ID 175)

Figure 39a





Figure 39b

Final TCR Display PCT.WorkFile.txt

Organization Applicant

Street : 57C Milton Park
City : Abingdon
State : Oxfordshire
Country : England
PostalCode : OX14 4RX
PhoneNumber : +44 1235 438600
FaxNumber : +44 1235 438601
EmailAddress : martin.green@avidex.com
<110> OrganizationName : Avidex Ltd

Individual Applicant

Street : Avidex Ltd, 57C Milton Park
City : Abingdon
State : Oxfordshire
Country : England
PostalCode : OX14 4RX
PhoneNumber : +44 1235 438600
FaxNumber : +44 1235 438601
EmailAddress : bent.jakobsen@avidex.com
<110> LastName : Jakobsen
<110> FirstName : Bent
<110> MiddleInitial : K
<110> Suffix : Dr

Individual Applicant

Street : Avidex Ltd, 57C Milton Park
City : Abingdon
State : Oxfordshire
Country : England
PostalCode : OX14 4RX
PhoneNumber : +44 1235 438600
FaxNumber : +44 1235 438601
EmailAddress : torben.andersen@avidex.com
<110> LastName : Andersen
<110> FirstName : Torben
<110> MiddleInitial : B
<110> Suffix : Dr

Individual Applicant

Street : Avidex Ltd, 57C Milton Park
City : Abingdon
State : Oxfordshire
Country : England
PostalCode : OX14 4RX
PhoneNumber : +44 1235 438600
FaxNumber : +44 1235 438601
EmailAddress : peter.molloy@avidex.com
<110> LastName : Molloy
<110> FirstName : Peter
<110> MiddleInitial : E
<110> Suffix : Dr

Individual Applicant

Street : Avidex Ltd, 57C Milton Park
City : Abingdon
State : Oxfordshire
Country : England
PostalCode : OX14 4RX
PhoneNumber : +44 1235 438600
FaxNumber : +44 1235 438601
EmailAddress : jonathan.boulter@avidex.com
<110> LastName : Boulter

Final TCR Display PCT.WorkFile.txt

<110> FirstName : Jonathan
<110> MiddleInitial : M
<110> Suffix : Dr

Individual Applicant

Street : Avidex Ltd, 57C Milton Park
City : Abingdon
State : Oxfordshire
Country : England
PostalCode : OX14 4RX
PhoneNumber : +44 1235 438600
FaxNumber : +44 1235 438601
EmailAddress : yi.li@avidex.com
<110> LastName : Li
<110> FirstName : Yi
<110> MiddleInitial :
<110> Suffix : Dr

Application Project

<120> Title : Substances
<130> AppFileReference : Case No 19
<140> CurrentAppNumber : GB 0226227.7
<141> CurrentFilingDate : 2002-11-09

Earlier Applications

<150> PriorAppNumber : GB0226227.7
<151> PriorFilingDate : 2002-11-09

Earlier Applications

<150> PriorAppNumber : GB 0301814.0
<151> PriorFilingDate : 2003-01-25

Earlier Applications

<150> PriorAppNumber : GB 0304067.2
<151> PriorFilingDate : 2003-02-22

Earlier Applications

<150> PriorAppNumber : GB 0311397.4
<151> PriorFilingDate : 2003-05-16

Earlier Applications

<150> PriorAppNumber : GB 0316356.5
<151> PriorFilingDate : 2003-07-11

Earlier Applications

<150> PriorAppNumber : US 60/436,323
<151> PriorFilingDate : 2003-04-16

Sequence

<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
DSDVYITDKT VLDMRSMDFK
<212> Type : PRT
<211> Length : 20
SequenceName : SEQ ID 1
SequenceDescription :

Sequence

Final TCR Display PCT.workFile.txt

<213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 QSKDSDVYIT DKTVLDMRSM 20
 <212> Type : PRT
 <211> Length : 20
 SequenceName : SEQ ID 2
 SequenceDescription :

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 DIQNPDPAVY QLRDSKSSDK 20
 <212> Type : PRT
 <211> Length : 20
 SequenceName : SEQ ID 3
 SequenceDescription :

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 DPAVYQLRDS KSSDKSVCLF 20
 <212> Type : PRT
 <211> Length : 20
 SequenceName : SEQ ID 4
 SequenceDescription :

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 NGKEVHSGVS TDPQPLKEQP 20
 <212> Type : PRT
 <211> Length : 20
 SequenceName : SEQ ID 5
 SequenceDescription :

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 ALNDSRYALS SRLRVSATFW 20
 <212> Type : PRT
 <211> Length : 20
 SequenceName : SEQ ID 6
 SequenceDescription :

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 PPEVAVFEPS EAEISHTQKA 20
 <212> Type : PRT
 <211> Length : 20
 SequenceName : SEQ ID 7
 SequenceDescription :

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 KEVHSGVSTD PQPLKEQPAL 20
 <212> Type : PRT
 <211> Length : 20
 SequenceName : SEQ ID 8
 SequenceDescription :

Final TCR Display PCT.WorkFile.txt

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
VFPPEVAVFE PSEAEISHTQ
-----
<212> Type : PRT
<211> Length : 20
SequenceName : SEQ ID 9
SequenceDescription :

```

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
PYIQNPEPAV YQLKDRSQD STLCLFTDFD SQINVPKME SGTFFITDKTV LDMKAMDSKS
-----
NGAIAWSNQT SFTCQDIFKE TNATYPSSDV P
-----
<212> Type : PRT
<211> Length : 91
SequenceName : SEQ ID 10
SequenceDescription :

```

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
EDLRNVTPPK VSLFEPKAE IANKQKATLV CLARGFFPDH VELSWWVNGR EVHSGVSTDP
-----
QAYKESNYSY CLSSRLRVA TFWHNP RNHF RCQVQFHGLS EEDKWPEGSP KPVTQNISAE
-----
AWGRAD
-----
<212> Type : PRT
<211> Length : 126
SequenceName : SEQ ID 11
SequenceDescription :

```

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
ESGTFITDKT VLDMKAMDSK
-----
<212> Type : PRT
<211> Length : 20
SequenceName : SEQ ID 12
SequenceDescription :

```

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
KTMESGTFIT DKTVLDMKAM
-----
<212> Type : PRT
<211> Length : 20
SequenceName : SEQ ID 13
SequenceDescription :

```

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
YIQNPEPAVY QLKDRSQDS
-----
<212> Type : PRT
<211> Length : 20
SequenceName : SEQ ID 14
SequenceDescription :

```

Sequence

```

-----

```

Final TCR Display PCT.WorkFile.txt

```

<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
AVYQLKDPRS QDSTLCLFTD
<212> Type : PRT
<211> Length : 20
SequenceName : SEQ ID 15
SequenceDescription :

```

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
NGREVHSGVS TDPQAYKESN
<212> Type : PRT
<211> Length : 20
SequenceName : SEQ ID 16
SequenceDescription :

```

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
KESNYSYCLS SRLRVSATFW
<212> Type : PRT
<211> Length : 20
SequenceName : SEQ ID 17
SequenceDescription :

```

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
PPKVSLFEPS KAEIANKQKA
<212> Type : PRT
<211> Length : 20
SequenceName : SEQ ID 18
SequenceDescription :

```

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
REVHSGVSTD PQAYKESNYS
<212> Type : PRT
<211> Length : 20
SequenceName : SEQ ID 19
SequenceDescription :

```

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
VTPPKVSLFE PSKAEIANKQ
<212> Type : PRT
<211> Length : 20
SequenceName : SEQ ID 20
SequenceDescription :

```

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
LLFGYPVYV
<212> Type : PRT
<211> Length : 9
SequenceName : SEQ ID 21
SequenceDescription :

```

Final TCR Display PCT.WorkFile.txt

Sequence

```
-----  
<213> OrganismName : Synthetic Sequence  
<400> PreSequenceString :  
SLLMITQC 8  
<212> Type : PRT  
<211> Length : 8  
SequenceName : SEQ ID 22  
SequenceDescription :
```

Sequence

```
-----  
<213> OrganismName : Synthetic Sequence  
<400> PreSequenceString :  
LLGRNSFEV 9  
<212> Type : PRT  
<211> Length : 9  
SequenceName : SEQ ID 23  
SequenceDescription :
```

Sequence

```
-----  
<213> OrganismName : Synthetic Sequence  
<400> PreSequenceString :  
KLVALGINAV 10  
<212> Type : PRT  
<211> Length : 10  
SequenceName : SEQ ID 24  
SequenceDescription :
```

Sequence

```
-----  
<213> OrganismName : Synthetic Sequence  
<400> PreSequenceString :  
LLGDLFGV 8  
<212> Type : PRT  
<211> Length : 8  
SequenceName : SEQ ID 25  
SequenceDescription :
```

Sequence

```
-----  
<213> OrganismName : Synthetic Sequence  
<400> PreSequenceString :  
FLRGRAYGL 9  
<212> Type : PRT  
<211> Length : 9  
SequenceName : SEQ ID 26  
SequenceDescription :
```

Sequence

```
-----  
<213> OrganismName : Synthetic Sequence  
<400> PreSequenceString :  
HRCQAIRKK 9  
<212> Type : PRT  
<211> Length : 9  
SequenceName : SEQ ID27  
SequenceDescription :
```

Sequence

```
-----  
<213> OrganismName : Synthetic Sequence  
<400> PreSequenceString :  
YRSGIIAVV 9  
<212> Type : PRT  
<211> Length : 9  
SequenceName : SEQ ID 28
```

Final TCR Display PCT.workFile.txt
 SequenceDescription :

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 VYGFVRACL 9
 <212> Type : PRT
 <211> Length : 9
 SequenceName : SEQ ID 29
 SequenceDescription :

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 ILAKFLHWL 9
 <212> Type : PRT
 <211> Length : 9
 SequenceName : SEQ ID 30
 SequenceDescription :

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 LTLGEFLKL 9
 <212> Type : PRT
 <211> Length : 9
 SequenceName : SEQ ID 31
 SequenceDescription :

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 PKYVKQNTLK LA 12
 <212> Type : PRT
 <211> Length : 12
 SequenceName : SEQ ID 32
 SequenceDescription :

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 GILGFVFTL 9
 <212> Type : PRT
 <211> Length : 9
 SequenceName : SEQ ID 33
 SequenceDescription :

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 SLYNTVATL 9
 <212> Type : PRT
 <211> Length : 9
 SequenceName : SEQ ID 34
 SequenceDescription :

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 cacagacaaa tgtgtgctag acat 24
 <212> Type : DNA

Final TCR Display PCT.WorkFile.txt

```

<211> Length : 24
      SequenceName : SEQ ID 35
      SequenceDescription :

Custom Codon
-----
Sequence Name : SEQ ID 35

Sequence
-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
atgtctagca cacatttgtc tgtg
<212> Type : DNA
<211> Length : 24
      SequenceName : SEQ ID 36
      SequenceDescription :

Custom Codon
-----
Sequence Name : SEQ ID 36

Sequence
-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
cagtggggtc tgcacagacc c
<212> Type : DNA
<211> Length : 21
      SequenceName : SEQ ID 37
      SequenceDescription :

Custom Codon
-----
Sequence Name : SEQ ID 37

Sequence
-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
gggtctgtgc agaccccact g
<212> Type : DNA
<211> Length : 21
      SequenceName : SEQ ID 38
      SequenceDescription :

Custom Codon
-----
Sequence Name : SEQ ID 38

Sequence
-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
taataatacg tataataata ttctatttca aggagacagt c
<212> Type : DNA
<211> Length : 41
      SequenceName : SEQ ID 39
      SequenceDescription :

Custom Codon
-----
Sequence Name : SEQ ID 39

Sequence
-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :

```

Final TCR Display PCT.WorkFile.txt
 caatccagcg gctgccgtag gcaataggta ttccattatg actgtctcct tgaaatag 58

<212> Type : DNA
 <211> Length : 58
 SequenceName : SEQ ID 40
 SequenceDescription :

Custom Codon

Sequence Name : SEQ ID 40

Sequence

<213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 ctacggcagc cgctggattg ttattactcg cggcccagcc ggccatggcc cag 53

<212> Type : DNA
 <211> Length : 53
 SequenceName : SEQ ID 41
 SequenceDescription :

Custom Codon

Sequence Name : SEQ ID 41

Sequence

<213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 gttctgctcc acttccttct gggccatggc cggctgggcc g 41

<212> Type : DNA
 <211> Length : 41
 SequenceName : SEQ ID 42
 SequenceDescription :

Custom Codon

Sequence Name : SEQ ID 42

Sequence

<213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 cagaaggaag tggagcagaa c 21

<212> Type : DNA
 <211> Length : 21
 SequenceName : SEQ ID 43
 SequenceDescription :

Custom Codon

Sequence Name : SEQ ID 43

Sequence

<213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 cttcttaaag aattcttaat taacctaggt tattaggaac tttctgggct ggggaag 57

<212> Type : DNA
 <211> Length : 57
 SequenceName : SEQ ID 44
 SequenceDescription :

Final TCR Display PCT.WorkFile.txt

Custom Codon

Sequence Name : SEQ ID 44

Sequence

<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
gttaattaag aattctttaa gaaggagata tacatatgaa aaaattatta ttcgcaattc 60<212> Type : DNA
<211> Length : 60
SequenceName : SEQ ID 45
SequenceDescription :

Custom Codon

Sequence Name : SEQ ID 45

Sequence

<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
cgcgctgtga gaatagaaag gaacaactaa aggaattgcg aataataatt ttttcatatg 60<212> Type : DNA
<211> Length : 60
SequenceName : SEQ ID 46
SequenceDescription :

Custom Codon

Sequence Name : SEQ ID 46

Sequence

<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
ctttctattc tcacagcgcg caggctggtg tcactcagac 40
<212> Type : DNA
<211> Length : 40
SequenceName : SEQ ID 47
SequenceDescription :

Custom Codon

Sequence Name : SEQ ID 47

Sequence

<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
atgatgtcta gatgcggccg cgtctgctct accccaggcc tc 42
<212> Type : DNA
<211> Length : 42
SequenceName : SEQ ID 48
SequenceDescription :

Custom Codon

Sequence Name : SEQ ID 48

Sequence

<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :

Final TCR Display PCT.WorkFile.txt

gcatctagac atcatcacca tcatcactag actgttgaaa gttgttttagc aaaac 55

<212> Type : DNA
 <211> Length : 55
 SequenceName : SEQ ID 49
 SequenceDescription :

Custom Codon

Sequence Name : SEQ ID 49

Sequence

<213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 ctagagggta ccttattaag actccttatt acgcagtatg 40
 <212> Type : DNA
 <211> Length : 40
 SequenceName : SEQ ID 50
 SequenceDescription :

Custom Codon

Sequence Name : SEQ ID 50

Sequence

<213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 agctgcagct aatacgactc actataggaa caggccacca tggcgtcgat tatgctgagt 60
 gatatccttg tccggtggta ccctag 86
 <212> Type : DNA
 <211> Length : 86
 SequenceName : SEQ ID 51
 SequenceDescription :

Custom Codon

Sequence Name : SEQ ID 51

Sequence

<213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 gatcccatgg tggcctgttc ctatagttag tcgtattagc tgc 43
 <212> Type : DNA
 <211> Length : 43
 SequenceName : SEQ ID 52
 SequenceDescription :

Custom Codon

Sequence Name : SEQ ID 52

Sequence

<213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 agctgcagct aatacgactc actataggaa caggccacca tgg 43
 <212> Type : DNA
 <211> Length : 43
 SequenceName : SEQ ID 53
 SequenceDescription :

Custom Codon

Final TCR Display PCT.WorkFile.txt

Sequence Name : SEQ ID 53

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
ccaccatggg ccagaaggaa gtggagcaga actc          34
<212> Type : DNA
<211> Length : 34
      SequenceName : SEQ ID 54
      SequenceDescription :

```

Custom Codon

Sequence Name : SEQ ID 54

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
cgagagcccg tagaactgga cttg          24
<212> Type : DNA
<211> Length : 24
      SequenceName : SEQ ID 55
      SequenceDescription :

```

Custom Codon

Sequence Name : SEQ ID 55

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
gtggatccgg cgggtggcggg tcgaacgctg gtgtcactca gacccc          46
<212> Type : DNA
<211> Length : 46
      SequenceName : SEQ ID 56
      SequenceDescription :

```

Custom Codon

Sequence Name : SEQ ID 56

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
ccggatccac ctccgctga accgcctcca ccggtgacca caacctgggt ccctg          55
<212> Type : DNA
<211> Length : 55
      SequenceName : SEQ ID 57
      SequenceDescription :

```

Custom Codon

Sequence Name : SEQ ID 57

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
ctgagaattc ttatgactct ccgcggttga agctc          35
<212> Type : DNA
<211> Length : 35
      SequenceName : SEQ ID 58

```

Final TCR Display PCT.WorkFile.txt

SequenceDescription :

Custom Codon

Sequence Name : SEQ ID 58

Sequence

<213> OrganismName : Synthetic Sequence
<400> PreSequenceString : 32
tgacgaattc tgactctccg cggttgaagc tc
<212> Type : DNA
<211> Length : 32
SequenceName : SEQ ID 59
SequenceDescription :

Custom Codon

Sequence Name : SEQ ID 59

Sequence

<213> OrganismName : Synthetic Sequence
<400> PreSequenceString : 28
agctgcagct aatacgaactc actatagg
<212> Type : DNA
<211> Length : 28
SequenceName : SEQ ID 60
SequenceDescription :

Custom Codon

Sequence Name : SEQ ID 60

Sequence

<213> OrganismName : Synthetic Sequence
<400> PreSequenceString : 36
ggccaccatg ggcaacgctg gtgtcactca gacccc
<212> Type : DNA
<211> Length : 36
SequenceName : SEQ ID 61
SequenceDescription :

Custom Codon

Sequence Name : SEQ ID 61

Sequence

<213> OrganismName : Synthetic Sequence
<400> PreSequenceString : 40
tgaaccgctt ccaccgtctg ctctacccca ggcctcggcg
<212> Type : DNA
<211> Length : 40
SequenceName : SEQ ID 62
SequenceDescription :

Custom Codon

Sequence Name : SEQ ID 62

Sequence

<213> OrganismName : Synthetic Sequence
<400> PreSequenceString : 22
tgactctccg cggttgaagc tc
<212> Type : DNA

Final TCR Display PCT.WorkFile.txt

<211> Length : 22
 SequenceName : SEQ ID 63
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 63

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString : 29
 cagctggggg aagcttcagt ttggagcag
 <212> Type : DNA
 <211> Length : 29
 SequenceName : SEQ ID 64
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 64

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString : 29
 ctgctcaaaa ctgaagcttc ccccagctg
 <212> Type : DNA
 <211> Length : 29
 SequenceName : SEQ ID 65
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 65

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString : 29
 gtacttctgt gcctcgaggc cgggactag
 <212> Type : DNA
 <211> Length : 29
 SequenceName : SEQ ID 66
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 66

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString : 29
 ctagtcccgg cctcgaggca cagaagtac
 <212> Type : DNA
 <211> Length : 29
 SequenceName : SEQ ID 67
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 67

Sequence

 <213> OrganismName : Synthetic sequence
 <400> PreSequenceString :

Final TCR Display PCT.WorkFile.txt

cattttcagg gatagcaagc 20
 <212> Type : DNA
 <211> Length : 20
 SequenceName : SEQ ID 68
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 68

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 tcacacagga aacagctatg tcacacagga aacagctatg 40
 <212> Type : DNA
 <211> Length : 40
 SequenceName : SEQ ID 69
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 69

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 tgtgcctcga ggnknknkn knknknknkn cgaccagagc agtacttcg 49
 <212> Type : DNA
 <211> Length : 49
 SequenceName : SEQ ID 70
 SequenceDescription :

Feature

 Sequence: SEQ ID 70:
 <221> FeatureKey : misc_feature
 <222> LocationFrom : 1
 <222> LocationTo : 49
 Other Information : m is a or c; n is a or t or g or c; k is g or t
 CDSJoin : No

Custom Codon

 Sequence Name : SEQ ID 70

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 tgtgcctcga ggccgnknkn knknknknkn nnkccagagc agtacttcgg gc 52
 <212> Type : DNA
 <211> Length : 52
 SequenceName : SEQ ID 71
 SequenceDescription :

Feature

 Sequence: SEQ ID 71:
 <221> FeatureKey : misc_feature
 <222> LocationFrom :
 <222> LocationTo :
 Other Information : m is a or c; n is a or t or g or c; k is g or t
 CDSJoin : No

Final TCR Display PCT.WorkFile.txt

Feature

Sequence: SEQ ID 71:

<221> FeatureKey : misc_feature

<222> LocationFrom : 1

<222> LocationTo : 52

Other Information : m is a or c; n is a or t or g or c; k is g or t
CDSJoin : No

Custom Codon

Sequence Name : SEQ ID 71

Sequence

<213> OrganismName : Synthetic Sequence

<400> PreSequenceString :

tgtgcctcga ggccgnknkn knknknknkn nnkcgaccag agcagtactt cg 52

<212> Type : DNA

<211> Length : 52

SequenceName : SEQ ID 72

SequenceDescription :

Feature

Sequence: SEQ ID 72:

<221> FeatureKey : misc_feature

<222> LocationFrom : 1

<222> LocationTo : 52

Other Information : m is a or c; n is a or t or g or c; k is g or t
CDSJoin : No

Custom Codon

Sequence Name : SEQ ID 72

Sequence

<213> OrganismName : Synthetic Sequence

<400> PreSequenceString :

tgtgcctcga ggccgnknkn knknknknkn nnkggagggc gaccagagca g 51

<212> Type : DNA

<211> Length : 51

SequenceName : SEQ ID 73

SequenceDescription :

Feature

Sequence: SEQ ID 73:

<221> FeatureKey : misc_feature

<222> LocationFrom : 1

<222> LocationTo : 51

Other Information : m is a or c; n is a or t or g or c; k is g or t
CDSJoin : No

Custom Codon

Sequence Name : SEQ ID 73

Sequence

<213> OrganismName : Synthetic Sequence

<400> PreSequenceString :

tgtgcctcga ggccgggann knknknknkn nnknknkgggc gaccagagca gtac 54

Final TCR Display PCT.WorkFile.txt

<212> Type : DNA
 <211> Length : 54
 SequenceName : SEQ ID 74
 SequenceDescription :

Feature

 Sequence: SEQ ID 74:
 <221> FeatureKey : misc_feature
 <222> LocationFrom :
 <222> LocationTo :
 Other Information : m is a or c; n is a or t or g or c; k is g or t
 CDSJoin : No

Feature

 Sequence: SEQ ID 74:
 <221> FeatureKey : misc_feature
 <222> LocationFrom : 1
 <222> LocationTo : 54
 Other Information : m is a or c; n is a or t or g or c; k is g or t
 CDSJoin : No

Custom Codon

 Sequence Name : SEQ ID 74

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 tgtgcctcga ggnknknkn knknknknk ccagagcagt acttcgggc 49
 <212> Type : DNA
 <211> Length : 49
 SequenceName : SEQ ID 75
 SequenceDescription :

Feature

 Sequence: SEQ ID 75:
 <221> FeatureKey : misc_feature
 <222> LocationFrom :
 <222> LocationTo :
 Other Information : m is a or c; n is a or t or g or c; k is g or t
 CDSJoin : No

Feature

 Sequence: SEQ ID 75:
 <221> FeatureKey : misc_feature
 <222> LocationFrom : 1
 <222> LocationTo : 49
 Other Information : m is a or c; n is a or t or g or c; k is g or t
 CDSJoin : No

Custom Codon

 Sequence Name : SEQ ID 75

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 tgtgcctcga ggnknknkn knknknknk gagcagtact tcgggccg 48
 <212> Type : DNA
 <211> Length : 48

Final TCR Display PCT.WorkFile.txt

SequenceName : SEQ ID 76
 SequenceDescription :

Feature

Sequence: SEQ ID 76:

<221> FeatureKey : misc_feature

<222> LocationFrom : 1

<222> LocationTo : 48

Other Information : m is a or c; n is a or t or g or c; k is g or t
 CDSJoin : No

Custom Codon

Sequence Name : SEQ ID 76

Sequence

<213> OrganismName : Synthetic Sequence

<400> PreSequenceString :

tgtgcctcga ggnknknkn knknknknk cagtacttcg ggccgggc

48

<212> Type : DNA

<211> Length : 48

SequenceName : SEQ ID 77

SequenceDescription :

Feature

Sequence: SEQ ID 77:

<221> FeatureKey : misc_feature

<222> LocationFrom : 1

<222> LocationTo : 48

Other Information : m is a or c; n is a or t or g or c; k is g or t
 CDSJoin : No

Custom Codon

Sequence Name : SEQ ID 77

Sequence

<213> OrganismName : Synthetic Sequence

<400> PreSequenceString :

tgtgcctcga ggccggnkn knknknk ggg cgaccagagc agtacttcg

49

<212> Type : DNA

<211> Length : 49

SequenceName : SEQ ID 78

SequenceDescription :

Feature

Sequence: SEQ ID 78:

<221> FeatureKey : misc_feature

<222> LocationFrom :

<222> LocationTo :

Other Information : m is a or c; n is a or t or g or c; k is g or t
 CDSJoin : No

Feature

Sequence: SEQ ID 78:

<221> FeatureKey : misc_feature

<222> LocationFrom : 1

<222> LocationTo : 49

Other Information : m is a or c; n is a or t or g or c; k is g or t
 CDSJoin : No

Custom Codon

Final TCR Display PCT.WorkFile.txt

Sequence Name : SEQ ID 78

Sequence

<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
aaactgaagc ttmnmnmnmn nmnmnmntgt aacggcacag aggtag 46
<212> Type : DNA
<211> Length : 46
SequenceName : SEQ ID 79
SequenceDescription :

Feature

Sequence: SEQ ID 79:
<221> FeatureKey : misc_feature
<222> LocationFrom : 1
<222> LocationTo : 46
Other Information : m is a or c; n is a or t or g or c; k is g or t
CDSJoin : No

Custom Codon

Sequence Name : SEQ ID 79

Sequence

<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
aaactgaagc ttmnmnngc tgctmmtgt aacggcacag aggtag 46
<212> Type : DNA
<211> Length : 46
SequenceName : SEQ ID 80
SequenceDescription :

Feature

Sequence: SEQ ID 80:
<221> FeatureKey : misc_feature
<222> LocationFrom : 1
<222> LocationTo : 46
Other Information : m is a or c; n is a or t or g or c; k is g or t
CDSJoin : No

Custom Codon

Sequence Name : SEQ ID 80

Sequence

<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
aaactgaagc ttmnmnmnmn ngctgtcmnn tgtaacggca cagaggtag 49
<212> Type : DNA
<211> Length : 49
SequenceName : SEQ ID 81
SequenceDescription :

Feature

Sequence: SEQ ID 81:
<221> FeatureKey : misc_feature
<222> LocationFrom :
<222> LocationTo :
Other Information : m is a or c; n is a or t or g or c; k is g or t
CDSJoin : No

Final TCR Display PCT.WorkFile.txt

Feature

Sequence: SEQ ID 81:

<221> FeatureKey : misc_feature

<222> LocationFrom : 1

<222> LocationTo : 49

Other Information : m is a or c; n is a or t or g or c; k is g or t

CDSJoin : No

Custom Codon

Sequence Name : SEQ ID 81

Sequence

<213> OrganismName : Synthetic Sequence

<400> PreSequenceString :

aaactgaagc ttmnmnngc tgctmnaac ggcacagagg tag 43

<212> Type : DNA

<211> Length : 43

SequenceName : SEQ ID 82

SequenceDescription :

Feature

Sequence: SEQ ID 82:

<221> FeatureKey : misc_feature

<222> LocationFrom : 1

<222> LocationTo : 43

Other Information : m is a or c; n is a or t or g or c; k is g or t

CDSJoin : No

Custom Codon

Sequence Name : SEQ ID 82

Sequence

<213> OrganismName : Synthetic Sequence

<400> PreSequenceString :

gcctcgaggc cgggactagc gggagggcga ccagagcagt ag 42

<212> Type : DNA

<211> Length : 42

SequenceName : SEQ ID 83

SequenceDescription :

Custom Codon

Sequence Name : SEQ ID 83

Sequence

<213> OrganismName : Synthetic Sequence

<400> PreSequenceString :

ASRPGLAGGR PEQY 14

<212> Type : PRT

<211> Length : 14

SequenceName : SEQ ID 84

SequenceDescription :

Sequence

<213> OrganismName : Synthetic Sequence

<400> PreSequenceString :

gcctcgaggc cggggctgat gtagtgcgtag ccagagcagt ac 42

<212> Type : DNA

<211> Length : 42

SequenceName : SEQ ID 85

Final TCR Display PCT.workFile.txt
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 85

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 ASRPGLMSAX PEQY 14
 <212> Type : PRT
 <211> Length : 14
 SequenceName : SEQ ID 86
 SequenceDescription :

Feature

 Sequence: SEQ ID 86:
 <221> FeatureKey : MISC_FEATURE
 <222> LocationFrom : 1
 <222> LocationTo : 14
 Other Information : x denotes an amino acid residue encoded by an amber
 codon
 CDSJoin : No

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 gcctcgaggc cggggctgag gtcggcgtag ccagagcagt ac 42
 <212> Type : DNA
 <211> Length : 42
 SequenceName : SEQ ID 87
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 87

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 ASRPGLRSAX PEQY 14
 <212> Type : PRT
 <211> Length : 14
 SequenceName : SEQ ID 88
 SequenceDescription :

Feature

 Sequence: SEQ ID 88:
 <221> FeatureKey : MISC_FEATURE
 <222> LocationFrom : 1
 <222> LocationTo : 14
 Other Information : x denotes an amino acid residue encoded by an amber
 codon
 CDSJoin : No

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 gcctcgaggc cgggactagc gggagggcga ccagaggcgt ag 42
 <212> Type : DNA
 <211> Length : 42
 SequenceName : SEQ ID 89

Final TCR Display PCT.WorkFile.txt

SequenceDescription :

Custom Codon

Sequence Name : SEQ ID 89

Sequence

<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
ASRPGLAGGR PEAX 14
<212> Type : PRT
<211> Length : 14
SequenceName : SEQ ID 90
SequenceDescription :

Feature

Sequence: SEQ ID 90:
<221> FeatureKey : MISC_FEATURE
<222> LocationFrom :
<222> LocationTo :
Other Information : x denotes an amino acid residue encoded by an amber
codon
CDSJoin : No

Feature

Sequence: SEQ ID 90:
<221> FeatureKey : MISC_FEATURE
<222> LocationFrom : 1
<222> LocationTo : 14
Other Information : x denotes an amino acid residue encoded by an amber
codon
CDSJoin : No

Sequence

<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
gcctcgaggc cgggactagc gggagggcga ccagaggatt ag 42
<212> Type : DNA
<211> Length : 42
SequenceName : SEQ ID 91
SequenceDescription :

Custom Codon

Sequence Name : SEQ ID 91

Sequence

<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
ASRPGLAGGR PEDX 14
<212> Type : PRT
<211> Length : 14
SequenceName : SEQ ID 92
SequenceDescription :

Feature

Sequence: SEQ ID 92:
<221> FeatureKey : MISC_FEATURE
<222> LocationFrom : 1
<222> LocationTo : 14
Other Information : x denotes an amino acid residue encoded by an amber
codon

Final TCR Display PCT.WorkFile.txt

CDSJoin : No

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
gcctcgaggc cgggactagc gggagggcga ccagatcagt ag          42
<212> Type : DNA
<211> Length : 42
      SequenceName : SEQ ID 93
      SequenceDescription :
    
```

Custom Codon

 Sequence Name : SEQ ID 93

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
ASRPGLAGGR PDQX          14
<212> Type : PRT
<211> Length : 14
      SequenceName : SEQ ID 94
      SequenceDescription :
    
```

Feature

```

-----
Sequence: SEQ ID 94:
<221> FeatureKey : MISC_FEATURE
<222> LocationFrom :
<222> LocationTo :
      Other Information : x denotes an amino acid residue encoded by an amber
codon
      CDSJoin : No
    
```

Feature

```

-----
Sequence: SEQ ID 94:
<221> FeatureKey : MISC_FEATURE
<222> LocationFrom : 1
<222> LocationTo : 14
      Other Information : x denotes an amino acid residue encoded by an amber
codon
      CDSJoin : No
    
```

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
gcctcgaggc cgggtctgta ggctgggcga ccagagcagt ac          42
<212> Type : DNA
<211> Length : 42
      SequenceName : SEQ ID 95
      SequenceDescription :
    
```

Custom Codon

 Sequence Name : SEQ ID 95

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
ASRPGLXAGR PEQY          14
<212> Type : PRT
<211> Length : 14
      SequenceName : SEQ ID 96
    
```

Final TCR Display PCT.WorkFile.txt
 SequenceDescription :

Feature

 Sequence: SEQ ID 96:
 <221> FeatureKey : MISC_FEATURE
 <222> LocationFrom :
 <222> LocationTo :
 Other Information : x denotes an amino acid residue encoded by an amber
 codon
 CDSJoin : No

Feature

 Sequence: SEQ ID 96:
 <221> FeatureKey : MISC_FEATURE
 <222> LocationFrom : 1
 <222> LocationTo : 14
 Other Information : x denotes an amino acid residue encoded by an amber
 codon
 CDSJoin : No

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 gcctcgaggc cgggctggt tccggggcga ccagagcagt ag 42
 <212> Type : DNA
 <211> Length : 42
 SequenceName : SEQ ID 97
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 97

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 ASRPGLVPGR PEQX 14
 <212> Type : PRT
 <211> Length : 14
 SequenceName : SEQ ID 98
 SequenceDescription :

Feature

 Sequence: SEQ ID 98:
 <221> FeatureKey : MISC_FEATURE
 <222> LocationFrom :
 <222> LocationTo :
 Other Information : x denotes an amino acid residue encoded by an amber
 codon
 CDSJoin : No

Feature

 Sequence: SEQ ID 98:
 <221> FeatureKey : MISC_FEATURE
 <222> LocationFrom : 1
 <222> LocationTo : 14
 Other Information : x denotes an amino acid residue encoded by an amber
 codon
 CDSJoin : No

Sequence

Final TCR Display PCT.WorkFile.txt

<213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 gcctcgaggc cggggcttgt gtctgcttag ccagagcagt ac 42
 <212> Type : DNA
 <211> Length : 42
 SequenceName : SEQ ID 99
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 99

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 ASRPGLVSAX PEQY 14
 <212> Type : PRT
 <211> Length : 14
 SequenceName : SEQ ID 100
 SequenceDescription :

Feature

 Sequence: SEQ ID 100:
 <221> FeatureKey : MISC_FEATURE
 <222> LocationFrom : 1
 <222> LocationTo : 14
 Other Information : x denotes an amino acid residue encoded by an amber
 codon
 CDSJoin : No

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 gcctcgaggc cgggactagc gggagggcga ccacatccgt ag 42
 <212> Type : DNA
 <211> Length : 42
 SequenceName : SEQ ID 101
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 101

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 ASRPGLAGGR PHPX 14
 <212> Type : PRT
 <211> Length : 14
 SequenceName : SEQ ID 102
 SequenceDescription :

Feature

 Sequence: SEQ ID 102:
 <221> FeatureKey : MISC_FEATURE
 <222> LocationFrom :
 <222> LocationTo :
 Other Information : x denotes an amino acid residue encoded by an amber
 codon
 CDSJoin : No

Feature

Final TCR Display PCT.WorkFile.txt

Sequence: SEQ ID 102:

<221> FeatureKey : MISC_FEATURE

<222> LocationFrom : 1

<222> LocationTo : 14

Other Information : x denotes an amino acid residue encoded by an amber codon

CDSJoin : No

Sequence

<213> OrganismName : Synthetic Sequence

<400> PreSequenceString :

gcctcgaggc cgggactagc gggagggcga ccagatgcgt ag 42

<212> Type : DNA

<211> Length : 42

SequenceName : SEQ ID 103

SequenceDescription :

Custom Codon

Sequence Name : SEQ ID 103

Sequence

<213> OrganismName : Synthetic Sequence

<400> PreSequenceString :

ASRPGLAGGR PDAX 14

<212> Type : PRT

<211> Length : 14

SequenceName : SEQ 104

SequenceDescription :

Feature

Sequence: SEQ 104:

<221> FeatureKey : MISC_FEATURE

<222> LocationFrom : 1

<222> LocationTo : 14

Other Information : x denotes an amino acid residue encoded by an amber codon

CDSJoin : No

Sequence

<213> OrganismName : Synthetic Sequence

<400> PreSequenceString :

gcctcgaggc cgggtctgat tagtgcttag ccagagcagt ac 42

<212> Type : DNA

<211> Length : 42

SequenceName : SEQ ID 105

SequenceDescription :

Custom Codon

Sequence Name : SEQ ID 105

Sequence

<213> OrganismName : Synthetic Sequence

<400> PreSequenceString :

ASRPGLISAX PEQY 14

<212> Type : PRT

<211> Length : 14

SequenceName : SEQ ID 106

SequenceDescription :

Feature

Final TCR Display PCT.WorkFile.txt

Sequence: SEQ ID 106:

<221> FeatureKey : MISC_FEATURE

<222> LocationFrom : 1

<222> LocationTo : 14

Other Information : x denotes an amino acid residue encoded by an amber codon

CDSJoin : No

Sequence

<213> OrganismName : Synthetic Sequence

<400> PreSequenceString :

gccgttacaa ctgacagctg ggggaagctt cag 33

<212> Type : DNA

<211> Length : 33

SequenceName : SEQ ID 107

SequenceDescription :

Custom Codon

Sequence Name : SEQ ID 107

Sequence

<213> OrganismName : Synthetic Sequence

<400> PreSequenceString :

AVTTDSWGKL Q 11

<212> Type : PRT

<211> Length : 11

SequenceName : SEQ ID 108

SequenceDescription :

Sequence

<213> OrganismName : Synthetic Sequence

<400> PreSequenceString :

gccgttacaa ctgacagctg ggggccgctt cag 33

<212> Type : DNA

<211> Length : 33

SequenceName : SEQ ID 109

SequenceDescription :

Custom Codon

Sequence Name : SEQ ID 109

Sequence

<213> OrganismName : Synthetic Sequence

<400> PreSequenceString :

AVTTDSWGPL Q 11

<212> Type : PRT

<211> Length : 11

SequenceName : SEQ ID 110

SequenceDescription :

Sequence

<213> OrganismName : Synthetic Sequence

<400> PreSequenceString :

gccgttacaa ctgacagctg ggggaagatg cag 33

<212> Type : DNA

<211> Length : 33

SequenceName : SEQ ID 111

SequenceDescription :

Custom Codon

Final TCR Display PCT.WorkFile.txt

Sequence Name : SEQ ID 111

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
AVTTDSWGKM Q 11
<212> Type : PRT
<211> Length : 11
      SequenceName : SEQ ID 112
      SequenceDescription :
    
```

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
gccggttaca ctgacagctg ggggaagttg cat 33
<212> Type : DNA
<211> Length : 33
      SequenceName : SEQ ID 113
      SequenceDescription :
    
```

Custom Codon

Sequence Name : SEQ ID 113

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
AVTTDSWGKL H 11
<212> Type : PRT
<211> Length : 11
      SequenceName : SEQ ID 114
      SequenceDescription :
    
```

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
gccggttaca ctgacagctg ggggtagctt cat 33
<212> Type : DNA
<211> Length : 33
      SequenceName : SEQ ID 115
      SequenceDescription :
    
```

Custom Codon

Sequence Name : SEQ ID 115

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
AVTTDSWGXL H 11
<212> Type : PRT
<211> Length : 11
      SequenceName : SEQ ID 116
      SequenceDescription :
    
```

Feature

```

-----
Sequence: SEQ ID 116:
<221> FeatureKey : MISC_FEATURE
<222> LocationFrom :
<222> LocationTo :
      Other Information : x denotes an amino acid residue encoded by an amber
codon
    
```

Final TCR Display PCT.WorkFile.txt

CDSJoin : No

Feature

Sequence: SEQ ID 116:

<221> FeatureKey : MISC_FEATURE

<222> LocationFrom : 1

<222> LocationTo : 11

Other Information : x denotes an amino acid residue encoded by an amber

codon

CDSJoin : No

Sequence

<213> OrganismName : Synthetic Sequence

<400> PreSequenceString :

gccgttacaactgacagctgggggagctt cat

33

<212> Type : DNA

<211> Length : 33

SequenceName : SEQ ID 117

SequenceDescription :

Custom Codon

Sequence Name : SEQ ID 117

Sequence

<213> OrganismName : Synthetic Sequence

<400> PreSequenceString :

AVTTDSWGEL H

11

<212> Type : PRT

<211> Length : 11

SequenceName : SEQ ID 118

SequenceDescription :

Sequence

<213> OrganismName : Synthetic Sequence

<400> PreSequenceString :

gccgttacaactgacagctggggaggctg cat

33

<212> Type : DNA

<211> Length : 33

SequenceName : SEQ ID 119

SequenceDescription :

Custom Codon

Sequence Name : SEQ ID 119

Sequence

<213> OrganismName : Synthetic Sequence

<400> PreSequenceString :

AVTTDSWGRL H

11

<212> Type : PRT

<211> Length : 11

SequenceName : SEQ ID 120

SequenceDescription :

Sequence

<213> OrganismName : Synthetic Sequence

<400> PreSequenceString :

gccgttacaactgacagctggggcagctt cat

33

<212> Type : DNA

<211> Length : 33

SequenceName : SEQ ID 121

Final TCR Display PCT.workFile.txt
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 121

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString : 11
 AVTTDSWGQL H
 <212> Type : PRT
 <211> Length : 11
 SequenceName : SEQ ID 122
 SequenceDescription :

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString : 33
 gccggtacaa ctgacagctg ggggaagggtt cat
 <212> Type : DNA
 <211> Length : 33
 SequenceName : SEQ ID 123
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 123

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString : 11
 AVTTDSWGKV H
 <212> Type : PRT
 <211> Length : 11
 SequenceName : SEQ ID 124
 SequenceDescription :

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString : 33
 gccggtacaa ctgacagctg ggggaagggtg aat
 <212> Type : DNA
 <211> Length : 33
 SequenceName : SEQ ID 125
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 125

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString : 11
 AVTTDSWGKV N
 <212> Type : PRT
 <211> Length : 11
 SequenceName : SEQ ID 126
 SequenceDescription :

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :

```

Final TCR Display PCT.WorkFile.txt
gccgttaca ctgacagctg ggggaagctt ctg 33
<212> Type : DNA
<211> Length : 33
SequenceName : SEQ ID 127
SequenceDescription :

Custom Codon
-----
Sequence Name : SEQ ID 127

Sequence
-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
AVTTDSWGKL L 11
<212> Type : PRT
<211> Length : 11
SequenceName : SEQ ID 128
SequenceDescription :

Sequence
-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
ggaattcatc gatgcagaag gaagtggagc ag 32
<212> Type : DNA
<211> Length : 32
SequenceName : SEQ ID 129
SequenceDescription :

Custom Codon
-----
Sequence Name : SEQ ID 129

Sequence
-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
gtacacggcc gggtcagggt tctggatata c 31
<212> Type : DNA
<211> Length : 31
SequenceName : SEQ ID 130
SequenceDescription :

Custom Codon
-----
Sequence Name : SEQ ID 130

Sequence
-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
tctctcatta atgaatgctg gtgtcactca gacccc 36
<212> Type : DNA
<211> Length : 36
SequenceName : SEQ ID 131
SequenceDescription :

Custom Codon
-----
Sequence Name : SEQ ID 131

Sequence
-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
tagaaaccgg tggccaggca caccagtgtg gc 32
<212> Type : DNA

```

Final TCR Display PCT.WorkFile.txt

<211> Length : 32
 SequenceName : SEQ ID 132
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 132

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 ctgctctggt tccgcactc 19
 <212> Type : DNA
 <211> Length : 19
 SequenceName : SEQ ID 133
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 133

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 gagtgcgga cagagcag 19
 <212> Type : DNA
 <211> Length : 19
 SequenceName : SEQ ID 134
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 134

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 atatccagaa cccggatcct gccgtgta 28
 <212> Type : DNA
 <211> Length : 28
 SequenceName : SEQ ID 135
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 135

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 tacacggcag gaatccgggt tctggatat 29
 <212> Type : DNA
 <211> Length : 29
 SequenceName : SEQ ID 136
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 136

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :

```

Final TCR Display PCT.WorkFile.txt
ggagatatac atatgcagga ggtgacacag          30
<212> Type : DNA
<211> Length : 30
      SequenceName : SEQ ID 137
      SequenceDescription :

Custom Codon
-----
Sequence Name : SEQ ID 137

Sequence
-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
tacacggcag gatccggggtt ctggatatt          29
<212> Type : DNA
<211> Length : 29
      SequenceName : SEQ ID 138
      SequenceDescription :

Custom Codon
-----
Sequence Name : SEQ ID 138

Sequence
-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
ggagatatac atatgggtgt cactcagacc          30
<212> Type : DNA
<211> Length : 30
      SequenceName : SEQ ID 139
      SequenceDescription :

Custom Codon
-----
Sequence Name : SEQ ID 139

Sequence
-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
ccaagctta gtctgctcta ccccaggcct cggc          34
<212> Type : DNA
<211> Length : 34
      SequenceName : SEQ ID 140
      SequenceDescription :

Custom Codon
-----
Sequence Name : SEQ ID 140

Sequence
-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
gccggccatg gccaaacagg aggtgacgca gattcct          37
<212> Type : DNA
<211> Length : 37
      SequenceName : SEQ ID 141
      SequenceDescription :

Custom Codon
-----
Sequence Name : SEQ ID 141

Sequence
-----

```

Final TCR Display PCT.WorkFile.txt

<213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 cttcttaaag aattcttaat taacctaggt tattaggaac tttctgggct ggggaag 57

<212> Type : DNA
 <211> Length : 57
 SequenceName : SEQ ID 142
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 142

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 tcacagcgcg caggctgggtg tctactcagac cccaaa 36
 <212> Type : DNA
 <211> Length : 36
 SequenceName : SEQ ID 143
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 143

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 cgagagcccg tagaactgga cttg 24
 <212> Type : DNA
 <211> Length : 24
 SequenceName : SEQ ID 144
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 144

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 tctctcatta atgaatgctg gtgtcactca gacccc 36
 <212> Type : DNA
 <211> Length : 36
 SequenceName : SEQ ID 145
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 145

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 tagaaaccgg tggccaggca caccagtgtg g 31
 <212> Type : DNA
 <211> Length : 31
 SequenceName : SEQ ID 146
 SequenceDescription :

Custom Codon

Final TCR Display PCT.WorkFile.txt

Sequence Name : SEQ ID 146

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
atgcagaagg aagtggagca gaactctgga cccctcagtg ttccagaggg agccattgcc      60
tctctcaact gcacttacag tgaccgaggt tcccagtcct tcttctggta cagacaatat      120
tctgggaaaa gccctgagtt gataatgtcc atatactcca atggtgacaa agaagatgga      180
aggttttacag cacagctcaa taaagccagc cagtatgttt ctctgctcat cagagactcc      240
cagcccagtg attcagccac ctacctctgt gccgttacia ctgacagctg ggggaaattg      300
cagtttggag cagggacca ggttgtggtc accccagata tccagaacc tgaccctgcc      360
gtgtaccagc tgagagactc taaatccagt gacaagtctg tctgcctatt caccgatttt      420
gattctcaaa caaatgtgtc acaaagtaag gattctgatg tgtatatcac agacaaatgt      480
gtgctagaca tgaggtctat ggacttcaag agcaacagtg ctgtggcctg gagcaacaaa      540
tctgactttg catgtgcaaa cgccttcaac aacagcatta ttccagaaga caccttcttc      600
cccagcccag aaagttccta a                                     621
<212> Type : DNA
<211> Length : 621
SequenceName : SEQ ID 147
SequenceDescription :
    
```

Custom Codon

Sequence Name : SEQ ID 147

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
atgaacgctg gtgtcactca gaccccaaaa ttccaggtcc tgaagacagg acagagcatg      60
acactgcagt gtgcccagga tatgaacat gaatacatgt cctggatcgc acaagaccca      120
ggcatggggc tgaggctgat tcattactca gttgggtgctg gtatcactga ccaaggagaa      180
gtccccaatg gctacaatgt ctccagatca accacagagg atttcccgtc caggctgctg      240
tcggctgctc cctcccagac atctgtgtac ttctgtgcca gcaggccggg actagcggga      300
gggcgaccag agcagtactt cgggccgggc accaggctca cggtcacaga ggacctgaaa      360
aacgtgttcc cacccgaggt cgctgtgttt gagccatcag aagcagagat ctcccacacc      420
caaaaggcca cactggtgtg cctggccaca ggcttctacc ccgaccacgt ggagctgagc      480
tggtgggtga atgggaagga ggtgcacagt ggggtctgca cagaccgca gcccctcaag      540
gagcagcccc ccctcaatga ctccagatac gctctgagca gccgcctgag ggtctcggcc      600
accttctggc aggacccccg caaccacttc cgctgtcaag tccagttcta cgggctctcg      660
gagaatgacg agtggacca ggatagggcc aaaccgctca cccagatcgt cagcgccgag      720
gcctggggta gagcagacta a                                     741
<212> Type : DNA
<211> Length : 741
SequenceName : SEQ ID 148
    
```

Final TCR Display PCT.WorkFile.txt
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 148

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 MQKEVEQNSG PLSVPEGAIA SLNCTYSDRG SQSFFWYRQY SGKSPELIMS IYSNGDKEDG 60
 RFTAQLNKAS QYVLLIRDS QPSDSATYLC AVTTDSWGKL QFGAGTQVVV TPDIQNPDPA 120
 VYQLRDSKSS DKSVCFLTFDF DSQTNVSQSK DSDVYITDKC VLDMRSMDFK SNSAVAWSNK 180
 SDFACANAFN NSIIPEDTFF PSPACESS 206
 <212> Type : PRT
 <211> Length : 206
 SequenceName : SEQ ID 149
 SequenceDescription :

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 MNAGVTQTPK FQVLKTGQSM TLQCAQDMNH EYMSWYRQDP GMGLRLIHYS VGAGITDQGE 60
 VPNGYNVSRs TTEDFPLRLL SAAPSQTSVY FCASRPGLAG GRPEQYFGPG TRLTVTEDLK 120
 NVFPPEVAVF EPSEAEISHT QKATLVCLAT GFYPDHVELS WWVNGKEVHS GVCTDPQPLK 180
 EQPALNDSRY ALSSRLRVSA TFWQDPRNHF RCQVQFYGLS ENDEWTQDRA KPVTQIVSAE 240
 AWGRAD 246
 <212> Type : PRT
 <211> Length : 246
 SequenceName : SEQ ID 150
 SequenceDescription :

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 gttaactacg tcaggtggca cttttcgggg aatgtgctgc ggaacccta tttgtttatt 60
 tttctaaata cattcaata tgtatccgct catgagaaa taaccctgat aaatgcttca 120
 ataatattga aaaaggaaga gtatgagtat tcaacatttc cgtgtcgccc ttattccctt 180
 ttttgcgga ttttgccttc ctgtttttgc tcaccagaaa acgctggtga aagtaaaaga 240
 tgctgaagat cagttgggtg cagcagtggtg ttacatcgaa ctggatctca acagcggtaa 300
 gatccttgag agttttcgcc ccgaagaacg ttctccaatg atgagcactt ttaaagttct 360
 gctatgtggc gcggtattat cccgtgttga cgccgggcaa gagcaactcg gtcgccgcat 420
 aactatttct cagaatgact tggttgagta ctcaccagtc acagaaaagc atcttacgga 480
 tggcatgaca gtaagagaat tatgcagtgc tgccataacc atgagtgata aactgcggc 540
 caacttactt ctgacaacga tcggaggacc gaaggagcta accgcttttt tgcaacaat 600
 ggggatcat gtaactcgcc ttgatcgttg ggaaccggag ctgaatgaag ccatacaaa 660
 cgacgagcgt gacaccacga tgctgttagc aatggcaaca acgttgcgca aactattaac 720

Final TCR Display PCT.WorkFile.txt

tggcgaacta	cttactctag	cttccccggca	acaattaata	gactggatgg	aggcggataa	780
agttgcagga	ccacttctgc	gctcggccct	tccggctggc	tggtttattg	ctgataaatc	840
tgagagccgt	gagcgtgggt	ctcgcggat	cattgcagca	ctggggccag	atggtaagcc	900
ctcccgtatc	gtagttatct	acacgacggg	gagtcaggca	actatggatg	aacgaaatag	960
acagatcgct	gagataggtg	cctcactgat	taagcattgg	taactgtcag	accaagtta	1020
ctcatatata	ctttagattg	atctaccg	gttgataatc	agaaaagccc	caaaaacagg	1080
aagattgtat	aagcaaata	ttaaattgta	aacgttaata	ttttgttaa	attcgcgtta	1140
aatTTTTgtt	aatcagctc	atTTTTtaac	caataggccg	aatcggcaa	aatcccttat	1200
aatcaaaag	aatagcccga	gatagggttg	agtgttggtc	cagtttgaa	caagagtcca	1260
ctattaaaga	acgtggactc	caacgtcaaa	gggcgaaaa	ccgtctatca	gggcgatggc	1320
ccactacgtg	aaccatcacc	caaatcaagt	TTTTTgggg	cgaggtgccg	taaagcacta	1380
aatcggaaacc	ctaaaggag	ccccgattt	agagcttgac	gggaaagcg	aacgtggcga	1440
gaaaggaagg	gaagaaagcg	aaaggagcgg	gcgctagggc	gctggcaagt	gtagcggca	1500
cgctgcgcgt	aaccaccaca	cccgccgcg	ttaatgcgcc	gctacagggc	gcgtaaaagg	1560
atctaggtga	agatcctttt	tgataatctc	atgacaaaa	tcccttaacg	tgagttttcg	1620
ttccactgag	cgtcagacc	cgtagaaaag	atcaaaggat	cttcttgaga	tcctTTTTt	1680
ctgcgcgtaa	tctgctgctt	gcaaacaaaa	aaaccaccgc	taccagcgg	ggtttgtttg	1740
ccggatcaag	agctaccaac	tctTTTTccg	aaggtaactg	gcttcagcag	agcgcagata	1800
caaataactg	ttcttctagt	gtagccgtag	ttaggccacc	acttcaagaa	ctctgtagca	1860
ccgcctacat	acctcgctct	gctaatectg	ttaccagtgg	ctgctgccag	tggcgataag	1920
tcgtgtctta	ccgggttgg	ctcaagacga	tagttaccgg	ataaggcgca	gcggtcgggc	1980
tgaacggggg	gttcgtgcac	acagcccagc	ttggagcga	cgacctacac	cgaactgaga	2040
tacctacagc	gtgagctatg	agaaagcgcc	acgcttccc	aaggagaaa	ggcggacagg	2100
tatccggtaa	gcggcagggt	cggaacagga	gagcgcacga	gggagcttc	aggggaaac	2160
gcctggatc	tttatagtcc	tgctgggttt	cgccacctct	gacttgagcg	tcgatttttg	2220
tgatgctcgt	cagggggggc	gagcctatgg	aaaaacgcca	gcaacgggc	ctttttacgg	2280
ttcctggcct	tttgctggcc	ttttgctcac	atgtaatgtg	agttagctca	ctcattaggc	2340
accccaggct	ttacacttta	tgcttccggc	tcgtatgttg	tgtggaattg	tgagcggata	2400
acaatttcac	acagaaaca	gctatgacca	tgattacgcc	aagctacgta	taataatatt	2460
ctatttcaag	gagacagtca	taatgaaata	cctattgcct	acggcagccg	ctggattggt	2520
attactcgcg	gcccagccgg	ccatggccca	gaaggaagtg	gagcagaact	ctggaccct	2580
cagtgttcca	gagggagcca	ttgcctctct	caactgcact	tacagtgacc	gaggttcca	2640
gtccttcttc	tggtacagac	aatattctgg	gaaaagccct	gagttgataa	tgtccatata	2700
ctccaatggt	gacaaagaag	atggaagggt	tacagcacag	ctcaataaag	ccagccagta	2760

Final TCR Display PCT.WorkFile.txt

tgtttctctg	ctcatcagag	actcccagcc	cagtgattca	gccacctacc	tctgtgccgt	2820
tacaactgac	agctggggga	aattgcagtt	tggagcaggg	accaggttg	tggtcacccc	2880
agatatccag	aaccctgacc	ctgccgtgta	ccagctgaga	gactctaaat	ccagtgacaa	2940
gtctgtctgc	ctattcaccg	atthttgattc	tcaaacaaat	gtgtcacaaa	gtaaggattc	3000
tgatgtgtat	atcacagaca	aatgtgtgct	agacatgagg	tctatggact	tcaagagcaa	3060
cagtgtctgtg	gcctggagca	acaaatctga	ctttgcatgt	gcaaacgcct	tcaacaacag	3120
cattattcca	gaagacacct	tcttccccag	cccagaaagt	tcctaataac	ctaggttaat	3180
taagaattct	ttaagaagga	gatatacata	tgaaaaaatt	attattcgca	attcctttag	3240
ttgttccttt	ctattctcac	agcgcgcagg	ctggtgtcac	tcagaccca	aaattccagg	3300
tcctgaagac	aggacagagc	atgacactgc	agtgtgccca	ggatatgaac	catgaataca	3360
tgtcctggta	tcgacaagac	ccaggcatgg	ggctgaggct	gattcattac	tcagttgggtg	3420
ctggtatcac	tgaccaagga	gaagtcccca	atggctacaa	tgtctccaga	tcaaccacag	3480
aggatttccc	gctcaggctg	ctgtcggctg	ctccctcca	gacatctgtg	tacttctgtg	3540
ccagcaggcc	gggactagcg	ggagggcgac	cagagcagta	cttcgggccg	ggcaccaggc	3600
tcacggtcac	agaggacctg	aaaaacgtgt	tcccaccga	ggtcgctgtg	tttgagccat	3660
cagaagcaga	gatctcccac	acccaaaagg	ccacactggt	gtgcctggcc	acaggcttct	3720
accccagcca	cgtggagctg	agctggtggg	tgaatgggaa	ggaggtgcac	agtgggttct	3780
gcacagacc	gcagcccctc	aaggagcagc	ccgccctcaa	tgactccaga	tacgctctga	3840
gcagccgct	gagggctctg	gccaccttct	ggcaggacc	ccgcaaccac	ttccgctgtc	3900
aagtccagtt	ctacgggctc	tcggagaatg	acgagtggac	ccaggatagg	gccaacccg	3960
tcaccagat	cgtcagcgcc	gaggcctggg	gtagagcaga	cgcgccgca	tctagacatc	4020
atcaccatca	tcactagact	gttgaaagtt	gtttagcaaa	acccataca	gaaaattcat	4080
ttactaacgt	ctggaagac	gacaaaactt	tagatcgta	cgtaactat	gagggttgtc	4140
tgtggaatgc	tacagcggtt	gtagtttgta	ctggtgacga	aactcagtgt	tacggtacat	4200
gggttcctat	tgggcttgct	atccctgaaa	atgaggggtg	tggctctgag	ggtggcggtt	4260
ctgaggggtg	cggttctgag	ggtggcggtg	ctaaacctcc	tgagtacggt	gatacaccta	4320
ttccgggcta	tacttatatc	aaccctctcg	acggcactta	tccgcctggt	actgagcaaa	4380
accccgctaa	tcctaatect	tctcttgagg	agtctcagcc	tcttaatact	ttcatgtttc	4440
agaataatag	gttccgaaat	aggcaggggg	cattaactgt	ttatacgggc	actgttactc	4500
aaggcactga	ccccgttaa	acttattacc	agtacactcc	tgtatcatca	aaagccatgt	4560
atgacgctta	ctggaacggt	aaattcagag	actgcgcttt	ccattctggc	tttaatgagg	4620
atccattcgt	ttgtgaatat	caaggccaat	cgtctgacct	gcctcaacct	cctgtcaatg	4680
ctggcgcgcg	ctctggtggt	ggttctgggtg	gctgctctga	gggtgggtggc	tctgaggggtg	4740
gctggtctga	gggtggcggc	tctgagggag	gctggtccgg	tggtggctct	ggttccgggtg	4800

Final TCR Display PCT.WorkFile.txt

```

atthttgatta tgaaaagatg gcaaacgcta ataagggggc tatgaccgaa aatgccgatg      4860
aaaacgcgct acagtctgac gctaaaggca aacttgattc tgtcgctact gattacggtg      4920
ctgctatcga tggtttcatt ggtgacgttt ccggccttgc taatggtaat ggtgctactg      4980
gtgattttgc tggctctaata tcccaaatgg ctcaagtcgg tgacggtgat aattcacctt      5040
taatgaataa tttccgtaaa tatttacctt ccctccctca atcggttgaa tgtcgccctt      5100
ttgtctttag cgctggtaaa ccatatgaat tttctattga ttgtgacaaa ataaacttat      5160
tccgtgggtg ctttgcgttt cttttatatg ttgccacctt tatgtatgta ttttctacgt      5220
ttgctaacat actgcgtaat aaggagtctt aataaggtag cctctagtca aggcctatag      5280
tgagtcgtat tacggactgg ccgtcgtttt acaacgctgt gactgggaaa accctggcgt      5340
taccacaactt aatcgccttg cagcacatcc ccctttcgcc agctggcgta atagcgaaga      5400
ggccccgacc gatcgcctt cccaacagtt gcgagcctg aatggcgaat ggcgcttcgc      5460
ttgtaataaa agcccgcttc ggcgggcttt ttttt                                     5495
<212> Type : DNA
<211> Length : 5495
      SequenceName : SEQ ID 151
      SequenceDescription :
```

Custom Codon

Sequence Name : SEQ ID 151

Sequence

```

<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
agctgcagct aatacagctc actataggaa caggccacca tgggccagaa ggaagtggag      60
cagaactctg gaccctcag tgttccagag ggagccattg cctctctcaa ctgcacttac      120
agtgaccgag gttcccagtc cttcttctgg tacagacaat attctgggaa aagccctgag      180
ttgataatgt ccatatactc caatggtgac aaagaagatg gaaggtttac agcacagctc      240
aataaagcca gccagtatgt ttctctgctc atcagagact cccagcccag tgattcagcc      300
acctacctct gtgccgttac aactgacagc tgggggaaat tgcagtttg agcagggacc      360
caggttggtg tcaccggtgg aggcggttca ggcggagggt gatccggcgg tggcgggtcg      420
aacgctggtg tctctcagac cccaaaattc caggtcctga agacaggaca gagcatgaca      480
ctgcagtgtg cccaggatat gaacctatgaa tacatgtcct ggtatcgaca agaccaggc      540
atggggctga ggctgattca ttactcagtt ggtgctggta tctactgaca aggagaagtc      600
cccaatggct acaatgtctc cagatcaacc acagaggatt tcccgctcag gctgctgtcg      660
gctgctccct cccagacatc tgtgtacttc tgtgccagca ggccgggact agcgggaggg      720
cgaccagagc agtacttcgg gccgggcacc aggctcacgg tcacagagga cctgaaaaac      780
gtgttcccac ccgaggctgc tgtgtttgag ccatcagaag cagagatctc ccacaccaa      840
aaggccacac tgggtgtgcct ggccacaggc ttctacccc accacgtgga gctgagctgg      900
tgggtgaatg ggaaggaggt gcacagtggg gtcagcacag acccgagcc cctcaaggag      960
```

```

Final TCR Display PCT.WorkFile.txt
cagccccgcc tcaatgactc cagatagcgt ctgagcagcc gcctgagggt ctccggccacc 1020
ttctggcagg acccccgcaa ccacttccgc tgtcaagtcc agttctacgg gctctcggag 1080
aatgacgagt ggaccagga tagggccaaa cccgtcacc agatcgtag cgccgaggcc 1140
tggggtagag cagacggtgg aggcggttca ctgagcagca ccctgacgct gagcaaagca 1200
gactacgaga aacacaaagt ctacgcctgc gaagtcacc atcagggcct gagttcgccc 1260
gtcacaaaga gttcaaccg cggagagtca taagaattct cag 1303
<212> Type : DNA
<211> Length : 1303
SequenceName : SEQ ID 152
SequenceDescription :
    
```

Custom Codon

Sequence Name : SEQ ID 152

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
MQQKEVEQNS GPLSVPEGAI ASLNCTYS DR GSQSFYWRQ YSGKSPELIM SIYSNGDKED 60
GRFTAQLNKA SQYVSL LIRD SPSDSATYLC AVTTDSWGKL QFGAGTQVVV TGGGSGGGG 120
SGGGSNAGV TQPKFQVLK TGQSM TLQCA QDMNHEYMSW YRQDPGMGLR LIHYSVGAGI 180
TDQGEVPNGY NVSRSTTE DF PLRLLSAAPS QTSVYFCASR PGLAGGRPEQ YFGPGTRLTV 240
TEDLKNVFP P EVAVFEPSEA EISHTQKATL VCLATGFYPD HVELSWVNG KEVHSGVSTD 300
PQPLKEQPAL NDSRYALSS R LRVSATFWQD PRNHFR CQVQ FYGLSENDEW TQDRAKPV TQ 360
IVSAEAWGRA DGGGGSLSST LTLSKADY EK HKVYACEVTH QGLSSPVTKS FNRGES 416
    
```

```

<212> Type : PRT
<211> Length : 416
SequenceName : SEQ ID 153
SequenceDescription :
    
```

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
ctgctttccc ggagcactat gcggataaaa atatccaatt acagtactat tattacaaaa 60
gaatctgcag tccaccgtga aaagcccctt tacacgcgcc ttggggataa acaaataaaa 120
agatttatgt aagtttatac ataggcgagt actctgttat tgggactatt tacgaagtta 180
ttataacttt ttccttctca tactcataag ttgtaaaggc acagcgggaa taagggaaaa 240
aacgccgtaa aacggaagga caaaaacgag tgggtctttg cgaccacttt cttttctac 300
gacttctagt caaccacgt gtcacccaa tgtagcttga cctagagttg tcgccattct 360
aggaactctc aaaagcgggg cttcttgcaa aaggttacta ctctgaaaa tttcaagacg 420
atacaccgcy ccataatagg gcataactgc ggcccgttct cgttgagcca gcggcgtagt 480
tgataagagt cttactgaac caactcatga gtggtcagtg tcttttcgta gaatgcctac 540
cgtactgtca ttctcttaat acgtcacgac ggtattggta ctactattg tgacgccggt 600
    
```

Final TCR Display PCT.WorkFile.txt

tgaatgaaga	ctgttgctag	cctcctggct	tcctcgattg	gcaaaaaaac	gtgttgtacc	660
ccctagtaca	ttgagcggaa	ctagcaaccc	ttggcctcga	cttacttcgg	tatggtttgc	720
tgctcgcact	gtggtgctac	ggacatcggt	accgttggtg	caacgcgttt	gataattgac	780
cgcttgatga	atgagatcga	agggccgttg	ttaattatct	gacctacctc	cgctatttc	840
aacgtcctgg	tgaagacgcg	agccgggaag	gccgaccgac	caaataacga	ctatttagac	900
ctcggccact	cgcacccaga	gcgcatagt	aacgtcgtga	ccccggtcta	ccattcggga	960
gggcatagca	tcaatagatg	tgctgccct	cagtccgttg	atacctactt	gctttatctg	1020
tctagcgact	ctatccacgg	agtgactaat	tcgtaacat	tgacagtctg	gttcaaata	1080
gtatatatga	aatctaacta	aattttgaag	taaaaattaa	attttcctag	atccacttct	1140
aggaaaaact	attagagtac	tggttttagg	gaattgcact	caaaaagcaag	gtgactcgca	1200
gtctggggca	tcttttctag	tttcctagaa	gaactctagg	aaaaaaagac	gcgcattaga	1260
cgacgaacgt	ttgtttttt	ggtggcgatg	gtcgccacca	aacaaacggc	ctagttctcg	1320
atggttgaga	aaaaggcttc	cattgaccga	agtcgtctcg	cgctctatgg	ttatgacagg	1380
aagatcacat	cggcatcaat	ccggtggtga	agttcttgag	acatcgggc	ggatgtatgg	1440
agcgagacga	ttaggacaat	ggtcaccgac	gacggtcacc	gctattcagc	acagaatggc	1500
ccaacctgag	ttctgctatc	aatggcctat	tccgcgtcgc	cagcccgact	tgcccccaa	1560
gcacgtgtgt	cgggtcgaac	ctcgttgct	ggatgtggct	tgactctatg	gatgtcgcac	1620
tcgatactct	ttcgcggtgc	gaagggttc	cctctttccg	cctgtccata	ggccattcgc	1680
cgtdccagcc	ttgtcctctc	gcgtgctccc	tcgaaggctc	ccctttgcgg	accatagaaa	1740
tatcaggaca	gccccaaagc	gtggagactg	aactcgcagc	taaaaacact	acgagcagtc	1800
ccccgcctc	ggataccttt	ttgcggtcgt	tcgcccggaa	aaatgccaa	gaccggaaaa	1860
cgaccggaaa	acgagtgtac	aagaaaggac	gcaatagggg	actaagacac	ctattggcat	1920
aatggcggaa	actcactcga	ctatggcgag	cggcgtcggc	ttgctggctc	gcgtcgctca	1980
gtcactcgct	ccttcgcctt	ctcgcgggtt	atgcgtttgg	cggagagggg	cgcgcaaccg	2040
gctaagtaat	tacgtcgacc	gtgctgtcca	aagggtgac	ctttcgccc	tcactcgct	2100
tgcgtaatt	acactcaatc	gagtgagtaa	tccgtgggg	ccgaaatgtg	aaatacgaag	2160
gccgagcata	caacacacct	taacactcgc	ctattgttaa	agtgtgtcct	ttgtcgatac	2220
tggtactaat	gcggttcgac	gtcgattatg	ctgagtgata	tccttgtccg	gtggtaccct	2280
aggggccccat	ggctcgagct	taagtgaccg	gcagcaaaat	gttgacgac	tgaccctttt	2340
gggaccgcaa	tgggttgaat	tagcggaacg	tcgtgtaggg	ggaaagcgg	cgaccgcatt	2400
atcgcttctc	cgggcgtggc	tagcgggaag	ggttgtcaac	gcgtcggact	taccgcttac	2460
cgcgactac	gccataaaag	aggaatgcgt	agacacgcca	taaagtgtgg	cgtataccac	2520
gtgagagtca	tgtagacga	gactacggcg	tatcaattcg	gtcggggctg	tgggcgggtg	2580
tgggcgactg	cgcgggactg	cccgaacaga	cgagggccgt	aggcgaatgt	ctgttcgaca	2640

Final TCR Display PCT.WorkFile.txt

ctggcagagg ccctcgacgt acacagtctc caaaagtggc agtagtggct ttgcbgct 2699

<212> Type : DNA
 <211> Length : 2699
 SequenceName : SEQ ID 154
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 154

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 ccatgggcca gaaggaagtg gagcagaact ctggaccct cagtgttcca gagggagcca 60
 ttgctctct caactgcact tacagtgacc gaggttcca gtccttctc tggtagacagac 120
 aatattctgg gaaaagcct gagttgataa tgtccatata ctccaatggg gacaaagaag 180
 atggaagggt tacagcacag ctcaataaag ccagccagta tgtttctctg tcatcagag 240
 actcccagcc cagtgattca gccacctacc tctgtgccgt tacaactgac agctggggga 300
 aattgcagtt tggagcaggg acccagggtg tggtcaccgg tggaggcggg tcaggcggag 360
 gtggatccgg cgggtggcggg tcgaacgctg gtgtcactca gaccccaaaa ttccaggctc 420
 tgaagacagg acagagcatg aactgcagt gtgcccagga tatgaacat gaatacatgt 480
 cctggtatcg acaagacca ggcattggggc tgaggctgat tcattactca gttggtgctg 540
 gtatcactga ccaaggagaa gtcccaatg gctacaatgt ctccagatca accacagagg 600
 atttcccgtc caggctgctg tcggctgctc cctcccagac atctgtgtac ttctgtgcca 660
 gcaggccggg actagcggga gggcgaccag agcagtactt cgggccggg accaggctca 720
 cggtcacaga ggacctgaaa aacgtgttcc caccgaggt cgctgtgtt gagccatcag 780
 aagcagagat ctcccacacc caaaaggcca cactgggtgtg cctggccaca ggcttctacc 840
 ccgaccacgt ggagctgagc tgggtgggtga atgggaagga ggtgcacagt ggggtcagca 900
 cagaccgcga gccctcaag gagcagcccg cctcaatga ctccagatac gctctgagca 960
 gccgcctgag ggtctcggcc accttctggc aggacccccg caaccacttc cgctgtcaag 1020
 tccagttcta cgggctctcg gagaatgacg agtggacca ggatagggcc aaaccgtca 1080
 cccagatcgt cagcgcagag gcctggggta gagcagcgg tggaggcggg tcaactcagca 1140
 gcaccctgac gctgagcaaa gcagactacg agaaacaaa agtctacgcc tgcgaagtca 1200
 cccatcaggg cctgagttcg cccgtcaca agagcttcaa ccgaggagag tcataagaat 1260
 tc 1262

<212> Type : DNA
 <211> Length : 1262
 SequenceName : SEQ ID 155
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 155

Final TCR Display PCT.WorkFile.txt

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
gctggtgtca ctcagacccc aaaattccag gtcctgaaga caggacagag catgacactg      60
cagtgtgccc aggatatgaa ccatgaatac atgtcctggt atcgacaaga cccaggcatg      120
gggctgaggc tgattcatta ctcagttggt gctggtatca ctgaccaagg agaagtcccc      180
aatggctaca atgtctccag atcaaccaca gaggatttcc cgctcaggct gctgtcggct      240
gctccctccc agacatctgt gtacttctgt gcccaggcggc cgggactagc gggaggggtga      300
ccagagcagt acttcgggccc gggcaccagg ctcacgggtca cagaggacct gaaaaacgtg      360
ttcccacccg aggtcgctgt gtttgagcca tcagaagcag agatctcca cacccaaaag      420
gccacactgg tgtgcctggc cacaggcttc taccgccgacc acgtggagct gagctggtgg      480
gtgaatggga aggaggtgca cagtgggggtc tgcacagacc cgcagcccct caaggagcag      540
cccgcctca atgactccag atacgctctg agcagccgcc tgagggtctc ggccaccttc      600
tggcaggacc cccgcaacca cttccgctgt caagtccagt tctacgggct ctcggagaat      660
gacgagtgga cccaggatag ggccaaaccc gtcaccaga tcgtcagcgc cgaggcctgg      720
ggtagagcag ac                                                                732
<212> Type : DNA
<211> Length : 732
      SequenceName : SEQ ID 156
      SequenceDescription :
    
```

Custom Codon

Sequence Name : SEQ ID 156

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
AGVTQTPKFQ VLKGTQSM TL QCAQDMNHEY MSWYRQDPGM GLRLIHYSVG AGITDQGEVP      60
NGYNVSRSTT EDFPLRLLSA APSQTSVYFC ASRPLAGGX PEQYFGPGTR LVTEDLKNV      120
FPPEVAVFEP SEAEISHTQK ATLVCLATGF YPDHVELSWW VNGKEVHSGV CTDPQPLKEQ      180
PALNDSRYAL SSRLRVSATF WQDPRNHFR C QVQFYGLSEN DEWTQDRAKP VTQIVSAEAW      240
GRAD                                                                244
<212> Type : PRT
<211> Length : 244
      SequenceName : SEQ ID 157
      SequenceDescription :
    
```

Feature

```

-----
Sequence: SEQ ID 157:
<221> FeatureKey : MISC_FEATURE
<222> LocationFrom : 1
<222> LocationTo : 244
      Other Information : X denotes an amino acid residue encoded by an opal
codon, this is normally translated as a tryptophan
      CDSJoin : No
    
```

Sequence

Final TCR Display PCT.WorkFile.txt

```

<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
gctggtgtca ctcagacccc aaaattccag gtcctgaaga caggacagag catgacactg      60
tagtgtgccc aggatatgaa ccatgaatac atgtcctggt atcgacaaga cccagggcatg      120
gggctgaggc tgattcatta ctcagttggt gctggtatca ctgaccaagg agaagtcccc      180
aatggctaca atgtctccag atcaaccaca gaggatttcc cgctcaggct gctgtcggct      240
gctccctccc agacatctgt gtacttctgt gccagcaggc cgggactagc gggagggcga      300
ccagagcagt acttcgggccc gggcaccagg ctcacgggtca cagaggacct gaaaaacgtg      360
ttcccacccg aggtcgctgt gtttgagcca tcagaagcag agatctcca cacccaaaag      420
gccacactgg tgtgcctggc cacaggcttc taccgccacc acgtggagct gagctggtgg      480
gtgaatggga aggaggtgca cagtggggtc tgcacagacc cgcagcccct caaggagcag      540
cccgccctca atgactccag atacgctctg agcagccgcc tgagggcttc ggccaccttc      600
tggcaggacc cccgcaacca cttccgctgt caagtccagt tctacgggct ctcggagaat      660
gacgagtgga cccaggatag ggccaaaccc gtcaccaga tcgtcagcgc cgaggcctgg      720
gtagagcag ac                                                                732
<212> Type : DNA
<211> Length : 732
SequenceName : SEQ ID 158
SequenceDescription :

```

Custom Codon

Sequence Name : SEQ ID 158

Sequence

```

-----
<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
gctggtgtca ctcagacccc aaaattccag gtcctgaaga caggacagag catgacactg      60
cagtgtgccc aggatatgaa ccatgaatac atgtcctggt atcgacaaga cccagggcatg      120
gggctgaggc tgattcatta ctcagttggt gctggtatca ctgaccaagg agaagtcccc      180
aatggctaca atgtctccag atcaaccaca gaggatttcc cgctcaggct gctgtcggct      240
gctccctccc agacatctgt gtacttctgt gcctcagaggc cggggctgat gagtgcggaa      300
ccagagcagt acttcgggccc gggcaccagg ctcacgggtca cagaggacct gaaaaacgtg      360
ttcccacccg aggtcgctgt gtttgagcca tcagaagcag agatctcca cacccaaaag      420
gccacactgg tgtgcctggc caccggttc taccgccacc acgtggagct gagctggtgg      480
gtgaatggga aggaggtgca cagtggggtc tgcacagacc cgcagcccct caaggagcag      540
cccgccctca atgactccag atacgctctg agcagccgcc tgagggcttc ggccaccttc      600
tggcaggacc cccgcaacca cttccgctgt caagtccagt tctacgggct ctcggagaat      660
gacgagtgga cccaggatag ggccaaaccc gtcaccaga tcgtcagcgc cgaggcctgg      720
gtagagcag actaagcttg aattc                                                                745
<212> Type : DNA
<211> Length : 745
SequenceName : SEQ ID 159

```

Final TCR Display PCT.WorkFile.txt
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 159

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 MNAGVTQTPK FQVLKTGQSM TLQCAQDMNH EYMSWYRQDP GMGLRLIHYS VGAGITDQGE 60
 VPNGYNVSR S TTEDFPLRLL SAAPSQTSVY FCASRPGLMS AEPEQYFGPG TRLTVTEDLK 120
 NVFPPEVAVF EPSEAEISHT QKATLVCLAT GFYPDHVELS WWVNGKEVHS GVCTDPQPLK 180
 EQPALNDSRY ALSSRLRVSA TFWQDPRNHF RCQVQFYGLS ENDEWTQDRA KPVTQIVSAE 240
 AWGRAD 246
 <212> Type : PRT
 <211> Length : 246
 SequenceName : SEQ ID 160
 SequenceDescription :

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 AGVTQTPKFQ VLKTGQSMTL QCAQDMNHEY MSWYRQDPGM GLRLIHYSVG AGITDQGEVP 60
 NGYNVSRSTT EDFPLRLLSA APSQTSVYFC ASRPGLMSAQ PEQYFGPGTR LTVTEDLKNV 120
 FPPEVAVFEP SEAEISHTQK ATLVCLATGF YPDHVELSWW VNGKEVHSGV CTDQPPLKEQ 180
 PALNDSRYAL SSRLRVSATF WQDPRNHFRC QVQFYGLSEN DEWTQDRAKP VTQIVSAEAW 240
 GRAD 244
 <212> Type : PRT
 <211> Length : 244
 SequenceName : SEQ ID 161
 SequenceDescription :

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 atgcaggagg tgacacagat tcctgcagct ctgagtgtcc cagaaggaga aaacttggtt 60
 ctcaactgca gtttactga tagcgctatt tacaacctcc agtggtttag gcaggaccct 120
 gggaaaggtc tcacatctct gttgcttatt cagtcaagtc agagagagca aacaagtgga 180
 agacttaatg cctcgctgga taaatcatca ggacgtagta cttatacat tgcagcttct 240
 cagcctggtg actcagccac ctacctctgt gctgtgaggc ccacatcagg aggaagctac 300
 atacctacat ttggaagagg aaccagcctt attgttcac cgtatatcca gaaccctgac 360
 cctgccgtgt accagctgag agactctaaa tccagtgaca agtctgtctg cctattcacc 420
 gattttgatt ctcaaacaaa tgtgtcacia agtaaggatt ctgatgtgta tatcacagac 480
 aaatgtgtgc tagacatgag gtctatggac ttcaagagca acagtgtgtg ggcctggagc 540
 aacaaatctg actttgcatg tgcaaacgcc ttcaacaaca gcattattcc agaagacacc 600
 ttcttcccca gccagaaaag ttcctaa 627
 <212> Type : DNA

Final TCR Display PCT.WorkFile.txt

<211> Length : 627
 SequenceName : SEQ ID 162
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 162

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 atgggtgtca ctcagacccc aaaattccag gtcctgaaga caggacagag catgacactg 60
 cagtgtgccc aggatatgaa ccatgaatac atgtcctggt atcgacaaga cccaggcatg 120
 gggctgaggc tgattcatta ctcagttggt gctggtatca ctgaccaagg agaagtcccc 180
 aatggctaca atgtctccag atcaaccaca gaggatttcc cgctcaggct gctgtcggct 240
 gtcacctccc agacatctgt gtacttctgt gccagcagtt acgtcgggaa caccggggag 300
 ctgttttttg gagaaggctc taggctgacc gtactggagg acctgaaaaa cgtgttccca 360
 cccgaggtcg ctgtgtttga gccatcagaa gcagagatct cccacacca aaaggccaca 420
 ctggtgtgcc tggccacagg cttctacccc gaccacgtgg agctgagctg gtgggtgaat 480
 ggaaggagg tgcacagtgg ggtctgcaca gacccgcagc ccctcaagga gcagcccgcc 540
 ctcaatgact ccagatacgc tctgagcagc cgctgaggg tctcggccac cttctggcag 600
 gacccccgca accacttccg ctgtcaagtc cagttctacg ggctctcggg gaatgacgag 660
 tggaccagg atagggccaa acccgtcacc cagatcgta gcgccgaggc ctggggtaga 720
 gcagactaa 729

<212> Type : DNA
 <211> Length : 729
 SequenceName : SEQ ID 163
 SequenceDescription :

Custom Codon

 Sequence Name : SEQ ID 163

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 MQEVTQIPAA LSVPEGENLV LNCSFTDSAI YNLQWFRQDP GKGLTSLLLI QSSQREQTSG 60
 RLNASLDKSS GRSTLYIAAS QPGDSATYLC AVRPTSGGSY IPTFGRGTSL IVHPYIQNPD 120
 PAVYQLRDSK SSDKSVCLFT DFDSQTNVSQ SKDSDVYITD KCVLDMRSMD FKSNSAVAWS 180
 NKSDFACANA FNNSIIPEDT FFPSPESP 208

<212> Type : PRT
 <211> Length : 208
 SequenceName : SEQ ID 164
 SequenceDescription :

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 MGVTTQPKFQ VLKGTQSM TL QCAQDMNHEY MSWYRQDPGM GLRLIHYSVG AGITDQGEVP 60

Final TCR Display PCT,workFile.txt
 NGYNVSRSTT EDFPLRLLSA APSQTSVYFC ASSYVGNTGE LFFGEGSRLT VLEDLKNVFP 120
 PEVAVFEPSE AEISHTQKAT LVCLATGFYP DHVELSWWVN GKEVHSGVCT DPQPLKEQPA 180
 LNSDRYALSS RLRVSATFWQ DPRNHFRQV QFYGLSENDE WTQDRAKPVT QIVSAEAWGR 240
 AD 242

<212> Type : PRT
 <211> Length : 242
 SequenceName : SEQ ID 165
 SequenceDescription :

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 ttcttgccct ttgctggcc ttttgctcac atgtaatgtg agttagctca aaggaccgga 60
 aaacgaccgg aaaacgagtg tacattacac tcaatcgagt ctcattaggc accccaggct 120
 ttacacttta tgcttccggc tcgtatgttg gagtaatccg tgggggccga aatgtgaaat 180
 acgaaggccg agcatacaac tgtggaattg tgagcggata acaatttcac acaggaaaca 240
 gctatgacca acaccttaac actcgcctat tgttaaagtg tgcctttgt cgatactggt 300
 tgattacgcc aagctacgta ctttaagtatt ctatttcaag gagacagtca actaatgcgg 360
 ttcgatgcat gaattcataa gataaagttc ctctgtcagt taatgaaata cctattgcct 420
 acggcagccg ctggattggt attactcgcg attactttat ggataacgga tgccgtcggc 480
 gacctaaca taatgagcgc gccagccgg ccatggccaa acaggagggt acgcagattc 540
 ctgcagctct cgggtcggcc ggtaccgggt tgcctccac tgcgtctaag gacgtcgaga 600
 gagtgtccca gaaggagaaa acttggttct caactgcagt ttcactgata ctacagggt 660
 cttcctcttt tgaaccaaga gttgacgtca aagtactat gcgctattta caacctccag 720
 tggtttaggc aggaccctgg gaaaggtctc cgcgataaat gttggagggt accaaatccg 780
 tcctgggacc ctttccagag acatctctgt tgcttattca gtcaagtcag agagagcaaa 840
 caagtggaag tgtagagaca acgaataagt cagttcagtc tctctcgttt gttcaccttc 900
 acttaatgcc tcgctggata aatcatcagg acgtagtact ttatacattg tgaattacgg 960
 agcgacctat ttagtagtcc tgcacatga aatatgtaac cagcttctca gcctggtgac 1020
 tcagccacct acctctgtgc tgtgaggccc gtcgaagagt cggaccactg agtcggtgga 1080
 tggagacacg aactccggg acatcaggag gaagctacat acctacattt ggaagaggaa 1140
 ccagccttat tgtagtctc cttcgatgta tggatgtaaa ctttctcctt ggtcggata 1200
 tgttcatccg tatatccaga acccgatcc tgccgtgtac cagctgagag acaagtaggc 1260
 atataggtct tgggcctagg acggcacatg gtcgactctc actctaaatc cagtgacaag 1320
 tctgtctgcc tattcaccga ttttgattct tgagatttag gtcactgttc agacagacgg 1380
 ataagtggct aaaactaaga caaacaatg tgtcacaag taaggattct gatgtgtata 1440
 tcacagacaa gtttgtttac acagtgtttc attcctaaga ctacacatat agtgtctggt 1500
 atgtgtgcta gacatgaggt ctatggactt caagagcaac agtgctgtgg tacacacgat 1560

Final TCR Display PCT.WorkFile.txt

```

ctgtactcca gatacctgaa gttctcgttg tcacgacacc cctggagcaa caaatctgac 1620
tttgcattgtg caaacgcctt caacaacagc ggacctcgtt gtttagactg aaacgtacac 1680
gtttgctggaa gttgttgctg attattccag aagacacctt cttccccagc ccagaaagt 1740
cctaataacc taataaggct ttctgtggaa gaaggggtcg ggtctttcaa ggattattgg 1800
taggttaatt aagaattctt taagaagggg atatacatat gaaaaaatta atccaattaa 1860
ttcttaagaa attcttcccc tatatgtata cttttttaat ttattcgcaa ttcctttagt 1920
tgttcctttc tattctcaca gcgcgcaggg aataagcgtt aaggaaatca acaaggaaaag 1980
ataagagtgt cgcgctccg tgggtgctact cagaccccaa aattccaggt cctgaagaca 2040
ggacagagca accacagtga gtctgggggtt ttaaggcca ggacttctgt cctgtctcgt 2100
tgactctgca gtgtgcccag gatatgaacc atgaatacat gtctgtgtat actgtgacgt 2160
cacacgggtc ctatacttg tacttatgta caggaccata cgacaagacc caggcatggg 2220
gctgaggctg attcattact cagttggtgc gctgttctgg gtccgtacct cgactccgac 2280
taagtaatga gtcaaccacg tgggtatcact gaccaaggag aagtcccaa tggctacaat 2340
gtctccagat accatagtga ctggttcctc ttcaggggtt accgatgta cagaggctca 2400
caaccacaga ggatttcccg ctcaaggctgc tgtcggctgc tccctcccag gttggtgtct 2460
cctaaagggc gagtccgacg acagccgacg agggagggc acatctgtgt acttctgtgc 2520
cagcagttac gtcgggaaca ccggggagct tgtagacaca tgaagacacg gtcgtcaatg 2580
cagcccttgt ggcccctcga gttttttgga gaaggctcta ggctgaccgt actggaggac 2640
ctgaaaaacg caaaaaacct cttccgagat ccgactggca tgacctcctg gactttttgc 2700
tgttcccacc cgaggtcgtc gtgtttgagc catcagaagc agagatctcc acaaggggtg 2760
gctccagcga cacaaactcg gtagtcttcg tctctagagg cacacccaaa aggccacact 2820
gggtgtcctg gccacaggct tctaccccga gtgtggggtt tccggtgtga ccacacggac 2880
cgggtgccga agatggggct ccacgtggag ctgagctggt ggggtgaatgg gaaggaggtg 2940
cacagtgggg ggtgcacctc gactcgacca ccacttacc cttcctccac gtgtcacccc 3000
tctgcacaga cccgcagccc ctcaaggagc agcccgcct caatgactcc agacgtgtct 3060
gggcgtcggg gagttcctcg tcgggcggga gttactgagg agatacgctc tgagcagccg 3120
cctgaggggtc tcggccacct tctggcagga tctatgagc actcgtcggc ggactcccag 3180
agccggtgga agaccgtcct cccccgaac cacttccgct gtcaagtcca gttctacggg 3240
ctctcggaga gggggcggtg gtgaaggcga cagttcaggt caagatgcc gagagcctct 3300
atgacgagtg gaccaggat agggccaaac ccgtcaccca gatcgtcagc tactgctcac 3360
ctgggtccta tcccggtttg ggcagtgggt ctagcagtcg gccgaggcct ggggtagagc 3420
agacgcggcc gcacggctcc ggaccccatc tcgtctgcgc cggcgt 3466
<212> Type : DNA
<211> Length : 3466
SequenceName : SEQ ID 166
SequenceDescription :
    
```

Final TCR Display PCT.workFile.txt

Custom Codon

 Sequence Name : SEQ ID 166

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 KYLLPTAAAG LLLLAAPAM AKQEVTPIPA ALSVPEGENL VLNCSFTDSA IYNLQWFRQD 60
 PGKGLTSLLL IQSSQREQTS GRLNASLDKS SGRSTLYIAA SQPGDSATYL CAVRPTSGGS 120
 YIPTFGRGTS LIVHPYIQNP DPAVYQLRDS KSSDKSVCLF TDFDSQTNVS QSKDSVYIT 180
 DKCVLDMRSM DFKSNSAVAW SNKSDFACAN AFNNSIIPED TFFPSPESSM KLLFAIPLV 240
 VPFYSHSAQA GVTQTPKFQV LKTGQSMTLQ CAQDMNHEYM SWYRQDPGMG LRLIHYSVGA 300
 GITDQGEVFN GYNVSRSTTE DFPLRLLSAA PSQTSVYFCA SSYVGNTGEL FFGEGSRLTV 360
 LEDLKNVFPF EVAVFEPSEA EISHTQKATL VCLATGFYPD HVLSWVWNG KEVHSGVCTD 420
 PQPLKEQPAL NDSRYALSSR LRVSATFWQD PRNHFRQVQ FYGLSENDEW TQDRAKPVTQ 480
 IVSAEAWGRA DAAA 494
 <212> Type : PRT
 <211> Length : 494
 SequenceName : SEQ ID 167
 SequenceDescription :

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 ggatccatgg ccataagtgg agtccctgtg ctaggatttt tcatcatagc tgtgctgatg 60
 agcgctcagg aatcatgggc tatcaaagaa gaacatgtga tcatccaggc cgagttctat 120
 ctgaatcctg accaatcagg cgagtttatg tttgactttg atggtgatga gattttccat 180
 gtggatatgg caaagaagga gacggtctgg cggcttgaag aatttgacg atttgccagc 240
 tttgaggctc aaggtgcatt ggccaacata gctgtggaca aagccaacct ggaaatcatg 300
 acaaagcgct ccaactatac tccgatcacc aatgtacctc cagaggtaac tgtgctcacg 360
 aacagccctg tggaactgag agagcccaac gtcctcatct gtttcatcga caagttcacc 420
 ccaccagtgg tcaatgtcac gtggcttcga aatggaaaac ctgtcaccac aggagtgtca 480
 gagacagtct tctgcccag ggaagaccac cttttccgca agttccacta tctccccttc 540
 ctgccctcaa ctgaggacgt ttacgactgc aggggtggagc actggggcct ggatgagcct 600
 cttctcaagc actgggagtt tgatgctcca agccctctcc cagagactac agagaacgtg 660
 gatgggggtc tgactgatac actccaagcg gagacagatc aacttgaaga caagaagtct 720
 gcgttgcaga ccgagattgc caatctactg aaagagaagg aaaaactaga gttcatcctg 780
 gcagcttacg gatctggtgg tggcttgaac gatatttttg aagctcagaa aatcgaatgg 840
 catgagtagg atcc 854
 <212> Type : DNA
 <211> Length : 854
 SequenceName : SEQ ID 168
 SequenceDescription :

Final TCR Display PCT.WorkFile.txt

Custom Codon

Sequence Name : SEQ ID 168

Sequence

<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :
aattctactc gtaaagcgag ttgaaggatc atatttagtt gcgtttatga gataagattg 60
aaagcacgtg taaaatgttt cccgcgcggt ggcacaacta tttacaatgc ggccaagtta 120
taaaagattc taatctgata tgttttaaaa cacctttgcg gcccgagttg tttgctgacg 180
tgactagcga agaagatgtg tggaccgcag aacagatagt aaaacaaaac cctagtattg 240
gagcaataat cgatttaacc aacacgtcta aatattatga tgggtgtgcat tttttgcggg 300
cgggcctggt atacaaaaaa attcaagtac ctggccagac tttgccgcct gaaagcatag 360
ttcaagaatt tattgacacg gtaaaagaat ttacagaaaa gtgtcccggc atgttgggtg 420
gcggtgactg cacacacggt attaatcgca cgggttacet ggtgtgcaga tatttaatgc 480
acaccctggg tattgcgccg caggaagcca tagatagatt cgaaaaagcc agaggtcaca 540
aaattgaaag acaaaattac gttcaagatt tattaattta attaataata tttgcattct 600
ttaacaaata ctttatccta ttttcaaatt gttgcgcttc ttccagcgaa ccaaaactat 660
gcttcgcttg ctccgtttag cttgtagccg atcagtgccg ttgttccaat cgacggtagg 720
attaggccgg atattctcca ccacaatggt ggcaacggtg atgttacggt tatgcttttg 780
gttttccacg tacgtctttt ggccggtaat agccgtaaac gtagtgccgt cgcgcgtcac 840
gcacaacacc ggatgtttgc gcttgctcgc ggggtattga accgcgcgat ccgacaaatc 900
caccactttg gcaactaaat cggtgacctg cgcgtctttt ttctgcatta tttcgtcttt 960
cttttgcatg gtttcttgga agccggtgta catgcggttt agatcagtca tgacgcgcgt 1020
gacctgcaaa tctttggcct cgatctgctt gtccttgatg gcaacgatgc gttcaataaa 1080
ctcttgtttt ttaacaagtt cctcggtttt ttgcccacc accgcttgca gcgcgtttgt 1140
gtgctcggtg aatgtcgaac tcagcttagt caccaactgt ttgctctcct cctcccgttg 1200
tttgatcgcg ggatcgtact tgccggtgca gagcacttga ggaattactt cttctaaaag 1260
ccattcttgt aattctatgg cgtaaggcaa tttggacttc ataactagct gaatcacgcc 1320
ggatttagta atgagcactg tatgcccgtg caaatacagc gggtcgcccc ttttcacgac 1380
gctgttagag gtagggcccc cttttggat ggtctgctca aataacgatt tgtatttatt 1440
gtctacatga acacgtatag ctttatcaca aactgtatat tttaaactgt tagcgacgtc 1500
cttgccacg aaccggacct gttggtcgcg ctctagcacg taccgcaggt tgaacgtatc 1560
ttctccaaat ttaaattctc caattttaac gcgagccatt ttgatacacg tgtgtcgatt 1620
ttgcaacaac tattgttttt taacgcaaac taaacttatt gtggttaagca ataattaaat 1680
atgggggaac atgcccgcct acaacactcg tcgttatgaa cgcagacggc gccggctctcg 1740
gcgcaagcgg ctaaaacgtg ttgctcgttc aacgcggcaa acatcgcaaa agccaatagt 1800

Final TCR Display PCT.WorkFile.txt

acagttttga	tttgcataatt	aacggcgatt	ttttaaatta	tcttatttaa	taaatagtta	1860
tgagcctac	aactccccgc	ccgcgttgac	tcgctgcacc	tcgagcagtt	cgttgacgcc	1920
ttcctccgtg	tggccgaaca	cgtcgagcgg	gtggtcgatg	accagcggcg	tgccgcacgc	1980
gacgcacaag	tatctgtaca	ccgaatgatc	gtcgggcgaa	ggcacgtcgg	cctccaagtg	2040
gcaatattgg	caaattcgaa	aatatataca	gttgggttgt	ttgcgcatat	ctatcgtggc	2100
gttgggcatg	tacgtccgaa	cgttgatttg	catgcaagcc	gaaattaaat	cattgcgatt	2160
agtgcgatta	aaacgttgta	catcctcgct	tttaatcatg	ccgtcgatta	aatcgcgcaa	2220
tcgagtcaag	tgatcaaagt	gtggaataat	gttttctttg	tattcccag	tcaagcgag	2280
cgcgatTTTT	aacaaactag	ccatcttgta	agttagtttc	atttaatgca	actttatcca	2340
ataatatatt	atgtatcgca	cgtaagaat	taacaatgcy	cccgttgctg	catctcaaca	2400
cgactatgat	agagatcaaa	taaagcgcga	attaaatagc	ttgcgacgca	acgtgcacga	2460
tctgtgcacg	cgttccggca	cgagctttga	ttgtaataag	tttttacgaa	gcgatgacat	2520
gacccccgta	gtgacaacga	tcacgcccaa	aagaactgcc	gactacaaaa	ttaccgagta	2580
tgctcggtag	gttaaaaacta	ttaagccatc	caatcgaccg	ttagtcgaat	caggaccgct	2640
ggtagcgagaa	gccgcgaagt	atggcgaatg	catcgtataa	cggtggagt	ccgctcatta	2700
gagcgtcatg	tttagacaag	aaagctacat	atttaattga	tcccgatgat	tttattgata	2760
aattgaccct	aactccatac	acggtattct	acaatggcgg	ggttttggtc	aaaatttccg	2820
gactgcgatt	gtacatgctg	ttaacggctc	cgcccactat	taatgaaatt	aaaaattcca	2880
attttaaaaa	acgcagcaag	agaaacattt	gtatgaaaga	atgcgtagaa	ggaaagaaaa	2940
atgtcgtcga	catgctgaac	aacaagatta	atatgcctcc	gtgtataaaa	aaaatattga	3000
acgatttgaa	agaaaacaat	gtaccgcgcg	gcggtatgta	caggaagagg	tttatactaa	3060
actgttacat	tgcaaacgtg	gtttcgtgtg	ccaagtgtga	aaaccgatgt	ttaatcaagg	3120
ctctgacgca	tttctacaac	cacgactcca	agtgtgtggg	tgaagtcatg	catcttttaa	3180
tcaaatccca	agatgtgtat	aaaccaccaa	actgccaaaa	aatgaaaact	gtcgacaagc	3240
tctgtccggt	tgctggcaac	tgcaagggtc	tcaatcctat	ttgtaattat	tgaataataa	3300
aacaattata	aatgctaaat	ttgtttttta	ttaacgatac	aaaccaaacg	caacaagaac	3360
atttgtagta	ttatctataa	ttgaaaacgc	gtagttataa	tcgctgaggt	aatattttaa	3420
atcattttca	aatgattcac	agttaatttg	cgacaatata	attttatttt	cacataaact	3480
agacgccttg	tcgtcttctt	cttcgtattc	cttctctttt	tcatttttct	cctcataaaa	3540
attaacatag	ttattatcgt	atccatata	gtatctatcg	tatagagtaa	atTTTTTgtt	3600
gtcataaata	tatatgtctt	ttttaatggg	gtgtatagta	ccgctgcgca	tagTTTTtct	3660
gtaatttaca	acagtgcctat	tttctggtag	ttcttcggag	tgtgttgctt	taattattaa	3720
atttatataa	tcaatgaatt	tgggatcgtc	ggTTTTgtac	aatatgTTgc	cggcatagta	3780
cgagcttct	tctagttcaa	ttacaccatt	ttttagcagc	accgattaa	cataactttc	3840

Final TCR Display PCT.WorkFile.txt

caaaatgttg	tacgaaccgt	taaaca	caaaa	cagttcacct	cccttttcta	tactattgtc	3900	
tgcgagcagt	tgtttgttgt	taaaaataac	agccattgta	atgagacgca	caaactaata		3960	
tcacaaactg	gaaatgtcta	tcaatatata	gttgctgatg	atccagcatg	ataagataca		4020	
ttgatgagtt	tggacaaacc	acaactagaa	tgcagtgaaa	aaaatgcttt	atttgtgaaa		4080	
tttgtgatgc	tattgcttta	tttghtaacca	ttataagctg	caataaaca	gttccgagtt		4140	
tgtcagaaag	cagaccaa	ac	agcggttgga	ataatagcga	gaacagagaa	atagcggcaa	4200	
aaataatacc	cgtatcactt	ttgctgat	at	ggttgatgtc	atgtagccaa	atcgggaaaa	4260	
acgggaagta	ggctcccatg	ataaaaaagt	aaaagaaaa	gaataaac	cg	aacatccaaa	4320	
agtttgtg	ttttaa	atag	tacataatgg	atttccttac	gcgaaatacg	ggcagacatg	4380	
gcctgcccgg	ttattattat	ttttgacacc	agaccaactg	gtaatgtag	cgaccggcgc		4440	
tcagctggaa	ttcagatctg	tgattgtaaa	taaaatgtaa	tttacagtat	agtattttaa		4500	
ttaatataca	aatgatttga	taataattct	tatttaacta	taatata	ttg	tgttgggttg	4560	
aattaaaggt	cccggcatcc	tcaaatgcat	aatttc	atag	tcccccttgt	tgtaagtgat	4620	
gcgtatttct	gaatctttgt	aaaatagcac	acaagactcc	aacgcg	tttg	gcgttttatt	4680	
ttcttgctcg	actctagttt	attagcctc	tagagatccg	tatttatagg	tttttttatt		4740	
acaaaactgt	tacgaaaaca	gtaaaatact	tatttatttg	cgagatggtt	atcattttaa		4800	
ttatctccat	gatccaataa	acctagaata	aagggccga	cctttaattc	aaccaacac		4860	
aatatattat	agttaaataa	gaattattat	caaatcattt	gtatattaat	taaaatacta		4920	
tactgtaaat	tacat	ttat	ttacaatcac	agatcccggg	gatccgggta	ttagtacatt	4980	
tattaagcgc	tagattctgt	gcgttgttga	tttacagaca	attggtgtac	gtattttaat		5040	
aattcattaa	atttataatc	tttaggggtg	tatgtagag	cgaaaatcaa	atgattttca		5100	
gcgtctttat	atctgaattt	aaatattaaa	tcctcaatag	at	tttgtaaaa	taggtttcga	5160	
ttagtttcaa	acaagggttg	tttttccgaa	ccgatggctg	gactatctaa	tggattttc	g	5220	
ctcaacgcca	caaaacttgc	caaatcttgt	agcagcaatc	tagctttgtc	gatattcgtt		5280	
tggtgtttgt	tttghtaataa	aggttcgacg	tcgttcaaaa	tattatgcgc	ttttgtattt		5340	
ctttcatcac	tgtcgttagt	gtacaattga	ctcgacgtaa	acacgttaaa	taaagcttgg		5400	
acatatttaa	catcgggcgt	gtagcttta	ttaggccgat	tatcgtcgtc	gtccaaccc		5460	
tcgtcgtag	aagttgcttc	cgaagacgat	tttgccatag	ccacacgacg	cctattaatt		5520	
gtgtcggcta	acacgtccgc	gatcaaat	gtagttgagc	tttttggaat	tatttctgat		5580	
tg	cgggcggtt	tttgggcggg	tttcaatcta	actgtgccc	at	tttaattc	agacaacacg	5640
ttagaaagcg	atggtgcagg	cggtggtaac	at	ttcagacg	gcaaatctac	taatggcggc	5700	
ggtggtggag	ctgatgataa	atctaccatc	ggtggaggcg	caggcggggc	tggcggcgga		5760	
ggcggaggcg	gaggtggtg	cggtgatgca	gacggcgggtt	taggctcaa	tgtctcttta		5820	
ggcaacacag	tcggcacctc	aactattgta	ctggtttcgg	gcgccgtttt	tggtttgacc		5880	

Final TCR Display PCT.WorkFile.txt

ggctctgagac	gagtgcgatt	tttttcgttt	ctaatagctt	ccaacaattg	ttgtctgtcg	5940
tctaaaggtg	cagcggggtg	aggttccgct	ggcattgggtg	gagcggggcg	caattcagac	6000
atcgatgggtg	gtgggtgggtg	tggaggcgct	ggaatgttag	gcacgggaga	agggtgtggc	6060
ggcggtgccg	ccggtataat	ttgttctggt	ttagtttggt	cgcgcacgat	tgtgggcacc	6120
ggcgcaggcg	ccgctggctg	cacaacggaa	ggctgctctg	ttcgaggcag	cgcttgggggt	6180
gggtggcaatt	caatattata	attggaatac	aatcgtaaa	aatctgctat	aagcattgta	6240
atctcgtat	cgtttaccgt	gccgatattt	aacaaccgct	caatgtaagc	aattgtattg	6300
taaagagatt	gtctcaagct	cggatcgatc	ccgcacgccg	ataacaagcc	ttttcatttt	6360
tactacagca	ttgtagtggc	gagacacttc	gctgtctctg	acgtacatgt	atgctttggt	6420
gtcaaaaacg	tcggtggcaa	gctttaaaat	atttaaaaga	acatctctgt	tcagaccac	6480
tgtgttgtcg	taaatgttgt	ttttgataat	ttgcgcttcc	gcagtatcga	cacgttcaaa	6540
aaattgatgc	gcatcaattt	tgttgttctt	attattgaat	aaataagatt	gtacagattc	6600
atatctacga	ttcgtcatgg	ccaccacaaa	tgctacgctg	caaacgctgg	tacaatttta	6660
cgaaaactgc	aaaaacgtca	aaactcggta	taaaataatc	aacgggctgt	ttggcaaaaat	6720
atctatttta	tcgcacaagc	ccactagcaa	attgtatttg	cagaaaacaa	tttcggcgca	6780
caattttaac	gctgacgaaa	taaaagttca	ccagttaatg	agcgaccacc	caaattttat	6840
aaaaatctat	tttaatcacg	gttccatcaa	caaccaagtg	atcgtgatgg	actacattga	6900
ctgtcccgat	ttatttgaaa	cactacaaat	taaaggcgag	ctttcgtacc	aacttgtag	6960
caatattatt	agacagctgt	gtgaagcgct	caacgatttg	cacaagcaca	atctcataca	7020
caacgacata	aaactcgaaa	atgtcttata	tttcgaagca	cttgatcgcg	tgtatgtttg	7080
cgattacgga	ttgtgcaaac	acgaaaactc	acttagcgtg	cacgacggca	cgttggagta	7140
ttttagtccg	gaaaaaattc	gacacacaac	tatgcacggt	tcgtttgact	ggtacgcggc	7200
gtgttaacat	acaagttgct	aaccggcggc	cgacacccat	ttgaaaaaag	cgaagacgaa	7260
atgttgact	tgaatagcat	gaagcgtcgt	cagcaataca	atgacattgg	cgttttaaaa	7320
cacgttcgta	acgttaacgc	tcgtgacttt	gtgtactgcc	taacaagata	caacatagat	7380
tgtagactca	caaattacaa	acaaattata	aaacatgagt	ttttgtcgta	aaaatgccac	7440
ttgttttacg	agtagaattc	ccagcttggc	actggccgtc	gttttacaac	gtcgtgactg	7500
ggaaaaccct	ggcgttacc	aacttaatcg	ccttgacgca	catccccctt	tcgccagctg	7560
gcgtaatagc	gaagaggccc	gcaccgatcg	cccttcccaa	cagttgcgca	gcctgaatgg	7620
cgaatggcgc	ctgatgcggt	atcttctcct	tacgcatctg	tgcggtatct	cacaccgcat	7680
atggtgcact	ctcagtacaa	tctgctctga	tgccgcatag	ttaagccagc	cccgacacc	7740
gccaacacc	gctgacgcgc	cctgacgggc	ttgtctgtct	ccggcatccg	cttacagaca	7800
agctgtgacc	gtctccggga	gctgcatgtg	tcagaggttt	tcaccgtcat	caccgaaacg	7860
cgcgacgaa	agggcctcgt	gatacgccta	tttttatagg	ttaatgtcat	gataataatg	7920

Final TCR Display PCT.WorkFile.txt						
gtttcttaga	cgtcaggtgg	cacttttcgg	ggaaatgtgc	gcggaacccc	tatttgttta	7980
tttttctaaa	tacattcaaa	tatgtatccg	ctcatgagac	aataaccctg	ataaatgctt	8040
caataatatt	gaaaaaggaa	gagtatgagt	attcaacatt	tccgtgtcgc	ccttattccc	8100
ttttttgcgg	cattttgcct	tcctgttttt	gctcacccag	aaacgctggt	gaaagtaaaa	8160
gatgctgaag	atcagttggg	tgcacgagtg	ggttacatcg	aactggatct	caacagcggg	8220
aagatccttg	agagttttcg	ccccgaagaa	cgttttccaa	tgatgagcac	ttttaagtt	8280
ctgctatgtg	gcgcggtatt	atcccgtatt	gacgccgggc	aagagcaact	cggtcgcggc	8340
atacactatt	ctcagaatga	cttggttgag	tactcaccag	tcacagaaaa	gcatcttacg	8400
gatggcatga	cagtaagaga	attatgcagt	gctgccataa	ccatgagtga	taacactgcg	8460
gccaaacttac	ttctgacaac	gatcggagga	ccgaaggagc	taaccgcttt	tttgacaaac	8520
atgggggatc	atgtaactcg	ccttgatcgt	tggaaccgg	agctgaatga	agccatacca	8580
aacgacgagc	gtgacaccac	gatgcctgta	gcaatggcaa	caacgttgcg	caaactatta	8640
actggcgaac	tacttactct	agcttcccgg	caacaattaa	tagactggat	ggaggcggat	8700
aaagttgcag	gaccacttct	gcgctcggcc	cttccggctg	gctggtttat	tgctgataaa	8760
tctggagccg	gtgagcgtgg	gtctcgcggt	atcattgcag	cactggggcc	agatggtaag	8820
ccctcccgta	tcgtagttat	ctacacgacg	gggagtcagg	caactatgga	tgaacgaaat	8880
agacagatcg	ctgagatagg	tgcttactg	attaagcatt	ggtaactgtc	agaccaagtt	8940
tactcatata	tacttttagat	tgatttaaaa	cttcattttt	aatttaaaag	gatctaggtg	9000
aagatccttt	ttgataatct	catgacccaa	atcccttaac	gtgagttttc	gttccactga	9060
gcgtcagacc	ccgtagaaaa	gatcaaagga	tcttcttgag	atcctttttt	tctgcgcgta	9120
atctgctgct	tgcaaacaaa	aaaaccaccg	ctaccagcgg	tggtttgttt	gccggatcaa	9180
gagctaccaa	ctctttttcc	gaaggtaact	ggcttcagca	gagcgcagat	accaataact	9240
gtccttctag	tgtagccgta	gttaggccac	cacttcaaga	actctgtagc	accgcctaca	9300
tacctcgctc	tgctaatcct	gttaccagtg	gctgctgcca	gtggcgataa	gtcgtgtcct	9360
accgggttgg	actcaagacg	atagttaccg	gataaggcgc	agcggtcggg	ctgaacgggg	9420
ggttcgtgca	cacagcccag	cttgagcgga	acgacctaca	ccgaactgag	atacctacag	9480
cgtagcatt	gagaaagcgc	cacgcttccc	gaaggagaaa	aggcggacag	gtatccggta	9540
agcggcaggg	tcggaacagg	agagcgcacg	agggagcttc	cagggggaaa	cgcttggtat	9600
ctttatagtc	ctgtcggggt	tcgccacctc	tgacttgagc	gtcgattttt	gtgatgctcg	9660
tcaggggggc	ggagcctatg	gaaaaacgcc	agcaacgcgg	ccttttttacg	gttcctggcc	9720
ttttgctggc	cttttgctca	catgttcttt	cctgcgttat	cccctgattc	tgtggataac	9780
cgtattaccg	ctttgagtg	agctgatacc	gctcgcggca	gccgaacgac	cgagcgcagc	9840
gagtcagtga	gcgaggaagc	ggaagagcgc	ccaatacgca	aaccgcctct	ccccgcgcgt	9900
tggccgattc	attaatgcag	ctggcacgac	aggtttcccg	actggaaagc	gggcagtgag	9960

Final TCR Display PCT.WorkFile.txt

```

cgcaacgcaa ttaatgtgag ttagctcact cattaggcac cccaggcttt acactttatg 10020
cttccggctc gtatgttgtg tggaattgtg agcggataac aatttcacac aggaaacagc 10080
tatgaccatg attacg 10096
<212> Type : DNA
<211> Length : 10096
      SequenceName : SEQ ID 169
      SequenceDescription :
```

Custom Codon

Sequence Name : SEQ ID 169

Sequence

<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :

```

ggtaccggat ccagcatggt gtgtctgaag ctccctggag gtcctgcat gacagcgtg 60
acagtgcacac tgatggtgct gagctcccca ctggctttgt ccggagacac cggacctaaag 120
tacgtcaagc agaacacact gaaactggct tccggtggcg gatctctagt tccacgcggt 180
agtggaggcg gtggttccgg agacacgcgt ccacgtttct tgtggcagct taagtttgaa 240
tgtcatttct tcaatgggac ggagcgggtg cggttgctgg aaagatgcat ctataaccaa 300
gaggagtccg tgcgcttcga cagcgacgtg ggggagtacc gggcggtgac ggagctgggg 360
cggcctgatg ccgagtactg gaacagccag aaggacctcc tggagcagag gcgggcccgcg 420
gtggacacct actgcagaca caactacggg gttggtgaga gcttcacagt gcagcggcga 480
gttgagccta aggtgactgt gtatccttca aagaccagc ccctgcagca ccacaacctc 540
ctggtctgct ctgtgagtgg tttctatcca ggcagcattg aagtcagggtg gttccggaac 600
ggccaggaag agaaggctgg ggtggtgtcc acaggcctga tccagaatgg agattggacc 660
ttccagacc tggtgatgct ggaaacagtt cctcggagtg gagaggttta cacctgccaa 720
gtggagcacc caagtgtgac gagccctctc acagtggaat ggagagcacg gtctgaatct 780
gcacagagca aggtcgacgg aggcgggtggg ggtagaatcg cccggctgga ggaaaaagtg 840
aaaaccttga aagctcagaa ctcggagctg gcgtccacgg ccaacatgct cagggaaacg 900
gtggcacagc ttaaacagaa agtcatgaac tactaggatc c 941
<212> Type : DNA
<211> Length : 941
      SequenceName : SEQ ID 170
      SequenceDescription :
```

Custom Codon

Sequence Name : SEQ ID 170

Sequence

<213> OrganismName : Synthetic Sequence
<400> PreSequenceString :

```

MNAGVTQTPK FQVLKTGQSM TLQCAQDMNH EYMSWYRQDP GMGLRLIHYS VGAGITDQGE 60
VPNGYNVRSR TTEDFPLRLL SAAPSQTSVY FCASRPGLAG GRPEQYFGPG TRLTVT 116
<212> Type : PRT
```

Final TCR Display PCT.WorkFile.txt

<211> Length : 116
 SequenceName : SEQ ID 171
 SequenceDescription :

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 MNAGVTQTPK FQVLKTGQSM TLQCAQDMNH EYMSWYRQDP GMGLRLIHYS VGAGITDQGE 60
 VPNGYNVSRs TTEDFPLRLL SAAPSQTSVY FCASRPGLMS AXPEQYFGPG TRLTVT 116

<212> Type : PRT
 <211> Length : 116
 SequenceName : SEQ ID 172
 SequenceDescription :

Feature

 Sequence: SEQ ID 172:
 <221> FeatureKey : MISC_FEATURE
 <222> LocationFrom : 1
 <222> LocationTo : 116
 Other Information : where x is e, q or r
 CDSJoin : No

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 MNAGVTQTPK FQVLKTGQSM TLQCAQDMNH EYMSWYRQDP GMGLRLIHYS VGAGITDQGE 60
 VPNGYNVSRs TTEDFPLRLL SAAPSQTSVY FCASRPGLAG GRPEDQYFGP GTRLTVT 117

<212> Type : PRT
 <211> Length : 117
 SequenceName : SEQ ID 173
 SequenceDescription :

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 MNAGVTQTPK FQVLKTGQSM TLQCAQDMNH EYMSWYRQDP GMGLRLIHYS VGAGITDQGE 60
 VPNGYNVSRs TTEDFPLRLL SAAPSQTSVY FCASRPGLVP GRPEQQFGPG TRLTVT 116

<212> Type : PRT
 <211> Length : 116
 SequenceName : SEQ ID 174
 SequenceDescription :

Sequence

 <213> OrganismName : Synthetic Sequence
 <400> PreSequenceString :
 MNAGVTQTPK FQVLKTGQSM TLQCAQDMNH EYMSWYRQDP GMGLRLIHYS VGAGITDQGE 60
 VPNGYNVSRs TTEDFPLRLL SAAPSQTSVY FCASRPGLAG GRPHPQFGPG TRLTVT 116

<212> Type : PRT
 <211> Length : 116
 SequenceName : SEQ ID 175
 SequenceDescription :

Final TCR Display PCT.WorkFile.txt